#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Rare damaging variants in DNA repair and cell cycle pathways are associated with hippocampal and cognitive dysfunction: a combined genetic imaging study in first-episode treatment-naive patients with schizophrenia
#Text=Schizophrenia is a complex neurodevelopmental disorder where changes in both hippocampus and memory-related cognitive functions are central.
1-1	0-4	Rare	_	
1-2	5-13	damaging	_	
1-3	14-22	variants	_	
1-4	23-25	in	_	
1-5	26-29	DNA	_	
1-6	30-36	repair	_	
1-7	37-40	and	_	
1-8	41-45	cell	_	
1-9	46-51	cycle	_	
1-10	52-60	pathways	_	
1-11	61-64	are	_	
1-12	65-75	associated	_	
1-13	76-80	with	_	
1-14	81-92	hippocampal	_	
1-15	93-96	and	_	
1-16	97-106	cognitive	_	
1-17	107-118	dysfunction	_	
1-18	118-119	:	_	
1-19	120-121	a	_	
1-20	122-130	combined	_	
1-21	131-138	genetic	_	
1-22	139-146	imaging	_	
1-23	147-152	study	_	
1-24	153-155	in	_	
1-25	156-169	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[1]	
1-26	170-185	treatment-naive	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[1]	
1-27	186-194	patients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[1]	
1-28	195-199	with	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[1]	
1-29	200-213	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[1]	
1-30	214-227	Schizophrenia	_	
1-31	228-230	is	_	
1-32	231-232	a	_	
1-33	233-240	complex	_	
1-34	241-259	neurodevelopmental	_	
1-35	260-268	disorder	_	
1-36	269-274	where	_	
1-37	275-282	changes	_	
1-38	283-285	in	_	
1-39	286-290	both	_	
1-40	291-302	hippocampus	_	
1-41	303-306	and	_	
1-42	307-321	memory-related	_	
1-43	322-331	cognitive	_	
1-44	332-341	functions	_	
1-45	342-345	are	_	
1-46	346-353	central	_	
1-47	353-354	.	_	

#Text=However, the exact relationship between neurodevelopmental-genetic factors and hippocampal-cognitive dysfunction remains unclear.
2-1	355-362	However	_	
2-2	362-363	,	_	
2-3	364-367	the	_	
2-4	368-373	exact	_	
2-5	374-386	relationship	_	
2-6	387-394	between	_	
2-7	395-421	neurodevelopmental-genetic	_	
2-8	422-429	factors	_	
2-9	430-433	and	_	
2-10	434-455	hippocampal-cognitive	_	
2-11	456-467	dysfunction	_	
2-12	468-475	remains	_	
2-13	476-483	unclear	_	
2-14	483-484	.	_	

#Text=The general aim of our study is to link the occurrence of rare damaging mutations involved in susceptibility gene pathways to the structure and function of hippocampus in order to define genetically and phenotypically based subgroups in schizophrenia.
3-1	485-488	The	_	
3-2	489-496	general	_	
3-3	497-500	aim	_	
3-4	501-503	of	_	
3-5	504-507	our	_	
3-6	508-513	study	_	
3-7	514-516	is	_	
3-8	517-519	to	_	
3-9	520-524	link	_	
3-10	525-528	the	_	
3-11	529-539	occurrence	_	
3-12	540-542	of	_	
3-13	543-547	rare	_	
3-14	548-556	damaging	_	
3-15	557-566	mutations	_	
3-16	567-575	involved	_	
3-17	576-578	in	_	
3-18	579-593	susceptibility	_	
3-19	594-598	gene	_	
3-20	599-607	pathways	_	
3-21	608-610	to	_	
3-22	611-614	the	_	
3-23	615-624	structure	_	
3-24	625-628	and	_	
3-25	629-637	function	_	
3-26	638-640	of	_	
3-27	641-652	hippocampus	_	
3-28	653-655	in	_	
3-29	656-661	order	_	
3-30	662-664	to	_	
3-31	665-671	define	_	
3-32	672-683	genetically	_	
3-33	684-687	and	_	
3-34	688-702	phenotypically	_	
3-35	703-708	based	_	
3-36	709-718	subgroups	_	
3-37	719-721	in	_	
3-38	722-735	schizophrenia	_	
3-39	735-736	.	_	

#Text=In the present study, by analyzing the exome sequencing and magnetic resonance imaging data in 94 first-episode treatment-naive schizophrenia patients and 134 normal controls, we identified that a cluster of rare damaging variants (RDVs) enriched in DNA repair and cell cycle pathways was present only in a subgroup including 39 schizophrenic patients.
4-1	737-739	In	_	
4-2	740-743	the	_	
4-3	744-751	present	_	
4-4	752-757	study	_	
4-5	757-758	,	_	
4-6	759-761	by	_	
4-7	762-771	analyzing	_	
4-8	772-775	the	_	
4-9	776-781	exome	_	
4-10	782-792	sequencing	_	
4-11	793-796	and	_	
4-12	797-805	magnetic	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[2]	
4-13	806-815	resonance	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[2]	
4-14	816-823	imaging	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[2]	
4-15	824-828	data	_	
4-16	829-831	in	_	
4-17	832-834	94	_	
4-18	835-848	first-episode	_	
4-19	849-864	treatment-naive	_	
4-20	865-878	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
4-21	879-887	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
4-22	888-891	and	_	
4-23	892-895	134	_	
4-24	896-902	normal	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]	
4-25	903-911	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]	
4-26	911-912	,	_	
4-27	913-915	we	_	
4-28	916-926	identified	_	
4-29	927-931	that	_	
4-30	932-933	a	_	
4-31	934-941	cluster	_	
4-32	942-944	of	_	
4-33	945-949	rare	_	
4-34	950-958	damaging	_	
4-35	959-967	variants	_	
4-36	968-969	(	_	
4-37	969-973	RDVs	_	
4-38	973-974	)	_	
4-39	975-983	enriched	_	
4-40	984-986	in	_	
4-41	987-990	DNA	_	
4-42	991-997	repair	_	
4-43	998-1001	and	_	
4-44	1002-1006	cell	_	
4-45	1007-1012	cycle	_	
4-46	1013-1021	pathways	_	
4-47	1022-1025	was	_	
4-48	1026-1033	present	_	
4-49	1034-1038	only	_	
4-50	1039-1041	in	_	
4-51	1042-1043	a	_	
4-52	1044-1052	subgroup	_	
4-53	1053-1062	including	_	
4-54	1063-1065	39	_	
4-55	1066-1079	schizophrenic	_	
4-56	1080-1088	patients	_	
4-57	1088-1089	.	_	

#Text=Furthermore, we found that schizophrenic patients with this RDVs show increased resting-state functional connectivity (rsFC) between left hippocampus (especially for left dentate gyrus) and left inferior parietal cortex, as well as decreased rsFC between left hippocampus and cerebellum.
5-1	1090-1101	Furthermore	_	
5-2	1101-1102	,	_	
5-3	1103-1105	we	_	
5-4	1106-1111	found	_	
5-5	1112-1116	that	_	
5-6	1117-1130	schizophrenic	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[5]	
5-7	1131-1139	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[5]	
5-8	1140-1144	with	_	
5-9	1145-1149	this	_	
5-10	1150-1154	RDVs	_	
5-11	1155-1159	show	_	
5-12	1160-1169	increased	_	
5-13	1170-1183	resting-state	_	
5-14	1184-1194	functional	_	
5-15	1195-1207	connectivity	_	
5-16	1208-1209	(	_	
5-17	1209-1213	rsFC	_	
5-18	1213-1214	)	_	
5-19	1215-1222	between	_	
5-20	1223-1227	left	_	
5-21	1228-1239	hippocampus	_	
5-22	1240-1241	(	_	
5-23	1241-1251	especially	_	
5-24	1252-1255	for	_	
5-25	1256-1260	left	_	
5-26	1261-1268	dentate	_	
5-27	1269-1274	gyrus	_	
5-28	1274-1275	)	_	
5-29	1276-1279	and	_	
5-30	1280-1284	left	_	
5-31	1285-1293	inferior	_	
5-32	1294-1302	parietal	_	
5-33	1303-1309	cortex	_	
5-34	1309-1310	,	_	
5-35	1311-1313	as	_	
5-36	1314-1318	well	_	
5-37	1319-1321	as	_	
5-38	1322-1331	decreased	_	
5-39	1332-1336	rsFC	_	
5-40	1337-1344	between	_	
5-41	1345-1349	left	_	
5-42	1350-1361	hippocampus	_	
5-43	1362-1365	and	_	
5-44	1366-1376	cerebellum	_	
5-45	1376-1377	.	_	

#Text=Moreover, abnormal rsFC was related to the deficits of spatial working memory (SWM; that is known to recruit the hippocampus) in patients with the RDVs.
6-1	1378-1386	Moreover	_	
6-2	1386-1387	,	_	
6-3	1388-1396	abnormal	_	
6-4	1397-1401	rsFC	_	
6-5	1402-1405	was	_	
6-6	1406-1413	related	_	
6-7	1414-1416	to	_	
6-8	1417-1420	the	_	
6-9	1421-1429	deficits	_	
6-10	1430-1432	of	_	
6-11	1433-1440	spatial	_	
6-12	1441-1448	working	_	
6-13	1449-1455	memory	_	
6-14	1456-1457	(	_	
6-15	1457-1460	SWM	_	
6-16	1460-1461	;	_	
6-17	1462-1466	that	_	
6-18	1467-1469	is	_	
6-19	1470-1475	known	_	
6-20	1476-1478	to	_	
6-21	1479-1486	recruit	_	
6-22	1487-1490	the	_	
6-23	1491-1502	hippocampus	_	
6-24	1502-1503	)	_	
6-25	1504-1506	in	_	
6-26	1507-1515	patients	_	
6-27	1516-1520	with	_	
6-28	1521-1524	the	_	
6-29	1525-1529	RDVs	_	
6-30	1529-1530	.	_	

#Text=Taken together, our data demonstrate for the first time, to our knowledge, that damaging rare variants of genes in DNA repair and cell cycle pathways are associated with aberrant hippocampal rsFC, which was further relative to cognitive deficits in first-episode treatment-naive schizophrenia.
7-1	1531-1536	Taken	_	
7-2	1537-1545	together	_	
7-3	1545-1546	,	_	
7-4	1547-1550	our	_	
7-5	1551-1555	data	_	
7-6	1556-1567	demonstrate	_	
7-7	1568-1571	for	_	
7-8	1572-1575	the	_	
7-9	1576-1581	first	_	
7-10	1582-1586	time	_	
7-11	1586-1587	,	_	
7-12	1588-1590	to	_	
7-13	1591-1594	our	_	
7-14	1595-1604	knowledge	_	
7-15	1604-1605	,	_	
7-16	1606-1610	that	_	
7-17	1611-1619	damaging	_	
7-18	1620-1624	rare	_	
7-19	1625-1633	variants	_	
7-20	1634-1636	of	_	
7-21	1637-1642	genes	_	
7-22	1643-1645	in	_	
7-23	1646-1649	DNA	_	
7-24	1650-1656	repair	_	
7-25	1657-1660	and	_	
7-26	1661-1665	cell	_	
7-27	1666-1671	cycle	_	
7-28	1672-1680	pathways	_	
7-29	1681-1684	are	_	
7-30	1685-1695	associated	_	
7-31	1696-1700	with	_	
7-32	1701-1709	aberrant	_	
7-33	1710-1721	hippocampal	_	
7-34	1722-1726	rsFC	_	
7-35	1726-1727	,	_	
7-36	1728-1733	which	_	
7-37	1734-1737	was	_	
7-38	1738-1745	further	_	
7-39	1746-1754	relative	_	
7-40	1755-1757	to	_	
7-41	1758-1767	cognitive	_	
7-42	1768-1776	deficits	_	
7-43	1777-1779	in	_	
7-44	1780-1793	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[6]	
7-45	1794-1809	treatment-naive	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[6]	
7-46	1810-1823	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]	
7-47	1823-1824	.	_	

#Text=Therefore, our data provide some evidence for the occurrence of phenotypic alterations in hippocampal and SWM function in a genetically defined subgroup of schizophrenia.
8-1	1825-1834	Therefore	_	
8-2	1834-1835	,	_	
8-3	1836-1839	our	_	
8-4	1840-1844	data	_	
8-5	1845-1852	provide	_	
8-6	1853-1857	some	_	
8-7	1858-1866	evidence	_	
8-8	1867-1870	for	_	
8-9	1871-1874	the	_	
8-10	1875-1885	occurrence	_	
8-11	1886-1888	of	_	
8-12	1889-1899	phenotypic	_	
8-13	1900-1911	alterations	_	
8-14	1912-1914	in	_	
8-15	1915-1926	hippocampal	_	
8-16	1927-1930	and	_	
8-17	1931-1934	SWM	_	
8-18	1935-1943	function	_	
8-19	1944-1946	in	_	
8-20	1947-1948	a	_	
8-21	1949-1960	genetically	_	
8-22	1961-1968	defined	_	
8-23	1969-1977	subgroup	_	
8-24	1978-1980	of	_	
8-25	1981-1994	schizophrenia	_	
8-26	1994-1995	.	_	

#Text=Introduction
#Text=Schizophrenia, which affects ~1% of the population, is a devastating mental disorder characterized by a range of symptoms including abnormal perception, thinking, cognitive, emotion and social behavior and so on.
9-1	1996-2008	Introduction	_	
9-2	2009-2022	Schizophrenia	_	
9-3	2022-2023	,	_	
9-4	2024-2029	which	_	
9-5	2030-2037	affects	_	
9-6	2038-2039	~	_	
9-7	2039-2041	1%	_	
9-8	2042-2044	of	_	
9-9	2045-2048	the	_	
9-10	2049-2059	population	_	
9-11	2059-2060	,	_	
9-12	2061-2063	is	_	
9-13	2064-2065	a	_	
9-14	2066-2077	devastating	_	
9-15	2078-2084	mental	_	
9-16	2085-2093	disorder	_	
9-17	2094-2107	characterized	_	
9-18	2108-2110	by	_	
9-19	2111-2112	a	_	
9-20	2113-2118	range	_	
9-21	2119-2121	of	_	
9-22	2122-2130	symptoms	_	
9-23	2131-2140	including	_	
9-24	2141-2149	abnormal	_	
9-25	2150-2160	perception	_	
9-26	2160-2161	,	_	
9-27	2162-2170	thinking	_	
9-28	2170-2171	,	_	
9-29	2172-2181	cognitive	_	
9-30	2181-2182	,	_	
9-31	2183-2190	emotion	_	
9-32	2191-2194	and	_	
9-33	2195-2201	social	_	
9-34	2202-2210	behavior	_	
9-35	2211-2214	and	_	
9-36	2215-2217	so	_	
9-37	2218-2220	on	_	
9-38	2220-2221	.	_	

#Text=It is widely accepted that a complex interplay of genetic and environmental factors contributes to the etiology of schizophrenia, which therefore is regarded a neurodevelopmental disorder.
10-1	2222-2224	It	_	
10-2	2225-2227	is	_	
10-3	2228-2234	widely	_	
10-4	2235-2243	accepted	_	
10-5	2244-2248	that	_	
10-6	2249-2250	a	_	
10-7	2251-2258	complex	_	
10-8	2259-2268	interplay	_	
10-9	2269-2271	of	_	
10-10	2272-2279	genetic	_	
10-11	2280-2283	and	_	
10-12	2284-2297	environmental	_	
10-13	2298-2305	factors	_	
10-14	2306-2317	contributes	_	
10-15	2318-2320	to	_	
10-16	2321-2324	the	_	
10-17	2325-2333	etiology	_	
10-18	2334-2336	of	_	
10-19	2337-2350	schizophrenia	_	
10-20	2350-2351	,	_	
10-21	2352-2357	which	_	
10-22	2358-2367	therefore	_	
10-23	2368-2370	is	_	
10-24	2371-2379	regarded	_	
10-25	2380-2381	a	_	
10-26	2382-2400	neurodevelopmental	_	
10-27	2401-2409	disorder	_	
10-28	2409-2410	.	_	

#Text=During the last decades, researchers have made significant strides in teasing apart schizophrenia's convoluted genetic vulnerabilities.
11-1	2411-2417	During	_	
11-2	2418-2421	the	_	
11-3	2422-2426	last	_	
11-4	2427-2434	decades	_	
11-5	2434-2435	,	_	
11-6	2436-2447	researchers	_	
11-7	2448-2452	have	_	
11-8	2453-2457	made	_	
11-9	2458-2469	significant	_	
11-10	2470-2477	strides	_	
11-11	2478-2480	in	_	
11-12	2481-2488	teasing	_	
11-13	2489-2494	apart	_	
11-14	2495-2510	schizophrenia's	_	
11-15	2511-2521	convoluted	_	
11-16	2522-2529	genetic	_	
11-17	2530-2545	vulnerabilities	_	
11-18	2545-2546	.	_	

#Text=These included initial epidemiology studies within family, twin and adoption, and then linkage studies mainly using microsatellite markers to candidate genes and genome-wide association studies.
12-1	2547-2552	These	_	
12-2	2553-2561	included	_	
12-3	2562-2569	initial	_	
12-4	2570-2582	epidemiology	_	
12-5	2583-2590	studies	_	
12-6	2591-2597	within	_	
12-7	2598-2604	family	_	
12-8	2604-2605	,	_	
12-9	2606-2610	twin	_	
12-10	2611-2614	and	_	
12-11	2615-2623	adoption	_	
12-12	2623-2624	,	_	
12-13	2625-2628	and	_	
12-14	2629-2633	then	_	
12-15	2634-2641	linkage	_	
12-16	2642-2649	studies	_	
12-17	2650-2656	mainly	_	
12-18	2657-2662	using	_	
12-19	2663-2677	microsatellite	_	
12-20	2678-2685	markers	_	
12-21	2686-2688	to	_	
12-22	2689-2698	candidate	_	
12-23	2699-2704	genes	_	
12-24	2705-2708	and	_	
12-25	2709-2720	genome-wide	_	
12-26	2721-2732	association	_	
12-27	2733-2740	studies	_	
12-28	2740-2741	.	_	

#Text=Recently, genome-wide association studies identified that some common variants with small to moderate effects as well as rare but gene-disrupting copy number variants are significantly associated with schizophrenia.
13-1	2742-2750	Recently	_	
13-2	2750-2751	,	_	
13-3	2752-2763	genome-wide	_	
13-4	2764-2775	association	_	
13-5	2776-2783	studies	_	
13-6	2784-2794	identified	_	
13-7	2795-2799	that	_	
13-8	2800-2804	some	_	
13-9	2805-2811	common	_	
13-10	2812-2820	variants	_	
13-11	2821-2825	with	_	
13-12	2826-2831	small	_	
13-13	2832-2834	to	_	
13-14	2835-2843	moderate	_	
13-15	2844-2851	effects	_	
13-16	2852-2854	as	_	
13-17	2855-2859	well	_	
13-18	2860-2862	as	_	
13-19	2863-2867	rare	_	
13-20	2868-2871	but	_	
13-21	2872-2887	gene-disrupting	_	
13-22	2888-2892	copy	_	
13-23	2893-2899	number	_	
13-24	2900-2908	variants	_	
13-25	2909-2912	are	_	
13-26	2913-2926	significantly	_	
13-27	2927-2937	associated	_	
13-28	2938-2942	with	_	
13-29	2943-2956	schizophrenia	_	
13-30	2956-2957	.	_	

#Text=Studies using the whole-exome sequencing technologies have also revealed that rare damaging nonsense and loss-of-function variants and/or de novo variants conferred higher risk to schizophrenia.
14-1	2958-2965	Studies	_	
14-2	2966-2971	using	_	
14-3	2972-2975	the	_	
14-4	2976-2987	whole-exome	_	
14-5	2988-2998	sequencing	_	
14-6	2999-3011	technologies	_	
14-7	3012-3016	have	_	
14-8	3017-3021	also	_	
14-9	3022-3030	revealed	_	
14-10	3031-3035	that	_	
14-11	3036-3040	rare	_	
14-12	3041-3049	damaging	_	
14-13	3050-3058	nonsense	_	
14-14	3059-3062	and	_	
14-15	3063-3079	loss-of-function	_	
14-16	3080-3088	variants	_	
14-17	3089-3092	and	_	
14-18	3092-3093	/	_	
14-19	3093-3095	or	_	
14-20	3096-3098	de	_	
14-21	3099-3103	novo	_	
14-22	3104-3112	variants	_	
14-23	3113-3122	conferred	_	
14-24	3123-3129	higher	_	
14-25	3130-3134	risk	_	
14-26	3135-3137	to	_	
14-27	3138-3151	schizophrenia	_	
14-28	3151-3152	.	_	

#Text=However, to validate these variants in population remains challenging because of the low frequency and effect sizes.
15-1	3153-3160	However	_	
15-2	3160-3161	,	_	
15-3	3162-3164	to	_	
15-4	3165-3173	validate	_	
15-5	3174-3179	these	_	
15-6	3180-3188	variants	_	
15-7	3189-3191	in	_	
15-8	3192-3202	population	_	
15-9	3203-3210	remains	_	
15-10	3211-3222	challenging	_	
15-11	3223-3230	because	_	
15-12	3231-3233	of	_	
15-13	3234-3237	the	_	
15-14	3238-3241	low	_	
15-15	3242-3251	frequency	_	
15-16	3252-3255	and	_	
15-17	3256-3262	effect	_	
15-18	3263-3268	sizes	_	
15-19	3268-3269	.	_	

#Text=Converging evidence from studies of common and rare variants identified broad classes of genes and pathways involved in calcium ion channel, synaptic plasticity and neurodevelopment processes, chromatin remodeling and synaptic network.
16-1	3270-3280	Converging	_	
16-2	3281-3289	evidence	_	
16-3	3290-3294	from	_	
16-4	3295-3302	studies	_	
16-5	3303-3305	of	_	
16-6	3306-3312	common	_	
16-7	3313-3316	and	_	
16-8	3317-3321	rare	_	
16-9	3322-3330	variants	_	
16-10	3331-3341	identified	_	
16-11	3342-3347	broad	_	
16-12	3348-3355	classes	_	
16-13	3356-3358	of	_	
16-14	3359-3364	genes	_	
16-15	3365-3368	and	_	
16-16	3369-3377	pathways	_	
16-17	3378-3386	involved	_	
16-18	3387-3389	in	_	
16-19	3390-3397	calcium	_	
16-20	3398-3401	ion	_	
16-21	3402-3409	channel	_	
16-22	3409-3410	,	_	
16-23	3411-3419	synaptic	_	
16-24	3420-3430	plasticity	_	
16-25	3431-3434	and	_	
16-26	3435-3451	neurodevelopment	_	
16-27	3452-3461	processes	_	
16-28	3461-3462	,	_	
16-29	3463-3472	chromatin	_	
16-30	3473-3483	remodeling	_	
16-31	3484-3487	and	_	
16-32	3488-3496	synaptic	_	
16-33	3497-3504	network	_	
16-34	3504-3505	.	_	

#Text=Although these results show significant leads for identifying susceptibility genes of schizophrenia, the exact and specific genetic factors contributing to the abnormal neurodevelopment processes in schizophrenia remain inconclusive.
17-1	3506-3514	Although	_	
17-2	3515-3520	these	_	
17-3	3521-3528	results	_	
17-4	3529-3533	show	_	
17-5	3534-3545	significant	_	
17-6	3546-3551	leads	_	
17-7	3552-3555	for	_	
17-8	3556-3567	identifying	_	
17-9	3568-3582	susceptibility	_	
17-10	3583-3588	genes	_	
17-11	3589-3591	of	_	
17-12	3592-3605	schizophrenia	_	
17-13	3605-3606	,	_	
17-14	3607-3610	the	_	
17-15	3611-3616	exact	_	
17-16	3617-3620	and	_	
17-17	3621-3629	specific	_	
17-18	3630-3637	genetic	_	
17-19	3638-3645	factors	_	
17-20	3646-3658	contributing	_	
17-21	3659-3661	to	_	
17-22	3662-3665	the	_	
17-23	3666-3674	abnormal	_	
17-24	3675-3691	neurodevelopment	_	
17-25	3692-3701	processes	_	
17-26	3702-3704	in	_	
17-27	3705-3718	schizophrenia	_	
17-28	3719-3725	remain	_	
17-29	3726-3738	inconclusive	_	
17-30	3738-3739	.	_	

#Text=A key brain region in schizophrenia is the hippocampus where reduced volume in especially left (rather than right) hippocampus as well as resting-state functional connectivity (rsFC) differences to other regions have been observed.
18-1	3740-3741	A	_	
18-2	3742-3745	key	_	
18-3	3746-3751	brain	_	
18-4	3752-3758	region	_	
18-5	3759-3761	in	_	
18-6	3762-3775	schizophrenia	_	
18-7	3776-3778	is	_	
18-8	3779-3782	the	_	
18-9	3783-3794	hippocampus	_	
18-10	3795-3800	where	_	
18-11	3801-3808	reduced	_	
18-12	3809-3815	volume	_	
18-13	3816-3818	in	_	
18-14	3819-3829	especially	_	
18-15	3830-3834	left	_	
18-16	3835-3836	(	_	
18-17	3836-3842	rather	_	
18-18	3843-3847	than	_	
18-19	3848-3853	right	_	
18-20	3853-3854	)	_	
18-21	3855-3866	hippocampus	_	
18-22	3867-3869	as	_	
18-23	3870-3874	well	_	
18-24	3875-3877	as	_	
18-25	3878-3891	resting-state	_	
18-26	3892-3902	functional	_	
18-27	3903-3915	connectivity	_	
18-28	3916-3917	(	_	
18-29	3917-3921	rsFC	_	
18-30	3921-3922	)	_	
18-31	3923-3934	differences	_	
18-32	3935-3937	to	_	
18-33	3938-3943	other	_	
18-34	3944-3951	regions	_	
18-35	3952-3956	have	_	
18-36	3957-3961	been	_	
18-37	3962-3970	observed	_	
18-38	3970-3971	.	_	

#Text=This corresponds to the observation of neuropsychological deficits, especially dysfunctional spatial working memory (SWM) and logical memory in patients with schizophrenia.
19-1	3972-3976	This	_	
19-2	3977-3988	corresponds	_	
19-3	3989-3991	to	_	
19-4	3992-3995	the	_	
19-5	3996-4007	observation	_	
19-6	4008-4010	of	_	
19-7	4011-4029	neuropsychological	_	
19-8	4030-4038	deficits	_	
19-9	4038-4039	,	_	
19-10	4040-4050	especially	_	
19-11	4051-4064	dysfunctional	_	
19-12	4065-4072	spatial	_	
19-13	4073-4080	working	_	
19-14	4081-4087	memory	_	
19-15	4088-4089	(	_	
19-16	4089-4092	SWM	_	
19-17	4092-4093	)	_	
19-18	4094-4097	and	_	
19-19	4098-4105	logical	_	
19-20	4106-4112	memory	_	
19-21	4113-4115	in	_	
19-22	4116-4124	patients	_	
19-23	4125-4129	with	_	
19-24	4130-4143	schizophrenia	_	
19-25	4143-4144	.	_	

#Text=However, the exact linkage between hippocampus and memory deficits on the one hand and underlying genetic-neurodevelopmental changes on the other hand remain unclear.
20-1	4145-4152	However	_	
20-2	4152-4153	,	_	
20-3	4154-4157	the	_	
20-4	4158-4163	exact	_	
20-5	4164-4171	linkage	_	
20-6	4172-4179	between	_	
20-7	4180-4191	hippocampus	_	
20-8	4192-4195	and	_	
20-9	4196-4202	memory	_	
20-10	4203-4211	deficits	_	
20-11	4212-4214	on	_	
20-12	4215-4218	the	_	
20-13	4219-4222	one	_	
20-14	4223-4227	hand	_	
20-15	4228-4231	and	_	
20-16	4232-4242	underlying	_	
20-17	4243-4269	genetic-neurodevelopmental	_	
20-18	4270-4277	changes	_	
20-19	4278-4280	on	_	
20-20	4281-4284	the	_	
20-21	4285-4290	other	_	
20-22	4291-4295	hand	_	
20-23	4296-4302	remain	_	
20-24	4303-4310	unclear	_	
20-25	4310-4311	.	_	

#Text=The general aim of our study was to conduct multilevel genetic imaging cognitive investigation in a unique large sample of first-episode treatment-naive schizophrenic patients.
21-1	4312-4315	The	_	
21-2	4316-4323	general	_	
21-3	4324-4327	aim	_	
21-4	4328-4330	of	_	
21-5	4331-4334	our	_	
21-6	4335-4340	study	_	
21-7	4341-4344	was	_	
21-8	4345-4347	to	_	
21-9	4348-4355	conduct	_	
21-10	4356-4366	multilevel	_	
21-11	4367-4374	genetic	_	
21-12	4375-4382	imaging	_	
21-13	4383-4392	cognitive	_	
21-14	4393-4406	investigation	_	
21-15	4407-4409	in	_	
21-16	4410-4411	a	_	
21-17	4412-4418	unique	_	
21-18	4419-4424	large	_	
21-19	4425-4431	sample	_	
21-20	4432-4434	of	_	
21-21	4435-4448	first-episode	_	
21-22	4449-4464	treatment-naive	_	
21-23	4465-4478	schizophrenic	_	
21-24	4479-4487	patients	_	
21-25	4487-4488	.	_	

#Text=For that purpose, we combined genetic analysis of neurodevelopmentally related genes with structural and functional imaging of the hippocampus and related cognitive measures.
22-1	4489-4492	For	_	
22-2	4493-4497	that	_	
22-3	4498-4505	purpose	_	
22-4	4505-4506	,	_	
22-5	4507-4509	we	_	
22-6	4510-4518	combined	_	
22-7	4519-4526	genetic	_	
22-8	4527-4535	analysis	_	
22-9	4536-4538	of	_	
22-10	4539-4559	neurodevelopmentally	_	
22-11	4560-4567	related	_	
22-12	4568-4573	genes	_	
22-13	4574-4578	with	_	
22-14	4579-4589	structural	_	
22-15	4590-4593	and	_	
22-16	4594-4604	functional	_	
22-17	4605-4612	imaging	_	
22-18	4613-4615	of	_	
22-19	4616-4619	the	_	
22-20	4620-4631	hippocampus	_	
22-21	4632-4635	and	_	
22-22	4636-4643	related	_	
22-23	4644-4653	cognitive	_	
22-24	4654-4662	measures	_	
22-25	4662-4663	.	_	

#Text=Specifically, genetic investigation in schizophrenic (and healthy) subjects served to determine specific genetic neurodevelopmentally relevant subtypes, which were then further characterized phenotypically using structural and functional hippocampal imaging as well as related cognitive, that is, memory measures.
23-1	4664-4676	Specifically	_	
23-2	4676-4677	,	_	
23-3	4678-4685	genetic	_	
23-4	4686-4699	investigation	_	
23-5	4700-4702	in	_	
23-6	4703-4716	schizophrenic	_	
23-7	4717-4718	(	_	
23-8	4718-4721	and	_	
23-9	4722-4729	healthy	_	
23-10	4729-4730	)	_	
23-11	4731-4739	subjects	_	
23-12	4740-4746	served	_	
23-13	4747-4749	to	_	
23-14	4750-4759	determine	_	
23-15	4760-4768	specific	_	
23-16	4769-4776	genetic	_	
23-17	4777-4797	neurodevelopmentally	_	
23-18	4798-4806	relevant	_	
23-19	4807-4815	subtypes	_	
23-20	4815-4816	,	_	
23-21	4817-4822	which	_	
23-22	4823-4827	were	_	
23-23	4828-4832	then	_	
23-24	4833-4840	further	_	
23-25	4841-4854	characterized	_	
23-26	4855-4869	phenotypically	_	
23-27	4870-4875	using	_	
23-28	4876-4886	structural	_	
23-29	4887-4890	and	_	
23-30	4891-4901	functional	_	
23-31	4902-4913	hippocampal	_	
23-32	4914-4921	imaging	_	
23-33	4922-4924	as	_	
23-34	4925-4929	well	_	
23-35	4930-4932	as	_	
23-36	4933-4940	related	_	
23-37	4941-4950	cognitive	_	
23-38	4950-4951	,	_	
23-39	4952-4956	that	_	
23-40	4957-4959	is	_	
23-41	4959-4960	,	_	
23-42	4961-4967	memory	_	
23-43	4968-4976	measures	_	
23-44	4976-4977	.	_	

#Text=The first specific aim was to unravel unique rare damaging variants (RDVs) in a unique sample of first-episode treatment-naive schizophrenia patients relative to healthy controls by using whole-exome sequencing approach, and then apply Gene Ontology (GO) enrichment strategy to identify gene pathways.
24-1	4978-4981	The	_	
24-2	4982-4987	first	_	
24-3	4988-4996	specific	_	
24-4	4997-5000	aim	_	
24-5	5001-5004	was	_	
24-6	5005-5007	to	_	
24-7	5008-5015	unravel	_	
24-8	5016-5022	unique	_	
24-9	5023-5027	rare	_	
24-10	5028-5036	damaging	_	
24-11	5037-5045	variants	_	
24-12	5046-5047	(	_	
24-13	5047-5051	RDVs	_	
24-14	5051-5052	)	_	
24-15	5053-5055	in	_	
24-16	5056-5057	a	_	
24-17	5058-5064	unique	_	
24-18	5065-5071	sample	_	
24-19	5072-5074	of	_	
24-20	5075-5088	first-episode	_	
24-21	5089-5104	treatment-naive	_	
24-22	5105-5118	schizophrenia	_	
24-23	5119-5127	patients	_	
24-24	5128-5136	relative	_	
24-25	5137-5139	to	_	
24-26	5140-5147	healthy	_	
24-27	5148-5156	controls	_	
24-28	5157-5159	by	_	
24-29	5160-5165	using	_	
24-30	5166-5177	whole-exome	_	
24-31	5178-5188	sequencing	_	
24-32	5189-5197	approach	_	
24-33	5197-5198	,	_	
24-34	5199-5202	and	_	
24-35	5203-5207	then	_	
24-36	5208-5213	apply	_	
24-37	5214-5218	Gene	_	
24-38	5219-5227	Ontology	_	
24-39	5228-5229	(	_	
24-40	5229-5231	GO	_	
24-41	5231-5232	)	_	
24-42	5233-5243	enrichment	_	
24-43	5244-5252	strategy	_	
24-44	5253-5255	to	_	
24-45	5256-5264	identify	_	
24-46	5265-5269	gene	_	
24-47	5270-5278	pathways	_	
24-48	5278-5279	.	_	

#Text=Consequently, we focused on the RDVs in DNA repair and cell cycle pathways for the following reasons.
25-1	5280-5292	Consequently	_	
25-2	5292-5293	,	_	
25-3	5294-5296	we	_	
25-4	5297-5304	focused	_	
25-5	5305-5307	on	_	
25-6	5308-5311	the	_	
25-7	5312-5316	RDVs	_	
25-8	5317-5319	in	_	
25-9	5320-5323	DNA	_	
25-10	5324-5330	repair	_	
25-11	5331-5334	and	_	
25-12	5335-5339	cell	_	
25-13	5340-5345	cycle	_	
25-14	5346-5354	pathways	_	
25-15	5355-5358	for	_	
25-16	5359-5362	the	_	
25-17	5363-5372	following	_	
25-18	5373-5380	reasons	_	
25-19	5380-5381	.	_	

#Text=First, the majority of these genes in DNA repair and cell cycle pathways are most highly expressed in various brain regions, such as hippocampus; previous studies suggested indeed that genes involved in the regulation of cell cycle and DNA repair significantly influence the hippocampus function in schizophrenia.
26-1	5382-5387	First	_	
26-2	5387-5388	,	_	
26-3	5389-5392	the	_	
26-4	5393-5401	majority	_	
26-5	5402-5404	of	_	
26-6	5405-5410	these	_	
26-7	5411-5416	genes	_	
26-8	5417-5419	in	_	
26-9	5420-5423	DNA	_	
26-10	5424-5430	repair	_	
26-11	5431-5434	and	_	
26-12	5435-5439	cell	_	
26-13	5440-5445	cycle	_	
26-14	5446-5454	pathways	_	
26-15	5455-5458	are	_	
26-16	5459-5463	most	_	
26-17	5464-5470	highly	_	
26-18	5471-5480	expressed	_	
26-19	5481-5483	in	_	
26-20	5484-5491	various	_	
26-21	5492-5497	brain	_	
26-22	5498-5505	regions	_	
26-23	5505-5506	,	_	
26-24	5507-5511	such	_	
26-25	5512-5514	as	_	
26-26	5515-5526	hippocampus	_	
26-27	5526-5527	;	_	
26-28	5528-5536	previous	_	
26-29	5537-5544	studies	_	
26-30	5545-5554	suggested	_	
26-31	5555-5561	indeed	_	
26-32	5562-5566	that	_	
26-33	5567-5572	genes	_	
26-34	5573-5581	involved	_	
26-35	5582-5584	in	_	
26-36	5585-5588	the	_	
26-37	5589-5599	regulation	_	
26-38	5600-5602	of	_	
26-39	5603-5607	cell	_	
26-40	5608-5613	cycle	_	
26-41	5614-5617	and	_	
26-42	5618-5621	DNA	_	
26-43	5622-5628	repair	_	
26-44	5629-5642	significantly	_	
26-45	5643-5652	influence	_	
26-46	5653-5656	the	_	
26-47	5657-5668	hippocampus	_	
26-48	5669-5677	function	_	
26-49	5678-5680	in	_	
26-50	5681-5694	schizophrenia	_	
26-51	5694-5695	.	_	

#Text=However, how the expression profile of these genes in cell cycle and DNA repair pathways map spatially and temporally during the critical neurodevelopmental stage in specifically the hippocampus in schizophrenia remains unclear.
27-1	5696-5703	However	_	
27-2	5703-5704	,	_	
27-3	5705-5708	how	_	
27-4	5709-5712	the	_	
27-5	5713-5723	expression	_	
27-6	5724-5731	profile	_	
27-7	5732-5734	of	_	
27-8	5735-5740	these	_	
27-9	5741-5746	genes	_	
27-10	5747-5749	in	_	
27-11	5750-5754	cell	_	
27-12	5755-5760	cycle	_	
27-13	5761-5764	and	_	
27-14	5765-5768	DNA	_	
27-15	5769-5775	repair	_	
27-16	5776-5784	pathways	_	
27-17	5785-5788	map	_	
27-18	5789-5798	spatially	_	
27-19	5799-5802	and	_	
27-20	5803-5813	temporally	_	
27-21	5814-5820	during	_	
27-22	5821-5824	the	_	
27-23	5825-5833	critical	_	
27-24	5834-5852	neurodevelopmental	_	
27-25	5853-5858	stage	_	
27-26	5859-5861	in	_	
27-27	5862-5874	specifically	_	
27-28	5875-5878	the	_	
27-29	5879-5890	hippocampus	_	
27-30	5891-5893	in	_	
27-31	5894-5907	schizophrenia	_	
27-32	5908-5915	remains	_	
27-33	5916-5923	unclear	_	
27-34	5923-5924	.	_	

#Text=We therefore hypothesized that we could distinguish two genetic subtypes in schizophrenia, one with RDVs and one without RDVs, as related to hippocampal developmental function.
28-1	5925-5927	We	_	
28-2	5928-5937	therefore	_	
28-3	5938-5950	hypothesized	_	
28-4	5951-5955	that	_	
28-5	5956-5958	we	_	
28-6	5959-5964	could	_	
28-7	5965-5976	distinguish	_	
28-8	5977-5980	two	_	
28-9	5981-5988	genetic	_	
28-10	5989-5997	subtypes	_	
28-11	5998-6000	in	_	
28-12	6001-6014	schizophrenia	_	
28-13	6014-6015	,	_	
28-14	6016-6019	one	_	
28-15	6020-6024	with	_	
28-16	6025-6029	RDVs	_	
28-17	6030-6033	and	_	
28-18	6034-6037	one	_	
28-19	6038-6045	without	_	
28-20	6046-6050	RDVs	_	
28-21	6050-6051	,	_	
28-22	6052-6054	as	_	
28-23	6055-6062	related	_	
28-24	6063-6065	to	_	
28-25	6066-6077	hippocampal	_	
28-26	6078-6091	developmental	_	
28-27	6092-6100	function	_	
28-28	6100-6101	.	_	

#Text=On the basis of these considerations, the second specific aim consisted of measuring especially rsFC (as controlled for by structural volume) of the hippocampus in the same patients using brain magnetic resonance imaging (MRI), and to explore the relationship among genes, rsFC of the hippocampus and related neurocognitive functions.
29-1	6102-6104	On	_	
29-2	6105-6108	the	_	
29-3	6109-6114	basis	_	
29-4	6115-6117	of	_	
29-5	6118-6123	these	_	
29-6	6124-6138	considerations	_	
29-7	6138-6139	,	_	
29-8	6140-6143	the	_	
29-9	6144-6150	second	_	
29-10	6151-6159	specific	_	
29-11	6160-6163	aim	_	
29-12	6164-6173	consisted	_	
29-13	6174-6176	of	_	
29-14	6177-6186	measuring	_	
29-15	6187-6197	especially	_	
29-16	6198-6202	rsFC	_	
29-17	6203-6204	(	_	
29-18	6204-6206	as	_	
29-19	6207-6217	controlled	_	
29-20	6218-6221	for	_	
29-21	6222-6224	by	_	
29-22	6225-6235	structural	_	
29-23	6236-6242	volume	_	
29-24	6242-6243	)	_	
29-25	6244-6246	of	_	
29-26	6247-6250	the	_	
29-27	6251-6262	hippocampus	_	
29-28	6263-6265	in	_	
29-29	6266-6269	the	_	
29-30	6270-6274	same	_	
29-31	6275-6283	patients	_	
29-32	6284-6289	using	_	
29-33	6290-6295	brain	_	
29-34	6296-6304	magnetic	_	
29-35	6305-6314	resonance	_	
29-36	6315-6322	imaging	_	
29-37	6323-6324	(	_	
29-38	6324-6327	MRI	_	
29-39	6327-6328	)	_	
29-40	6328-6329	,	_	
29-41	6330-6333	and	_	
29-42	6334-6336	to	_	
29-43	6337-6344	explore	_	
29-44	6345-6348	the	_	
29-45	6349-6361	relationship	_	
29-46	6362-6367	among	_	
29-47	6368-6373	genes	_	
29-48	6373-6374	,	_	
29-49	6375-6379	rsFC	_	
29-50	6380-6382	of	_	
29-51	6383-6386	the	_	
29-52	6387-6398	hippocampus	_	
29-53	6399-6402	and	_	
29-54	6403-6410	related	_	
29-55	6411-6425	neurocognitive	_	
29-56	6426-6435	functions	_	
29-57	6435-6436	.	_	

#Text=We hypothesized different hippocampal rsFC patterns in those schizophrenic patients with RDVs when compared with the ones without RDVs.
30-1	6437-6439	We	_	
30-2	6440-6452	hypothesized	_	
30-3	6453-6462	different	_	
30-4	6463-6474	hippocampal	_	
30-5	6475-6479	rsFC	_	
30-6	6480-6488	patterns	_	
30-7	6489-6491	in	_	
30-8	6492-6497	those	_	
30-9	6498-6511	schizophrenic	_	
30-10	6512-6520	patients	_	
30-11	6521-6525	with	_	
30-12	6526-6530	RDVs	_	
30-13	6531-6535	when	_	
30-14	6536-6544	compared	_	
30-15	6545-6549	with	_	
30-16	6550-6553	the	_	
30-17	6554-6558	ones	_	
30-18	6559-6566	without	_	
30-19	6567-6571	RDVs	_	
30-20	6571-6572	.	_	

#Text=To further underline hippocampal involvement, we included cognitive measures like spatial and logical memory that have been shown to be associated with specifically hippocampal function.
31-1	6573-6575	To	_	
31-2	6576-6583	further	_	
31-3	6584-6593	underline	_	
31-4	6594-6605	hippocampal	_	
31-5	6606-6617	involvement	_	
31-6	6617-6618	,	_	
31-7	6619-6621	we	_	
31-8	6622-6630	included	_	
31-9	6631-6640	cognitive	_	
31-10	6641-6649	measures	_	
31-11	6650-6654	like	_	
31-12	6655-6662	spatial	_	
31-13	6663-6666	and	_	
31-14	6667-6674	logical	_	
31-15	6675-6681	memory	_	
31-16	6682-6686	that	_	
31-17	6687-6691	have	_	
31-18	6692-6696	been	_	
31-19	6697-6702	shown	_	
31-20	6703-6705	to	_	
31-21	6706-6708	be	_	
31-22	6709-6719	associated	_	
31-23	6720-6724	with	_	
31-24	6725-6737	specifically	_	
31-25	6738-6749	hippocampal	_	
31-26	6750-6758	function	_	
31-27	6758-6759	.	_	

#Text=We hypothesized that schizophrenic patients with RDVs may have different memory-related cognitive functions relative to schizophrenic patients without RDVs.
32-1	6760-6762	We	_	
32-2	6763-6775	hypothesized	_	
32-3	6776-6780	that	_	
32-4	6781-6794	schizophrenic	_	
32-5	6795-6803	patients	_	
32-6	6804-6808	with	_	
32-7	6809-6813	RDVs	_	
32-8	6814-6817	may	_	
32-9	6818-6822	have	_	
32-10	6823-6832	different	_	
32-11	6833-6847	memory-related	_	
32-12	6848-6857	cognitive	_	
32-13	6858-6867	functions	_	
32-14	6868-6876	relative	_	
32-15	6877-6879	to	_	
32-16	6880-6893	schizophrenic	_	
32-17	6894-6902	patients	_	
32-18	6903-6910	without	_	
32-19	6911-6915	RDVs	_	
32-20	6915-6916	.	_	

#Text=There are several unique advantages in the present study.
33-1	6917-6922	There	_	
33-2	6923-6926	are	_	
33-3	6927-6934	several	_	
33-4	6935-6941	unique	_	
33-5	6942-6952	advantages	_	
33-6	6953-6955	in	_	
33-7	6956-6959	the	_	
33-8	6960-6967	present	_	
33-9	6968-6973	study	_	
33-10	6973-6974	.	_	

#Text=First, this is the first investigation, to our knowledge, to study the contribution of RDVs to the imaging and neurocognitive phenotype of schizophrenia.
34-1	6975-6980	First	_	
34-2	6980-6981	,	_	
34-3	6982-6986	this	_	
34-4	6987-6989	is	_	
34-5	6990-6993	the	_	
34-6	6994-6999	first	_	
34-7	7000-7013	investigation	_	
34-8	7013-7014	,	_	
34-9	7015-7017	to	_	
34-10	7018-7021	our	_	
34-11	7022-7031	knowledge	_	
34-12	7031-7032	,	_	
34-13	7033-7035	to	_	
34-14	7036-7041	study	_	
34-15	7042-7045	the	_	
34-16	7046-7058	contribution	_	
34-17	7059-7061	of	_	
34-18	7062-7066	RDVs	_	
34-19	7067-7069	to	_	
34-20	7070-7073	the	_	
34-21	7074-7081	imaging	_	
34-22	7082-7085	and	_	
34-23	7086-7100	neurocognitive	_	
34-24	7101-7110	phenotype	_	
34-25	7111-7113	of	_	
34-26	7114-7127	schizophrenia	_	
34-27	7127-7128	.	_	

#Text=Second, we recruited first-episode treatment-naive patients with schizophrenia to rule out the confounding factors of chronicity of the illness and treatment effects on neuroimaging and neurocognitive assessments.
35-1	7129-7135	Second	_	
35-2	7135-7136	,	_	
35-3	7137-7139	we	_	
35-4	7140-7149	recruited	_	
35-5	7150-7163	first-episode	_	
35-6	7164-7179	treatment-naive	_	
35-7	7180-7188	patients	_	
35-8	7189-7193	with	_	
35-9	7194-7207	schizophrenia	_	
35-10	7208-7210	to	_	
35-11	7211-7215	rule	_	
35-12	7216-7219	out	_	
35-13	7220-7223	the	_	
35-14	7224-7235	confounding	_	
35-15	7236-7243	factors	_	
35-16	7244-7246	of	_	
35-17	7247-7257	chronicity	_	
35-18	7258-7260	of	_	
35-19	7261-7264	the	_	
35-20	7265-7272	illness	_	
35-21	7273-7276	and	_	
35-22	7277-7286	treatment	_	
35-23	7287-7294	effects	_	
35-24	7295-7297	on	_	
35-25	7298-7310	neuroimaging	_	
35-26	7311-7314	and	_	
35-27	7315-7329	neurocognitive	_	
35-28	7330-7341	assessments	_	
35-29	7341-7342	.	_	

#Text=Third, extending limits on the power to identifying specific loci responsible for the disorder, we improve the definition of the phenotype and/or reducing the phenotypic complexity of schizophrenia for genetic studies by combining the latter with cognitive (for example, neuropsychological) and neural (for example, neuroimaging measures) that are more closely related to the phenotype.
36-1	7343-7348	Third	_	
36-2	7348-7349	,	_	
36-3	7350-7359	extending	_	
36-4	7360-7366	limits	_	
36-5	7367-7369	on	_	
36-6	7370-7373	the	_	
36-7	7374-7379	power	_	
36-8	7380-7382	to	_	
36-9	7383-7394	identifying	_	
36-10	7395-7403	specific	_	
36-11	7404-7408	loci	_	
36-12	7409-7420	responsible	_	
36-13	7421-7424	for	_	
36-14	7425-7428	the	_	
36-15	7429-7437	disorder	_	
36-16	7437-7438	,	_	
36-17	7439-7441	we	_	
36-18	7442-7449	improve	_	
36-19	7450-7453	the	_	
36-20	7454-7464	definition	_	
36-21	7465-7467	of	_	
36-22	7468-7471	the	_	
36-23	7472-7481	phenotype	_	
36-24	7482-7485	and	_	
36-25	7485-7486	/	_	
36-26	7486-7488	or	_	
36-27	7489-7497	reducing	_	
36-28	7498-7501	the	_	
36-29	7502-7512	phenotypic	_	
36-30	7513-7523	complexity	_	
36-31	7524-7526	of	_	
36-32	7527-7540	schizophrenia	_	
36-33	7541-7544	for	_	
36-34	7545-7552	genetic	_	
36-35	7553-7560	studies	_	
36-36	7561-7563	by	_	
36-37	7564-7573	combining	_	
36-38	7574-7577	the	_	
36-39	7578-7584	latter	_	
36-40	7585-7589	with	_	
36-41	7590-7599	cognitive	_	
36-42	7600-7601	(	_	
36-43	7601-7604	for	_	
36-44	7605-7612	example	_	
36-45	7612-7613	,	_	
36-46	7614-7632	neuropsychological	_	
36-47	7632-7633	)	_	
36-48	7634-7637	and	_	
36-49	7638-7644	neural	_	
36-50	7645-7646	(	_	
36-51	7646-7649	for	_	
36-52	7650-7657	example	_	
36-53	7657-7658	,	_	
36-54	7659-7671	neuroimaging	_	
36-55	7672-7680	measures	_	
36-56	7680-7681	)	_	
36-57	7682-7686	that	_	
36-58	7687-7690	are	_	
36-59	7691-7695	more	_	
36-60	7696-7703	closely	_	
36-61	7704-7711	related	_	
36-62	7712-7714	to	_	
36-63	7715-7718	the	_	
36-64	7719-7728	phenotype	_	
36-65	7728-7729	.	_	

#Text=Materials and methods
#Text=Samples
#Text=There were total 234 participants including 97 first-episode treatment-naive patients with schizophrenia and 137 healthy controls.
37-1	7730-7739	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]	
37-2	7740-7743	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]	
37-3	7744-7751	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]	
37-4	7752-7759	Samples	_	
37-5	7760-7765	There	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-6	7766-7770	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-7	7771-7776	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-8	7777-7780	234	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-9	7781-7793	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-10	7794-7803	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-11	7804-7806	97	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-12	7807-7820	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-13	7821-7836	treatment-naive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-14	7837-7845	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-15	7846-7850	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-16	7851-7864	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-17	7865-7868	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-18	7869-7872	137	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-19	7873-7880	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-20	7881-7889	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
37-21	7889-7890	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=Patients with schizophrenia were recruited at the Mental Health Centre of the West China Hospital, Sichuan University, China.
38-1	7891-7899	Patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-2	7900-7904	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-3	7905-7918	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-4	7919-7923	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-5	7924-7933	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-6	7934-7936	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-7	7937-7940	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-8	7941-7947	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-9	7948-7954	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-10	7955-7961	Centre	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-11	7962-7964	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-12	7965-7968	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-13	7969-7973	West	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-14	7974-7979	China	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-15	7980-7988	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-16	7988-7989	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-17	7990-7997	Sichuan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-18	7998-8008	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-19	8008-8009	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-20	8010-8015	China	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
38-21	8015-8016	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	

#Text=Healthy volunteers were recruited from the community.
39-1	8017-8024	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-2	8025-8035	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-3	8036-8040	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-4	8041-8050	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-5	8051-8055	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-6	8056-8059	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-7	8060-8069	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-8	8069-8070	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	

#Text=The study was approved by the ethical committee in West China Hospital of Sichuan University.
40-1	8071-8074	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-2	8075-8080	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-3	8081-8084	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-4	8085-8093	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-5	8094-8096	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-6	8097-8100	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-7	8101-8108	ethical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-8	8109-8118	committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-9	8119-8121	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-10	8122-8126	West	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-11	8127-8132	China	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-12	8133-8141	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-13	8142-8144	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-14	8145-8152	Sichuan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-15	8153-8163	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-16	8163-8164	.	_	

#Text=All participants were Han Chinese and provided written informed consent for their participation in this study.
41-1	8165-8168	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
41-2	8169-8181	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
41-3	8182-8186	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
41-4	8187-8190	Han	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
41-5	8191-8198	Chinese	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
41-6	8199-8202	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
41-7	8203-8211	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
41-8	8212-8219	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
41-9	8220-8228	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
41-10	8229-8236	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
41-11	8237-8240	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
41-12	8241-8246	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
41-13	8247-8260	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
41-14	8261-8263	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
41-15	8264-8268	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
41-16	8269-8274	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
41-17	8274-8275	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	

#Text=Clinical and memory assessments
#Text=All patients were interviewed by a trained psychiatrist using the Structured Clinical Interview for the DSM-IV (SCID).
42-1	8276-8284	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
42-2	8285-8288	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
42-3	8289-8295	memory	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
42-4	8296-8307	assessments	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
42-5	8308-8311	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
42-6	8312-8320	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
42-7	8321-8325	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
42-8	8326-8337	interviewed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
42-9	8338-8340	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
42-10	8341-8342	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
42-11	8343-8350	trained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
42-12	8351-8363	psychiatrist	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
42-13	8364-8369	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
42-14	8370-8373	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
42-15	8374-8384	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
42-16	8385-8393	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
42-17	8394-8403	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
42-18	8404-8407	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
42-19	8408-8411	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
42-20	8412-8418	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
42-21	8419-8420	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
42-22	8420-8424	SCID	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
42-23	8424-8425	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
42-24	8425-8426	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	

#Text=DSM-IV criteria for schizophrenia were used for diagnosis.
43-1	8427-8433	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-2	8434-8442	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-3	8443-8446	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-4	8447-8460	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-5	8461-8465	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-6	8466-8470	used	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-7	8471-8474	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-8	8475-8484	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-9	8484-8485	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=Those who were initially diagnosed with schizophrenia from psychosis due to the illness duration (less than 6 months) were followed up for at least 6 months to meet the DSM-IV criteria for schizophrenia.
44-1	8486-8491	Those	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-2	8492-8495	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-3	8496-8500	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-4	8501-8510	initially	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-5	8511-8520	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-6	8521-8525	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-7	8526-8539	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[14]	
44-8	8540-8544	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-9	8545-8554	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-10	8555-8558	due	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-11	8559-8561	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-12	8562-8565	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-13	8566-8573	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-14	8574-8582	duration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-15	8583-8584	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-16	8584-8588	less	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-17	8589-8593	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-18	8594-8595	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-19	8596-8602	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-20	8602-8603	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-21	8604-8608	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-22	8609-8617	followed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-23	8618-8620	up	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-24	8621-8624	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-25	8625-8627	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-26	8628-8633	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-27	8634-8635	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-28	8636-8642	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-29	8643-8645	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-30	8646-8650	meet	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-31	8651-8654	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-32	8655-8661	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-33	8662-8670	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-34	8671-8674	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-35	8675-8688	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
44-36	8688-8689	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=Psychopathology associated with schizophrenia was evaluated using the positive and negative syndrome scale.
45-1	8690-8705	Psychopathology	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
45-2	8706-8716	associated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
45-3	8717-8721	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
45-4	8722-8735	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[15]	
45-5	8736-8739	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
45-6	8740-8749	evaluated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
45-7	8750-8755	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
45-8	8756-8759	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
45-9	8760-8768	positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[16]	
45-10	8769-8772	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[16]	
45-11	8773-8781	negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[16]	
45-12	8782-8790	syndrome	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[16]	
45-13	8791-8796	scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[16]	
45-14	8796-8797	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[16]	

#Text=Healthy controls were screened with the SCID-P non-patient version for the lifetime absence of psychiatric illnesses.
46-1	8798-8805	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-2	8806-8814	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-3	8815-8819	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-4	8820-8828	screened	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-5	8829-8833	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-6	8834-8837	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-7	8838-8844	SCID-P	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-8	8845-8856	non-patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-9	8857-8864	version	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-10	8865-8868	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-11	8869-8872	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-12	8873-8881	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-13	8882-8889	absence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-14	8890-8892	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-15	8893-8904	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-16	8905-8914	illnesses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-17	8914-8915	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=Subjects with the existence of organic brain disorders, alcohol or drug abuse, pregnancy or any severe physical illness, such as brain tumor or epilepsy, were excluded from the study.
47-1	8916-8924	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-2	8925-8929	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-3	8930-8933	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-4	8934-8943	existence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-5	8944-8946	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-6	8947-8954	organic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-7	8955-8960	brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-8	8961-8970	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-9	8970-8971	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-10	8972-8979	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-11	8980-8982	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-12	8983-8987	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-13	8988-8993	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-14	8993-8994	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-15	8995-9004	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-16	9005-9007	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-17	9008-9011	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-18	9012-9018	severe	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-19	9019-9027	physical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-20	9028-9035	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-21	9035-9036	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-22	9037-9041	such	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-23	9042-9044	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-24	9045-9050	brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-25	9051-9056	tumor	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-26	9057-9059	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-27	9060-9068	epilepsy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-28	9068-9069	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-29	9070-9074	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-30	9075-9083	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-31	9084-9088	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-32	9089-9092	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-33	9093-9098	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
47-34	9098-9099	.	_	

#Text=Schizophrenic patients and healthy controls completed SWM test in the Cambridge Neuropsychological Test Automated Battery (CANTAB; http://www.cantab.com) and immediate and delayed (30 min) logical memory subtest of the Wechsler Memory Scale, respectively.
48-1	9100-9113	Schizophrenic	_	
48-2	9114-9122	patients	_	
48-3	9123-9126	and	_	
48-4	9127-9134	healthy	_	
48-5	9135-9143	controls	_	
48-6	9144-9153	completed	_	
48-7	9154-9157	SWM	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-8	9158-9162	test	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-9	9163-9165	in	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-10	9166-9169	the	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-11	9170-9179	Cambridge	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-12	9180-9198	Neuropsychological	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-13	9199-9203	Test	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-14	9204-9213	Automated	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-15	9214-9221	Battery	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-16	9222-9223	(	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-17	9223-9229	CANTAB	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-18	9229-9230	;	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-19	9231-9235	http	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-20	9235-9236	:	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-21	9236-9237	/	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-22	9237-9238	/	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-23	9238-9252	www.cantab.com	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-24	9252-9253	)	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-25	9254-9257	and	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-26	9258-9267	immediate	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-27	9268-9271	and	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-28	9272-9279	delayed	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-29	9280-9281	(	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-30	9281-9283	30	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-31	9284-9287	min	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-32	9287-9288	)	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-33	9289-9296	logical	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-34	9297-9303	memory	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-35	9304-9311	subtest	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-36	9312-9314	of	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-37	9315-9318	the	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-38	9319-9327	Wechsler	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-39	9328-9334	Memory	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-40	9335-9340	Scale	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-41	9340-9341	,	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]	
48-42	9342-9354	respectively	_	
48-43	9354-9355	.	_	

#Text=MRI data acquisition
#Text=Overall, 74 healthy controls and 74 patients with schizophrenia underwent structural MRI scans on a Signa 3.0-T scanner (General Electric, Medical Systems, Milwaukee, WI, USA), whereas 65 healthy controls and 55 patients were scanned to obtain brain resting-state functional MRI in the Department of Radiology at West China Hospital.
49-1	9356-9359	MRI	_	
49-2	9360-9364	data	_	
49-3	9365-9376	acquisition	_	
49-4	9377-9384	Overall	_	
49-5	9384-9385	,	_	
49-6	9386-9388	74	_	
49-7	9389-9396	healthy	_	
49-8	9397-9405	controls	_	
49-9	9406-9409	and	_	
49-10	9410-9412	74	_	
49-11	9413-9421	patients	_	
49-12	9422-9426	with	_	
49-13	9427-9440	schizophrenia	_	
49-14	9441-9450	underwent	_	
49-15	9451-9461	structural	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[18]	
49-16	9462-9465	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[18]	
49-17	9466-9471	scans	_	
49-18	9472-9474	on	_	
49-19	9475-9476	a	_	
49-20	9477-9482	Signa	_	
49-21	9483-9486	3.0	_	
49-22	9486-9487	-	_	
49-23	9487-9488	T	_	
49-24	9489-9496	scanner	_	
49-25	9497-9498	(	_	
49-26	9498-9505	General	_	
49-27	9506-9514	Electric	_	
49-28	9514-9515	,	_	
49-29	9516-9523	Medical	_	
49-30	9524-9531	Systems	_	
49-31	9531-9532	,	_	
49-32	9533-9542	Milwaukee	_	
49-33	9542-9543	,	_	
49-34	9544-9546	WI	_	
49-35	9546-9547	,	_	
49-36	9548-9551	USA	_	
49-37	9551-9552	)	_	
49-38	9552-9553	,	_	
49-39	9554-9561	whereas	_	
49-40	9562-9564	65	_	
49-41	9565-9572	healthy	_	
49-42	9573-9581	controls	_	
49-43	9582-9585	and	_	
49-44	9586-9588	55	_	
49-45	9589-9597	patients	_	
49-46	9598-9602	were	_	
49-47	9603-9610	scanned	_	
49-48	9611-9613	to	_	
49-49	9614-9620	obtain	_	
49-50	9621-9626	brain	_	
49-51	9627-9640	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[19]	
49-52	9641-9651	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[19]	
49-53	9652-9655	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[19]	
49-54	9656-9658	in	_	
49-55	9659-9662	the	_	
49-56	9663-9673	Department	_	
49-57	9674-9676	of	_	
49-58	9677-9686	Radiology	_	
49-59	9687-9689	at	_	
49-60	9690-9694	West	_	
49-61	9695-9700	China	_	
49-62	9701-9709	Hospital	_	
49-63	9709-9710	.	_	

#Text=Detailed procedures of scanning are presented in Supplementary Information, sections 7 and 8.
50-1	9711-9719	Detailed	_	
50-2	9720-9730	procedures	_	
50-3	9731-9733	of	_	
50-4	9734-9742	scanning	_	
50-5	9743-9746	are	_	
50-6	9747-9756	presented	_	
50-7	9757-9759	in	_	
50-8	9760-9773	Supplementary	_	
50-9	9774-9785	Information	_	
50-10	9785-9786	,	_	
50-11	9787-9795	sections	_	
50-12	9796-9797	7	_	
50-13	9798-9801	and	_	
50-14	9802-9803	8	_	
50-15	9803-9804	.	_	

#Text=Sequencing and variant calling
#Text=All samples were sequenced using the TruSeq Exome Enrichment Kit (San Diego, CA, USA) optimized for IlluminaHiSeq2000 sequencing.
51-1	9805-9815	Sequencing	_	
51-2	9816-9819	and	_	
51-3	9820-9827	variant	_	
51-4	9828-9835	calling	_	
51-5	9836-9839	All	_	
51-6	9840-9847	samples	_	
51-7	9848-9852	were	_	
51-8	9853-9862	sequenced	_	
51-9	9863-9868	using	_	
51-10	9869-9872	the	_	
51-11	9873-9879	TruSeq	_	
51-12	9880-9885	Exome	_	
51-13	9886-9896	Enrichment	_	
51-14	9897-9900	Kit	_	
51-15	9901-9902	(	_	
51-16	9902-9905	San	_	
51-17	9906-9911	Diego	_	
51-18	9911-9912	,	_	
51-19	9913-9915	CA	_	
51-20	9915-9916	,	_	
51-21	9917-9920	USA	_	
51-22	9920-9921	)	_	
51-23	9922-9931	optimized	_	
51-24	9932-9935	for	_	
51-25	9936-9953	IlluminaHiSeq2000	_	
51-26	9954-9964	sequencing	_	
51-27	9964-9965	.	_	

#Text=The pipeline of raw data processing and variants calling is present in Supplementary Figure 2, which includes using Burrows-Wheeler Alignment tool alignment reads to the reference human genome (hg19); Picard tools (http://picard.sourceforge.net/) to collect quality statistics and fix read group problem; GATK for IN/DEL alignment; Samtools (http://samtools.sourceforge.net/) to filter out low-quality reads; and GATK to perform SNP and INDEL calling.
52-1	9966-9969	The	_	
52-2	9970-9978	pipeline	_	
52-3	9979-9981	of	_	
52-4	9982-9985	raw	_	
52-5	9986-9990	data	_	
52-6	9991-10001	processing	_	
52-7	10002-10005	and	_	
52-8	10006-10014	variants	_	
52-9	10015-10022	calling	_	
52-10	10023-10025	is	_	
52-11	10026-10033	present	_	
52-12	10034-10036	in	_	
52-13	10037-10050	Supplementary	_	
52-14	10051-10057	Figure	_	
52-15	10058-10059	2	_	
52-16	10059-10060	,	_	
52-17	10061-10066	which	_	
52-18	10067-10075	includes	_	
52-19	10076-10081	using	_	
52-20	10082-10097	Burrows-Wheeler	_	
52-21	10098-10107	Alignment	_	
52-22	10108-10112	tool	_	
52-23	10113-10122	alignment	_	
52-24	10123-10128	reads	_	
52-25	10129-10131	to	_	
52-26	10132-10135	the	_	
52-27	10136-10145	reference	_	
52-28	10146-10151	human	_	
52-29	10152-10158	genome	_	
52-30	10159-10160	(	_	
52-31	10160-10164	hg19	_	
52-32	10164-10165	)	_	
52-33	10165-10166	;	_	
52-34	10167-10173	Picard	_	
52-35	10174-10179	tools	_	
52-36	10180-10181	(	_	
52-37	10181-10185	http	_	
52-38	10185-10186	:	_	
52-39	10186-10187	/	_	
52-40	10187-10188	/	_	
52-41	10188-10210	picard.sourceforge.net	_	
52-42	10210-10211	/	_	
52-43	10211-10212	)	_	
52-44	10213-10215	to	_	
52-45	10216-10223	collect	_	
52-46	10224-10231	quality	_	
52-47	10232-10242	statistics	_	
52-48	10243-10246	and	_	
52-49	10247-10250	fix	_	
52-50	10251-10255	read	_	
52-51	10256-10261	group	_	
52-52	10262-10269	problem	_	
52-53	10269-10270	;	_	
52-54	10271-10275	GATK	_	
52-55	10276-10279	for	_	
52-56	10280-10282	IN	_	
52-57	10282-10283	/	_	
52-58	10283-10286	DEL	_	
52-59	10287-10296	alignment	_	
52-60	10296-10297	;	_	
52-61	10298-10306	Samtools	_	
52-62	10307-10308	(	_	
52-63	10308-10312	http	_	
52-64	10312-10313	:	_	
52-65	10313-10314	/	_	
52-66	10314-10315	/	_	
52-67	10315-10339	samtools.sourceforge.net	_	
52-68	10339-10340	/	_	
52-69	10340-10341	)	_	
52-70	10342-10344	to	_	
52-71	10345-10351	filter	_	
52-72	10352-10355	out	_	
52-73	10356-10367	low-quality	_	
52-74	10368-10373	reads	_	
52-75	10373-10374	;	_	
52-76	10375-10378	and	_	
52-77	10379-10383	GATK	_	
52-78	10384-10386	to	_	
52-79	10387-10394	perform	_	
52-80	10395-10398	SNP	_	
52-81	10399-10402	and	_	
52-82	10403-10408	INDEL	_	
52-83	10409-10416	calling	_	
52-84	10416-10417	.	_	

#Text=Validation of selected variants was conducted by Sanger sequencing.
53-1	10418-10428	Validation	_	
53-2	10429-10431	of	_	
53-3	10432-10440	selected	_	
53-4	10441-10449	variants	_	
53-5	10450-10453	was	_	
53-6	10454-10463	conducted	_	
53-7	10464-10466	by	_	
53-8	10467-10473	Sanger	_	
53-9	10474-10484	sequencing	_	
53-10	10484-10485	.	_	

#Text=Data analysis
#Text=We use PLINK and KGGSeq (http://statgenpro.psychiatry.hku.hk/limx/kggseq/doc/UserManual.html) to perform individual and variants' quality control.
54-1	10486-10490	Data	_	
54-2	10491-10499	analysis	_	
54-3	10500-10502	We	_	
54-4	10503-10506	use	_	
54-5	10507-10512	PLINK	_	
54-6	10513-10516	and	_	
54-7	10517-10523	KGGSeq	_	
54-8	10524-10525	(	_	
54-9	10525-10529	http	_	
54-10	10529-10530	:	_	
54-11	10530-10531	/	_	
54-12	10531-10532	/	_	
54-13	10532-10560	statgenpro.psychiatry.hku.hk	_	
54-14	10560-10561	/	_	
54-15	10561-10565	limx	_	
54-16	10565-10566	/	_	
54-17	10566-10572	kggseq	_	
54-18	10572-10573	/	_	
54-19	10573-10576	doc	_	
54-20	10576-10577	/	_	
54-21	10577-10592	UserManual.html	_	
54-22	10592-10593	)	_	
54-23	10594-10596	to	_	
54-24	10597-10604	perform	_	
54-25	10605-10615	individual	_	
54-26	10616-10619	and	_	
54-27	10620-10628	variants	_	
54-28	10628-10629	'	_	
54-29	10630-10637	quality	_	
54-30	10638-10645	control	_	
54-31	10645-10646	.	_	

#Text=We use software KGGSeq to integrate databases to annotate the minor allele frequency of variants, including Hapmap and 1000 Genome.
55-1	10647-10649	We	_	
55-2	10650-10653	use	_	
55-3	10654-10662	software	_	
55-4	10663-10669	KGGSeq	_	
55-5	10670-10672	to	_	
55-6	10673-10682	integrate	_	
55-7	10683-10692	databases	_	
55-8	10693-10695	to	_	
55-9	10696-10704	annotate	_	
55-10	10705-10708	the	_	
55-11	10709-10714	minor	_	
55-12	10715-10721	allele	_	
55-13	10722-10731	frequency	_	
55-14	10732-10734	of	_	
55-15	10735-10743	variants	_	
55-16	10743-10744	,	_	
55-17	10745-10754	including	_	
55-18	10755-10761	Hapmap	_	
55-19	10762-10765	and	_	
55-20	10766-10770	1000	_	
55-21	10771-10777	Genome	_	
55-22	10777-10778	.	_	

#Text=The cutoff frequency was set at 0.1% for rare variance.
56-1	10779-10782	The	_	
56-2	10783-10789	cutoff	_	
56-3	10790-10799	frequency	_	
56-4	10800-10803	was	_	
56-5	10804-10807	set	_	
56-6	10808-10810	at	_	
56-7	10811-10815	0.1%	_	
56-8	10816-10819	for	_	
56-9	10820-10824	rare	_	
56-10	10825-10833	variance	_	
56-11	10833-10834	.	_	

#Text=Methods implemented in PLINK/Seq (http://atgu.mgh.harvard.edu/plinkseq/) were employed for single site and gene-based association analysis.
57-1	10835-10842	Methods	_	
57-2	10843-10854	implemented	_	
57-3	10855-10857	in	_	
57-4	10858-10863	PLINK	_	
57-5	10863-10864	/	_	
57-6	10864-10867	Seq	_	
57-7	10868-10869	(	_	
57-8	10869-10873	http	_	
57-9	10873-10874	:	_	
57-10	10874-10875	/	_	
57-11	10875-10876	/	_	
57-12	10876-10896	atgu.mgh.harvard.edu	_	
57-13	10896-10897	/	_	
57-14	10897-10905	plinkseq	_	
57-15	10905-10906	/	_	
57-16	10906-10907	)	_	
57-17	10908-10912	were	_	
57-18	10913-10921	employed	_	
57-19	10922-10925	for	_	
57-20	10926-10932	single	_	
57-21	10933-10937	site	_	
57-22	10938-10941	and	_	
57-23	10942-10952	gene-based	_	
57-24	10953-10964	association	_	
57-25	10965-10973	analysis	_	
57-26	10973-10974	.	_	

#Text=After filtering, we performed GO enrichment analysis in 2895 mutations within 2442 genes in cases and 4484 mutations within 3481 genes in controls using GeneMANIA (http://www.genemania.org/).The results of enrichment indicated that two GO (GO: 0006281 and GO:0007049) only present in cases.
58-1	10975-10980	After	_	
58-2	10981-10990	filtering	_	
58-3	10990-10991	,	_	
58-4	10992-10994	we	_	
58-5	10995-11004	performed	_	
58-6	11005-11007	GO	_	
58-7	11008-11018	enrichment	_	
58-8	11019-11027	analysis	_	
58-9	11028-11030	in	_	
58-10	11031-11035	2895	_	
58-11	11036-11045	mutations	_	
58-12	11046-11052	within	_	
58-13	11053-11057	2442	_	
58-14	11058-11063	genes	_	
58-15	11064-11066	in	_	
58-16	11067-11072	cases	_	
58-17	11073-11076	and	_	
58-18	11077-11081	4484	_	
58-19	11082-11091	mutations	_	
58-20	11092-11098	within	_	
58-21	11099-11103	3481	_	
58-22	11104-11109	genes	_	
58-23	11110-11112	in	_	
58-24	11113-11121	controls	_	
58-25	11122-11127	using	_	
58-26	11128-11137	GeneMANIA	_	
58-27	11138-11139	(	_	
58-28	11139-11143	http	_	
58-29	11143-11144	:	_	
58-30	11144-11145	/	_	
58-31	11145-11146	/	_	
58-32	11146-11163	www.genemania.org	_	
58-33	11163-11164	/	_	
58-34	11164-11165	)	_	
58-35	11165-11166	.	_	
58-36	11166-11169	The	_	
58-37	11170-11177	results	_	
58-38	11178-11180	of	_	
58-39	11181-11191	enrichment	_	
58-40	11192-11201	indicated	_	
58-41	11202-11206	that	_	
58-42	11207-11210	two	_	
58-43	11211-11213	GO	_	
58-44	11214-11215	(	_	
58-45	11215-11217	GO	_	
58-46	11217-11218	:	_	
58-47	11219-11226	0006281	_	
58-48	11227-11230	and	_	
58-49	11231-11233	GO	_	
58-50	11233-11234	:	_	
58-51	11234-11241	0007049	_	
58-52	11241-11242	)	_	
58-53	11243-11247	only	_	
58-54	11248-11255	present	_	
58-55	11256-11258	in	_	
58-56	11259-11264	cases	_	
58-57	11264-11265	.	_	

#Text=We identified more mutations in controls (that is, 2895 mutations within 2442 genes in schizophrenic patients and 4484 mutations within 3481 genes in healthy controls) mainly because, in present study, the sample size in controls (134) is bigger than cases (94).
59-1	11266-11268	We	_	
59-2	11269-11279	identified	_	
59-3	11280-11284	more	_	
59-4	11285-11294	mutations	_	
59-5	11295-11297	in	_	
59-6	11298-11306	controls	_	
59-7	11307-11308	(	_	
59-8	11308-11312	that	_	
59-9	11313-11315	is	_	
59-10	11315-11316	,	_	
59-11	11317-11321	2895	_	
59-12	11322-11331	mutations	_	
59-13	11332-11338	within	_	
59-14	11339-11343	2442	_	
59-15	11344-11349	genes	_	
59-16	11350-11352	in	_	
59-17	11353-11366	schizophrenic	_	
59-18	11367-11375	patients	_	
59-19	11376-11379	and	_	
59-20	11380-11384	4484	_	
59-21	11385-11394	mutations	_	
59-22	11395-11401	within	_	
59-23	11402-11406	3481	_	
59-24	11407-11412	genes	_	
59-25	11413-11415	in	_	
59-26	11416-11423	healthy	_	
59-27	11424-11432	controls	_	
59-28	11432-11433	)	_	
59-29	11434-11440	mainly	_	
59-30	11441-11448	because	_	
59-31	11448-11449	,	_	
59-32	11450-11452	in	_	
59-33	11453-11460	present	_	
59-34	11461-11466	study	_	
59-35	11466-11467	,	_	
59-36	11468-11471	the	_	
59-37	11472-11478	sample	_	
59-38	11479-11483	size	_	
59-39	11484-11486	in	_	
59-40	11487-11495	controls	_	
59-41	11496-11497	(	_	
59-42	11497-11500	134	_	
59-43	11500-11501	)	_	
59-44	11502-11504	is	_	
59-45	11505-11511	bigger	_	
59-46	11512-11516	than	_	
59-47	11517-11522	cases	_	
59-48	11523-11524	(	_	
59-49	11524-11526	94	_	
59-50	11526-11527	)	_	
59-51	11527-11528	.	_	

#Text=The bigger sample size in controls provides the higher chance to identify mutations.
60-1	11529-11532	The	_	
60-2	11533-11539	bigger	_	
60-3	11540-11546	sample	_	
60-4	11547-11551	size	_	
60-5	11552-11554	in	_	
60-6	11555-11563	controls	_	
60-7	11564-11572	provides	_	
60-8	11573-11576	the	_	
60-9	11577-11583	higher	_	
60-10	11584-11590	chance	_	
60-11	11591-11593	to	_	
60-12	11594-11602	identify	_	
60-13	11603-11612	mutations	_	
60-14	11612-11613	.	_	

#Text=The weighted gene coexpression network analysis (WGCNA) was used for expression profile, all of which was carried out by the WGCNA R package.
61-1	11614-11617	The	_	
61-2	11618-11626	weighted	_	
61-3	11627-11631	gene	_	
61-4	11632-11644	coexpression	_	
61-5	11645-11652	network	_	
61-6	11653-11661	analysis	_	
61-7	11662-11663	(	_	
61-8	11663-11668	WGCNA	_	
61-9	11668-11669	)	_	
61-10	11670-11673	was	_	
61-11	11674-11678	used	_	
61-12	11679-11682	for	_	
61-13	11683-11693	expression	_	
61-14	11694-11701	profile	_	
61-15	11701-11702	,	_	
61-16	11703-11706	all	_	
61-17	11707-11709	of	_	
61-18	11710-11715	which	_	
61-19	11716-11719	was	_	
61-20	11720-11727	carried	_	
61-21	11728-11731	out	_	
61-22	11732-11734	by	_	
61-23	11735-11738	the	_	
61-24	11739-11744	WGCNA	_	
61-25	11745-11746	R	_	
61-26	11747-11754	package	_	
61-27	11754-11755	.	_	

#Text=All of Brain expression data from different points in life were acquired from a published study (The Human Brain Transcriptome).
62-1	11756-11759	All	_	
62-2	11760-11762	of	_	
62-3	11763-11768	Brain	_	
62-4	11769-11779	expression	_	
62-5	11780-11784	data	_	
62-6	11785-11789	from	_	
62-7	11790-11799	different	_	
62-8	11800-11806	points	_	
62-9	11807-11809	in	_	
62-10	11810-11814	life	_	
62-11	11815-11819	were	_	
62-12	11820-11828	acquired	_	
62-13	11829-11833	from	_	
62-14	11834-11835	a	_	
62-15	11836-11845	published	_	
62-16	11846-11851	study	_	
62-17	11852-11853	(	_	
62-18	11853-11856	The	_	
62-19	11857-11862	Human	_	
62-20	11863-11868	Brain	_	
62-21	11869-11882	Transcriptome	_	
62-22	11882-11883	)	_	
62-23	11883-11884	.	_	

#Text=Sample size and statistical power were conducted by the statistical software, Exome Power Calculation (http://darth.ssg.uab.edu:8080/epc/).
#Text=rsFC of bilateral hippocampus and six hippocampal subregions was calculated by seed-to-voxel analysis using Statistical Parametric Mapping (SPM8, http://www.fil.ion.ucl.ac.uk/spm) and data-processing assistant for resting-state functional MRI from resting-state functional MRI (Supplementary material).
63-1	11885-11891	Sample	_	
63-2	11892-11896	size	_	
63-3	11897-11900	and	_	
63-4	11901-11912	statistical	_	
63-5	11913-11918	power	_	
63-6	11919-11923	were	_	
63-7	11924-11933	conducted	_	
63-8	11934-11936	by	_	
63-9	11937-11940	the	_	
63-10	11941-11952	statistical	_	
63-11	11953-11961	software	_	
63-12	11961-11962	,	_	
63-13	11963-11968	Exome	_	
63-14	11969-11974	Power	_	
63-15	11975-11986	Calculation	_	
63-16	11987-11988	(	_	
63-17	11988-11992	http	_	
63-18	11992-11993	:	_	
63-19	11993-11994	/	_	
63-20	11994-11995	/	_	
63-21	11995-12012	darth.ssg.uab.edu	_	
63-22	12012-12013	:	_	
63-23	12013-12017	8080	_	
63-24	12017-12018	/	_	
63-25	12018-12021	epc	_	
63-26	12021-12022	/	_	
63-27	12022-12023	)	_	
63-28	12023-12024	.	_	
63-29	12025-12029	rsFC	_	
63-30	12030-12032	of	_	
63-31	12033-12042	bilateral	_	
63-32	12043-12054	hippocampus	_	
63-33	12055-12058	and	_	
63-34	12059-12062	six	_	
63-35	12063-12074	hippocampal	_	
63-36	12075-12085	subregions	_	
63-37	12086-12089	was	_	
63-38	12090-12100	calculated	_	
63-39	12101-12103	by	_	
63-40	12104-12117	seed-to-voxel	_	
63-41	12118-12126	analysis	_	
63-42	12127-12132	using	_	
63-43	12133-12144	Statistical	_	
63-44	12145-12155	Parametric	_	
63-45	12156-12163	Mapping	_	
63-46	12164-12165	(	_	
63-47	12165-12169	SPM8	_	
63-48	12169-12170	,	_	
63-49	12171-12175	http	_	
63-50	12175-12176	:	_	
63-51	12176-12177	/	_	
63-52	12177-12178	/	_	
63-53	12178-12199	www.fil.ion.ucl.ac.uk	_	
63-54	12199-12200	/	_	
63-55	12200-12203	spm	_	
63-56	12203-12204	)	_	
63-57	12205-12208	and	_	
63-58	12209-12224	data-processing	_	
63-59	12225-12234	assistant	_	
63-60	12235-12238	for	_	
63-61	12239-12252	resting-state	_	
63-62	12253-12263	functional	_	
63-63	12264-12267	MRI	_	
63-64	12268-12272	from	_	
63-65	12273-12286	resting-state	_	
63-66	12287-12297	functional	_	
63-67	12298-12301	MRI	_	
63-68	12302-12303	(	_	
63-69	12303-12316	Supplementary	_	
63-70	12317-12325	material	_	
63-71	12325-12326	)	_	
63-72	12326-12327	.	_	

#Text=The time courses averaged over all voxels of each hippocampus and six hippocampal subregions were extracted.
64-1	12328-12331	The	_	
64-2	12332-12336	time	_	
64-3	12337-12344	courses	_	
64-4	12345-12353	averaged	_	
64-5	12354-12358	over	_	
64-6	12359-12362	all	_	
64-7	12363-12369	voxels	_	
64-8	12370-12372	of	_	
64-9	12373-12377	each	_	
64-10	12378-12389	hippocampus	_	
64-11	12390-12393	and	_	
64-12	12394-12397	six	_	
64-13	12398-12409	hippocampal	_	
64-14	12410-12420	subregions	_	
64-15	12421-12425	were	_	
64-16	12426-12435	extracted	_	
64-17	12435-12436	.	_	

#Text=Pearson's correlation coefficients (r) between time courses of left/right hippocampus and all other voxels were calculated and transformed to Fisher's z-scores to derive rsFC maps.
65-1	12437-12446	Pearson's	_	
65-2	12447-12458	correlation	_	
65-3	12459-12471	coefficients	_	
65-4	12472-12473	(	_	
65-5	12473-12474	r	_	
65-6	12474-12475	)	_	
65-7	12476-12483	between	_	
65-8	12484-12488	time	_	
65-9	12489-12496	courses	_	
65-10	12497-12499	of	_	
65-11	12500-12504	left	_	
65-12	12504-12505	/	_	
65-13	12505-12510	right	_	
65-14	12511-12522	hippocampus	_	
65-15	12523-12526	and	_	
65-16	12527-12530	all	_	
65-17	12531-12536	other	_	
65-18	12537-12543	voxels	_	
65-19	12544-12548	were	_	
65-20	12549-12559	calculated	_	
65-21	12560-12563	and	_	
65-22	12564-12575	transformed	_	
65-23	12576-12578	to	_	
65-24	12579-12587	Fisher's	_	
65-25	12588-12596	z-scores	_	
65-26	12597-12599	to	_	
65-27	12600-12606	derive	_	
65-28	12607-12611	rsFC	_	
65-29	12612-12616	maps	_	
65-30	12616-12617	.	_	

#Text=Thus, 67 349 pairs of functional connectivity were calculated between right hippocampus and the other voxels of the brain, whereas 67 370 pairs of functional connectivity were computed between left hippocampus and the other voxels of the brain.
66-1	12618-12622	Thus	_	
66-2	12622-12623	,	_	
66-3	12624-12626	67	_	
66-4	12627-12630	349	_	
66-5	12631-12636	pairs	_	
66-6	12637-12639	of	_	
66-7	12640-12650	functional	_	
66-8	12651-12663	connectivity	_	
66-9	12664-12668	were	_	
66-10	12669-12679	calculated	_	
66-11	12680-12687	between	_	
66-12	12688-12693	right	_	
66-13	12694-12705	hippocampus	_	
66-14	12706-12709	and	_	
66-15	12710-12713	the	_	
66-16	12714-12719	other	_	
66-17	12720-12726	voxels	_	
66-18	12727-12729	of	_	
66-19	12730-12733	the	_	
66-20	12734-12739	brain	_	
66-21	12739-12740	,	_	
66-22	12741-12748	whereas	_	
66-23	12749-12751	67	_	
66-24	12752-12755	370	_	
66-25	12756-12761	pairs	_	
66-26	12762-12764	of	_	
66-27	12765-12775	functional	_	
66-28	12776-12788	connectivity	_	
66-29	12789-12793	were	_	
66-30	12794-12802	computed	_	
66-31	12803-12810	between	_	
66-32	12811-12815	left	_	
66-33	12816-12827	hippocampus	_	
66-34	12828-12831	and	_	
66-35	12832-12835	the	_	
66-36	12836-12841	other	_	
66-37	12842-12848	voxels	_	
66-38	12849-12851	of	_	
66-39	12852-12855	the	_	
66-40	12856-12861	brain	_	
66-41	12861-12862	.	_	

#Text=Statistical tests on the functional connectivity maps of hippocampus between patients with schizophrenia and healthy controls were performed using analysis of covariance with sex, age and education years, and volume of hippocampus as covariates in SPM8.
67-1	12863-12874	Statistical	_	
67-2	12875-12880	tests	_	
67-3	12881-12883	on	_	
67-4	12884-12887	the	_	
67-5	12888-12898	functional	_	
67-6	12899-12911	connectivity	_	
67-7	12912-12916	maps	_	
67-8	12917-12919	of	_	
67-9	12920-12931	hippocampus	_	
67-10	12932-12939	between	_	
67-11	12940-12948	patients	_	
67-12	12949-12953	with	_	
67-13	12954-12967	schizophrenia	_	
67-14	12968-12971	and	_	
67-15	12972-12979	healthy	_	
67-16	12980-12988	controls	_	
67-17	12989-12993	were	_	
67-18	12994-13003	performed	_	
67-19	13004-13009	using	_	
67-20	13010-13018	analysis	_	
67-21	13019-13021	of	_	
67-22	13022-13032	covariance	_	
67-23	13033-13037	with	_	
67-24	13038-13041	sex	_	
67-25	13041-13042	,	_	
67-26	13043-13046	age	_	
67-27	13047-13050	and	_	
67-28	13051-13060	education	_	
67-29	13061-13066	years	_	
67-30	13066-13067	,	_	
67-31	13068-13071	and	_	
67-32	13072-13078	volume	_	
67-33	13079-13081	of	_	
67-34	13082-13093	hippocampus	_	
67-35	13094-13096	as	_	
67-36	13097-13107	covariates	_	
67-37	13108-13110	in	_	
67-38	13111-13115	SPM8	_	
67-39	13115-13116	.	_	

#Text=The significant threshold was set at P<0.05, corrected for multiple comparisons based on Monte Carlo simulations.
68-1	13117-13120	The	_	
68-2	13121-13132	significant	_	
68-3	13133-13142	threshold	_	
68-4	13143-13146	was	_	
68-5	13147-13150	set	_	
68-6	13151-13153	at	_	
68-7	13154-13155	P	_	
68-8	13155-13156	<	_	
68-9	13156-13160	0.05	_	
68-10	13160-13161	,	_	
68-11	13162-13171	corrected	_	
68-12	13172-13175	for	_	
68-13	13176-13184	multiple	_	
68-14	13185-13196	comparisons	_	
68-15	13197-13202	based	_	
68-16	13203-13205	on	_	
68-17	13206-13211	Monte	_	
68-18	13212-13217	Carlo	_	
68-19	13218-13229	simulations	_	
68-20	13229-13230	.	_	

#Text=Subsequently, the mean Z-value of each cluster with a significant functional connectivity (FC) difference was extracted and were compared by analysis of variance followed by post hoc test (least significant difference) in SPSS 18.0, across patients with RDVs, patients without RDVs and healthy controls (SPSS, Chicago, IL, USA), significant level of P values were set at less than 0.05.
69-1	13231-13243	Subsequently	_	
69-2	13243-13244	,	_	
69-3	13245-13248	the	_	
69-4	13249-13253	mean	_	
69-5	13254-13261	Z-value	_	
69-6	13262-13264	of	_	
69-7	13265-13269	each	_	
69-8	13270-13277	cluster	_	
69-9	13278-13282	with	_	
69-10	13283-13284	a	_	
69-11	13285-13296	significant	_	
69-12	13297-13307	functional	_	
69-13	13308-13320	connectivity	_	
69-14	13321-13322	(	_	
69-15	13322-13324	FC	_	
69-16	13324-13325	)	_	
69-17	13326-13336	difference	_	
69-18	13337-13340	was	_	
69-19	13341-13350	extracted	_	
69-20	13351-13354	and	_	
69-21	13355-13359	were	_	
69-22	13360-13368	compared	_	
69-23	13369-13371	by	_	
69-24	13372-13380	analysis	_	
69-25	13381-13383	of	_	
69-26	13384-13392	variance	_	
69-27	13393-13401	followed	_	
69-28	13402-13404	by	_	
69-29	13405-13409	post	_	
69-30	13410-13413	hoc	_	
69-31	13414-13418	test	_	
69-32	13419-13420	(	_	
69-33	13420-13425	least	_	
69-34	13426-13437	significant	_	
69-35	13438-13448	difference	_	
69-36	13448-13449	)	_	
69-37	13450-13452	in	_	
69-38	13453-13457	SPSS	_	
69-39	13458-13462	18.0	_	
69-40	13462-13463	,	_	
69-41	13464-13470	across	_	
69-42	13471-13479	patients	_	
69-43	13480-13484	with	_	
69-44	13485-13489	RDVs	_	
69-45	13489-13490	,	_	
69-46	13491-13499	patients	_	
69-47	13500-13507	without	_	
69-48	13508-13512	RDVs	_	
69-49	13513-13516	and	_	
69-50	13517-13524	healthy	_	
69-51	13525-13533	controls	_	
69-52	13534-13535	(	_	
69-53	13535-13539	SPSS	_	
69-54	13539-13540	,	_	
69-55	13541-13548	Chicago	_	
69-56	13548-13549	,	_	
69-57	13550-13552	IL	_	
69-58	13552-13553	,	_	
69-59	13554-13557	USA	_	
69-60	13557-13558	)	_	
69-61	13558-13559	,	_	
69-62	13560-13571	significant	_	
69-63	13572-13577	level	_	
69-64	13578-13580	of	_	
69-65	13581-13582	P	_	
69-66	13583-13589	values	_	
69-67	13590-13594	were	_	
69-68	13595-13598	set	_	
69-69	13599-13601	at	_	
69-70	13602-13606	less	_	
69-71	13607-13611	than	_	
69-72	13612-13616	0.05	_	
69-73	13616-13617	.	_	

#Text=Analysis of covariance followed by post hoc test were applied to test the differences of functional connectivity and memory functions among patients with RDVs, patients without RDVs and healthy controls.
70-1	13618-13626	Analysis	_	
70-2	13627-13629	of	_	
70-3	13630-13640	covariance	_	
70-4	13641-13649	followed	_	
70-5	13650-13652	by	_	
70-6	13653-13657	post	_	
70-7	13658-13661	hoc	_	
70-8	13662-13666	test	_	
70-9	13667-13671	were	_	
70-10	13672-13679	applied	_	
70-11	13680-13682	to	_	
70-12	13683-13687	test	_	
70-13	13688-13691	the	_	
70-14	13692-13703	differences	_	
70-15	13704-13706	of	_	
70-16	13707-13717	functional	_	
70-17	13718-13730	connectivity	_	
70-18	13731-13734	and	_	
70-19	13735-13741	memory	_	
70-20	13742-13751	functions	_	
70-21	13752-13757	among	_	
70-22	13758-13766	patients	_	
70-23	13767-13771	with	_	
70-24	13772-13776	RDVs	_	
70-25	13776-13777	,	_	
70-26	13778-13786	patients	_	
70-27	13787-13794	without	_	
70-28	13795-13799	RDVs	_	
70-29	13800-13803	and	_	
70-30	13804-13811	healthy	_	
70-31	13812-13820	controls	_	
70-32	13820-13821	.	_	

#Text=Partial correlation analysis was used to analyze the relationship between the functional connectivities of bilateral hippocampus (and six hippocampal subregions) and cognitive, that is, memory functions, with age, sex and education years (and structural hippocampal volume) as covariance (Supplementary material).
71-1	13822-13829	Partial	_	
71-2	13830-13841	correlation	_	
71-3	13842-13850	analysis	_	
71-4	13851-13854	was	_	
71-5	13855-13859	used	_	
71-6	13860-13862	to	_	
71-7	13863-13870	analyze	_	
71-8	13871-13874	the	_	
71-9	13875-13887	relationship	_	
71-10	13888-13895	between	_	
71-11	13896-13899	the	_	
71-12	13900-13910	functional	_	
71-13	13911-13925	connectivities	_	
71-14	13926-13928	of	_	
71-15	13929-13938	bilateral	_	
71-16	13939-13950	hippocampus	_	
71-17	13951-13952	(	_	
71-18	13952-13955	and	_	
71-19	13956-13959	six	_	
71-20	13960-13971	hippocampal	_	
71-21	13972-13982	subregions	_	
71-22	13982-13983	)	_	
71-23	13984-13987	and	_	
71-24	13988-13997	cognitive	_	
71-25	13997-13998	,	_	
71-26	13999-14003	that	_	
71-27	14004-14006	is	_	
71-28	14006-14007	,	_	
71-29	14008-14014	memory	_	
71-30	14015-14024	functions	_	
71-31	14024-14025	,	_	
71-32	14026-14030	with	_	
71-33	14031-14034	age	_	
71-34	14034-14035	,	_	
71-35	14036-14039	sex	_	
71-36	14040-14043	and	_	
71-37	14044-14053	education	_	
71-38	14054-14059	years	_	
71-39	14060-14061	(	_	
71-40	14061-14064	and	_	
71-41	14065-14075	structural	_	
71-42	14076-14087	hippocampal	_	
71-43	14088-14094	volume	_	
71-44	14094-14095	)	_	
71-45	14096-14098	as	_	
71-46	14099-14109	covariance	_	
71-47	14110-14111	(	_	
71-48	14111-14124	Supplementary	_	
71-49	14125-14133	material	_	
71-50	14133-14134	)	_	
71-51	14134-14135	.	_	

#Text=Furthermore, Fisher's Z-transformation was used to transform the correlation coefficients(r value) to Z-score, and Z-test was used for testing the differences of correlations between groups.
72-1	14136-14147	Furthermore	_	
72-2	14147-14148	,	_	
72-3	14149-14157	Fisher's	_	
72-4	14158-14174	Z-transformation	_	
72-5	14175-14178	was	_	
72-6	14179-14183	used	_	
72-7	14184-14186	to	_	
72-8	14187-14196	transform	_	
72-9	14197-14200	the	_	
72-10	14201-14212	correlation	_	
72-11	14213-14225	coefficients	_	
72-12	14225-14226	(	_	
72-13	14226-14227	r	_	
72-14	14228-14233	value	_	
72-15	14233-14234	)	_	
72-16	14235-14237	to	_	
72-17	14238-14245	Z-score	_	
72-18	14245-14246	,	_	
72-19	14247-14250	and	_	
72-20	14251-14257	Z-test	_	
72-21	14258-14261	was	_	
72-22	14262-14266	used	_	
72-23	14267-14270	for	_	
72-24	14271-14278	testing	_	
72-25	14279-14282	the	_	
72-26	14283-14294	differences	_	
72-27	14295-14297	of	_	
72-28	14298-14310	correlations	_	
72-29	14311-14318	between	_	
72-30	14319-14325	groups	_	
72-31	14325-14326	.	_	

#Text=Corrections for multiple comparisons were applied as appropriate.
73-1	14327-14338	Corrections	_	
73-2	14339-14342	for	_	
73-3	14343-14351	multiple	_	
73-4	14352-14363	comparisons	_	
73-5	14364-14368	were	_	
73-6	14369-14376	applied	_	
73-7	14377-14379	as	_	
73-8	14380-14391	appropriate	_	
73-9	14391-14392	.	_	

#Text=Results
#Text=Genetic investigation of single nucleotide variants and In/Dels
#Text=In the current study, 234 subjects (97 patients with first-episode treatment-naive schizophrenia and 137 healthy controls) were collected for exome sequencing to identify those alleles, genes or gene networks that harbor rare coding variants of moderate or large effect on risk for schizophrenia (Supplementary Information, sections 1).
74-1	14393-14400	Results	_	
74-2	14401-14408	Genetic	_	
74-3	14409-14422	investigation	_	
74-4	14423-14425	of	_	
74-5	14426-14432	single	_	
74-6	14433-14443	nucleotide	_	
74-7	14444-14452	variants	_	
74-8	14453-14456	and	_	
74-9	14457-14459	In	_	
74-10	14459-14460	/	_	
74-11	14460-14464	Dels	_	
74-12	14465-14467	In	_	
74-13	14468-14471	the	_	
74-14	14472-14479	current	_	
74-15	14480-14485	study	_	
74-16	14485-14486	,	_	
74-17	14487-14490	234	_	
74-18	14491-14499	subjects	_	
74-19	14500-14501	(	_	
74-20	14501-14503	97	_	
74-21	14504-14512	patients	_	
74-22	14513-14517	with	_	
74-23	14518-14531	first-episode	_	
74-24	14532-14547	treatment-naive	_	
74-25	14548-14561	schizophrenia	_	
74-26	14562-14565	and	_	
74-27	14566-14569	137	_	
74-28	14570-14577	healthy	_	
74-29	14578-14586	controls	_	
74-30	14586-14587	)	_	
74-31	14588-14592	were	_	
74-32	14593-14602	collected	_	
74-33	14603-14606	for	_	
74-34	14607-14612	exome	_	
74-35	14613-14623	sequencing	_	
74-36	14624-14626	to	_	
74-37	14627-14635	identify	_	
74-38	14636-14641	those	_	
74-39	14642-14649	alleles	_	
74-40	14649-14650	,	_	
74-41	14651-14656	genes	_	
74-42	14657-14659	or	_	
74-43	14660-14664	gene	_	
74-44	14665-14673	networks	_	
74-45	14674-14678	that	_	
74-46	14679-14685	harbor	_	
74-47	14686-14690	rare	_	
74-48	14691-14697	coding	_	
74-49	14698-14706	variants	_	
74-50	14707-14709	of	_	
74-51	14710-14718	moderate	_	
74-52	14719-14721	or	_	
74-53	14722-14727	large	_	
74-54	14728-14734	effect	_	
74-55	14735-14737	on	_	
74-56	14738-14742	risk	_	
74-57	14743-14746	for	_	
74-58	14747-14760	schizophrenia	_	
74-59	14761-14762	(	_	
74-60	14762-14775	Supplementary	_	
74-61	14776-14787	Information	_	
74-62	14787-14788	,	_	
74-63	14789-14797	sections	_	
74-64	14798-14799	1	_	
74-65	14799-14800	)	_	
74-66	14800-14801	.	_	

#Text=Six samples were removed with low quality along with likely contamination after quality control and variant calling (Supplementary Information, sections 2 and 3).
75-1	14802-14805	Six	_	
75-2	14806-14813	samples	_	
75-3	14814-14818	were	_	
75-4	14819-14826	removed	_	
75-5	14827-14831	with	_	
75-6	14832-14835	low	_	
75-7	14836-14843	quality	_	
75-8	14844-14849	along	_	
75-9	14850-14854	with	_	
75-10	14855-14861	likely	_	
75-11	14862-14875	contamination	_	
75-12	14876-14881	after	_	
75-13	14882-14889	quality	_	
75-14	14890-14897	control	_	
75-15	14898-14901	and	_	
75-16	14902-14909	variant	_	
75-17	14910-14917	calling	_	
75-18	14918-14919	(	_	
75-19	14919-14932	Supplementary	_	
75-20	14933-14944	Information	_	
75-21	14944-14945	,	_	
75-22	14946-14954	sections	_	
75-23	14955-14956	2	_	
75-24	14957-14960	and	_	
75-25	14961-14962	3	_	
75-26	14962-14963	)	_	
75-27	14963-14964	.	_	

#Text=Quality control of all variants was conducted by in-house software KGGSeq.
76-1	14965-14972	Quality	_	
76-2	14973-14980	control	_	
76-3	14981-14983	of	_	
76-4	14984-14987	all	_	
76-5	14988-14996	variants	_	
76-6	14997-15000	was	_	
76-7	15001-15010	conducted	_	
76-8	15011-15013	by	_	
76-9	15014-15022	in-house	_	
76-10	15023-15031	software	_	
76-11	15032-15038	KGGSeq	_	
76-12	15038-15039	.	_	

#Text=The final data set comprised 94 schizophrenic cases and 134 controls.
77-1	15040-15043	The	_	
77-2	15044-15049	final	_	
77-3	15050-15054	data	_	
77-4	15055-15058	set	_	
77-5	15059-15068	comprised	_	
77-6	15069-15071	94	_	
77-7	15072-15085	schizophrenic	_	
77-8	15086-15091	cases	_	
77-9	15092-15095	and	_	
77-10	15096-15099	134	_	
77-11	15100-15108	controls	_	
77-12	15108-15109	.	_	

#Text=Detailed demographic and clinical information, as well as summary for sequencing quality, was shown in Table 1.
78-1	15110-15118	Detailed	_	
78-2	15119-15130	demographic	_	
78-3	15131-15134	and	_	
78-4	15135-15143	clinical	_	
78-5	15144-15155	information	_	
78-6	15155-15156	,	_	
78-7	15157-15159	as	_	
78-8	15160-15164	well	_	
78-9	15165-15167	as	_	
78-10	15168-15175	summary	_	
78-11	15176-15179	for	_	
78-12	15180-15190	sequencing	_	
78-13	15191-15198	quality	_	
78-14	15198-15199	,	_	
78-15	15200-15203	was	_	
78-16	15204-15209	shown	_	
78-17	15210-15212	in	_	
78-18	15213-15218	Table	_	
78-19	15219-15220	1	_	
78-20	15220-15221	.	_	

#Text=There were no significant differences in age, sex distribution and years of education (Table 1).
79-1	15222-15227	There	_	
79-2	15228-15232	were	_	
79-3	15233-15235	no	_	
79-4	15236-15247	significant	_	
79-5	15248-15259	differences	_	
79-6	15260-15262	in	_	
79-7	15263-15266	age	_	
79-8	15266-15267	,	_	
79-9	15268-15271	sex	_	
79-10	15272-15284	distribution	_	
79-11	15285-15288	and	_	
79-12	15289-15294	years	_	
79-13	15295-15297	of	_	
79-14	15298-15307	education	_	
79-15	15308-15309	(	_	
79-16	15309-15314	Table	_	
79-17	15315-15316	1	_	
79-18	15316-15317	)	_	
79-19	15317-15318	.	_	

#Text=On average, we obtained 7.67 Gb of mappable sequence data per individual after exome enrichment, targeting ~62 Mb from exons and their flanking regions.
80-1	15319-15321	On	_	
80-2	15322-15329	average	_	
80-3	15329-15330	,	_	
80-4	15331-15333	we	_	
80-5	15334-15342	obtained	_	
80-6	15343-15347	7.67	_	
80-7	15348-15350	Gb	_	
80-8	15351-15353	of	_	
80-9	15354-15362	mappable	_	
80-10	15363-15371	sequence	_	
80-11	15372-15376	data	_	
80-12	15377-15380	per	_	
80-13	15381-15391	individual	_	
80-14	15392-15397	after	_	
80-15	15398-15403	exome	_	
80-16	15404-15414	enrichment	_	
80-17	15414-15415	,	_	
80-18	15416-15425	targeting	_	
80-19	15426-15427	~	_	
80-20	15427-15429	62	_	
80-21	15430-15432	Mb	_	
80-22	15433-15437	from	_	
80-23	15438-15443	exons	_	
80-24	15444-15447	and	_	
80-25	15448-15453	their	_	
80-26	15454-15462	flanking	_	
80-27	15463-15470	regions	_	
80-28	15470-15471	.	_	

#Text=In all, 99.75% of the reads were properly aligned to the reference genome.
81-1	15472-15474	In	_	
81-2	15475-15478	all	_	
81-3	15478-15479	,	_	
81-4	15480-15486	99.75%	_	
81-5	15487-15489	of	_	
81-6	15490-15493	the	_	
81-7	15494-15499	reads	_	
81-8	15500-15504	were	_	
81-9	15505-15513	properly	_	
81-10	15514-15521	aligned	_	
81-11	15522-15524	to	_	
81-12	15525-15528	the	_	
81-13	15529-15538	reference	_	
81-14	15539-15545	genome	_	
81-15	15545-15546	.	_	

#Text=Our median read depth is ~45 ×, which is higher than the estimated average depth (33 ×) required for highly accurate downstream heterozygous variant detection.
82-1	15547-15550	Our	_	
82-2	15551-15557	median	_	
82-3	15558-15562	read	_	
82-4	15563-15568	depth	_	
82-5	15569-15571	is	_	
82-6	15572-15573	~	_	
82-7	15573-15575	45	_	
82-8	15576-15577	×	_	
82-9	15577-15578	,	_	
82-10	15579-15584	which	_	
82-11	15585-15587	is	_	
82-12	15588-15594	higher	_	
82-13	15595-15599	than	_	
82-14	15600-15603	the	_	
82-15	15604-15613	estimated	_	
82-16	15614-15621	average	_	
82-17	15622-15627	depth	_	
82-18	15628-15629	(	_	
82-19	15629-15631	33	_	
82-20	15632-15633	×	_	
82-21	15633-15634	)	_	
82-22	15635-15643	required	_	
82-23	15644-15647	for	_	
82-24	15648-15654	highly	_	
82-25	15655-15663	accurate	_	
82-26	15664-15674	downstream	_	
82-27	15675-15687	heterozygous	_	
82-28	15688-15695	variant	_	
82-29	15696-15705	detection	_	
82-30	15705-15706	.	_	

#Text=In addition, 88.60% of the captured target exons were covered by high-quality genotype calls at least 10 times to ensure good detection sensitivity.
83-1	15707-15709	In	_	
83-2	15710-15718	addition	_	
83-3	15718-15719	,	_	
83-4	15720-15726	88.60%	_	
83-5	15727-15729	of	_	
83-6	15730-15733	the	_	
83-7	15734-15742	captured	_	
83-8	15743-15749	target	_	
83-9	15750-15755	exons	_	
83-10	15756-15760	were	_	
83-11	15761-15768	covered	_	
83-12	15769-15771	by	_	
83-13	15772-15784	high-quality	_	
83-14	15785-15793	genotype	_	
83-15	15794-15799	calls	_	
83-16	15800-15802	at	_	
83-17	15803-15808	least	_	
83-18	15809-15811	10	_	
83-19	15812-15817	times	_	
83-20	15818-15820	to	_	
83-21	15821-15827	ensure	_	
83-22	15828-15832	good	_	
83-23	15833-15842	detection	_	
83-24	15843-15854	sensitivity	_	
83-25	15854-15855	.	_	

#Text=Technical sequencing metrics, including total coverage, proportion of deeply covered targets and initial mapping reads, indicated no difference between schizophrenic patients and healthy controls (Table 2).
84-1	15856-15865	Technical	_	
84-2	15866-15876	sequencing	_	
84-3	15877-15884	metrics	_	
84-4	15884-15885	,	_	
84-5	15886-15895	including	_	
84-6	15896-15901	total	_	
84-7	15902-15910	coverage	_	
84-8	15910-15911	,	_	
84-9	15912-15922	proportion	_	
84-10	15923-15925	of	_	
84-11	15926-15932	deeply	_	
84-12	15933-15940	covered	_	
84-13	15941-15948	targets	_	
84-14	15949-15952	and	_	
84-15	15953-15960	initial	_	
84-16	15961-15968	mapping	_	
84-17	15969-15974	reads	_	
84-18	15974-15975	,	_	
84-19	15976-15985	indicated	_	
84-20	15986-15988	no	_	
84-21	15989-15999	difference	_	
84-22	16000-16007	between	_	
84-23	16008-16021	schizophrenic	_	
84-24	16022-16030	patients	_	
84-25	16031-16034	and	_	
84-26	16035-16042	healthy	_	
84-27	16043-16051	controls	_	
84-28	16052-16053	(	_	
84-29	16053-16058	Table	_	
84-30	16059-16060	2	_	
84-31	16060-16061	)	_	
84-32	16061-16062	.	_	

#Text=Importantly, we found that schizophrenic patients enriched significantly more nonsynonymous and coding variants than controls (Table 2, P<0.001).
85-1	16063-16074	Importantly	_	
85-2	16074-16075	,	_	
85-3	16076-16078	we	_	
85-4	16079-16084	found	_	
85-5	16085-16089	that	_	
85-6	16090-16103	schizophrenic	_	
85-7	16104-16112	patients	_	
85-8	16113-16121	enriched	_	
85-9	16122-16135	significantly	_	
85-10	16136-16140	more	_	
85-11	16141-16154	nonsynonymous	_	
85-12	16155-16158	and	_	
85-13	16159-16165	coding	_	
85-14	16166-16174	variants	_	
85-15	16175-16179	than	_	
85-16	16180-16188	controls	_	
85-17	16189-16190	(	_	
85-18	16190-16195	Table	_	
85-19	16196-16197	2	_	
85-20	16197-16198	,	_	
85-21	16199-16200	P	_	
85-22	16200-16201	<	_	
85-23	16201-16206	0.001	_	
85-24	16206-16207	)	_	
85-25	16207-16208	.	_	

#Text=Allele counts between schizophrenic cases and healthy subjects did not show significant difference after adjustment (Supplementary Information, section 4).
86-1	16209-16215	Allele	_	
86-2	16216-16222	counts	_	
86-3	16223-16230	between	_	
86-4	16231-16244	schizophrenic	_	
86-5	16245-16250	cases	_	
86-6	16251-16254	and	_	
86-7	16255-16262	healthy	_	
86-8	16263-16271	subjects	_	
86-9	16272-16275	did	_	
86-10	16276-16279	not	_	
86-11	16280-16284	show	_	
86-12	16285-16296	significant	_	
86-13	16297-16307	difference	_	
86-14	16308-16313	after	_	
86-15	16314-16324	adjustment	_	
86-16	16325-16326	(	_	
86-17	16326-16339	Supplementary	_	
86-18	16340-16351	Information	_	
86-19	16351-16352	,	_	
86-20	16353-16360	section	_	
86-21	16361-16362	4	_	
86-22	16362-16363	)	_	
86-23	16363-16364	.	_	

#Text=We performed two series of gene-based tests: a one-sided burden test of an increased rare allele rate in cases (https://atgu.mgh.harvard.edu/plinkseq/) and the CALPHA test.
87-1	16365-16367	We	_	
87-2	16368-16377	performed	_	
87-3	16378-16381	two	_	
87-4	16382-16388	series	_	
87-5	16389-16391	of	_	
87-6	16392-16402	gene-based	_	
87-7	16403-16408	tests	_	
87-8	16408-16409	:	_	
87-9	16410-16411	a	_	
87-10	16412-16421	one-sided	_	
87-11	16422-16428	burden	_	
87-12	16429-16433	test	_	
87-13	16434-16436	of	_	
87-14	16437-16439	an	_	
87-15	16440-16449	increased	_	
87-16	16450-16454	rare	_	
87-17	16455-16461	allele	_	
87-18	16462-16466	rate	_	
87-19	16467-16469	in	_	
87-20	16470-16475	cases	_	
87-21	16476-16477	(	_	
87-22	16477-16482	https	_	
87-23	16482-16483	:	_	
87-24	16483-16484	/	_	
87-25	16484-16485	/	_	
87-26	16485-16505	atgu.mgh.harvard.edu	_	
87-27	16505-16506	/	_	
87-28	16506-16514	plinkseq	_	
87-29	16514-16515	/	_	
87-30	16515-16516	)	_	
87-31	16517-16520	and	_	
87-32	16521-16524	the	_	
87-33	16525-16531	CALPHA	_	
87-34	16532-16536	test	_	
87-35	16536-16537	.	_	

#Text=Both tests indicated that gene NRK (Nik Related Kinase, NM_198465, chrX: 105132399...105199499) had increased rare allele rate in cases (P⩽1.0 × 10−6).
88-1	16538-16542	Both	_	
88-2	16543-16548	tests	_	
88-3	16549-16558	indicated	_	
88-4	16559-16563	that	_	
88-5	16564-16568	gene	_	
88-6	16569-16572	NRK	_	
88-7	16573-16574	(	_	
88-8	16574-16577	Nik	_	
88-9	16578-16585	Related	_	
88-10	16586-16592	Kinase	_	
88-11	16592-16593	,	_	
88-12	16594-16596	NM	_	
88-13	16596-16597	_	_	
88-14	16597-16603	198465	_	
88-15	16603-16604	,	_	
88-16	16605-16609	chrX	_	
88-17	16609-16610	:	_	
88-18	16611-16620	105132399	_	
88-19	16620-16621	.	_	
88-20	16621-16622	.	_	
88-21	16622-16632	.105199499	_	
88-22	16632-16633	)	_	
88-23	16634-16637	had	_	
88-24	16638-16647	increased	_	
88-25	16648-16652	rare	_	
88-26	16653-16659	allele	_	
88-27	16660-16664	rate	_	
88-28	16665-16667	in	_	
88-29	16668-16673	cases	_	
88-30	16674-16675	(	_	
88-31	16675-16676	P	_	
88-32	16676-16677	⩽	_	
88-33	16677-16680	1.0	_	
88-34	16681-16682	×	_	
88-35	16683-16685	10	_	
88-36	16685-16686	−	_	
88-37	16686-16687	6	_	
88-38	16687-16688	)	_	
88-39	16688-16689	.	_	

#Text=However, even according to the most stringent Bofferroni correction (0.05/20000=2.5 × 10−6, 20 000 are the total gene number; the results of NRK gene still present significant statistical difference.
89-1	16690-16697	However	_	
89-2	16697-16698	,	_	
89-3	16699-16703	even	_	
89-4	16704-16713	according	_	
89-5	16714-16716	to	_	
89-6	16717-16720	the	_	
89-7	16721-16725	most	_	
89-8	16726-16735	stringent	_	
89-9	16736-16746	Bofferroni	_	
89-10	16747-16757	correction	_	
89-11	16758-16759	(	_	
89-12	16759-16763	0.05	_	
89-13	16763-16764	/	_	
89-14	16764-16769	20000	_	
89-15	16769-16770	=	_	
89-16	16770-16773	2.5	_	
89-17	16774-16775	×	_	
89-18	16776-16778	10	_	
89-19	16778-16779	−	_	
89-20	16779-16780	6	_	
89-21	16780-16781	,	_	
89-22	16782-16784	20	_	
89-23	16785-16788	000	_	
89-24	16789-16792	are	_	
89-25	16793-16796	the	_	
89-26	16797-16802	total	_	
89-27	16803-16807	gene	_	
89-28	16808-16814	number	_	
89-29	16814-16815	;	_	
89-30	16816-16819	the	_	
89-31	16820-16827	results	_	
89-32	16828-16830	of	_	
89-33	16831-16834	NRK	_	
89-34	16835-16839	gene	_	
89-35	16840-16845	still	_	
89-36	16846-16853	present	_	
89-37	16854-16865	significant	_	
89-38	16866-16877	statistical	_	
89-39	16878-16888	difference	_	
89-40	16888-16889	.	_	

#Text=Nine rare variants within NRK present in 13 schizophrenic patients, but not in healthy controls (Supplementary Table 1).
90-1	16890-16894	Nine	_	
90-2	16895-16899	rare	_	
90-3	16900-16908	variants	_	
90-4	16909-16915	within	_	
90-5	16916-16919	NRK	_	
90-6	16920-16927	present	_	
90-7	16928-16930	in	_	
90-8	16931-16933	13	_	
90-9	16934-16947	schizophrenic	_	
90-10	16948-16956	patients	_	
90-11	16956-16957	,	_	
90-12	16958-16961	but	_	
90-13	16962-16965	not	_	
90-14	16966-16968	in	_	
90-15	16969-16976	healthy	_	
90-16	16977-16985	controls	_	
90-17	16986-16987	(	_	
90-18	16987-17000	Supplementary	_	
90-19	17001-17006	Table	_	
90-20	17007-17008	1	_	
90-21	17008-17009	)	_	
90-22	17009-17010	.	_	

#Text=NRK is a protein-coding gene, which is associated with hypermobility syndrome, hyperinsulinemic and hypoglycemia.
91-1	17011-17014	NRK	_	
91-2	17015-17017	is	_	
91-3	17018-17019	a	_	
91-4	17020-17034	protein-coding	_	
91-5	17035-17039	gene	_	
91-6	17039-17040	,	_	
91-7	17041-17046	which	_	
91-8	17047-17049	is	_	
91-9	17050-17060	associated	_	
91-10	17061-17065	with	_	
91-11	17066-17079	hypermobility	_	
91-12	17080-17088	syndrome	_	
91-13	17088-17089	,	_	
91-14	17090-17106	hyperinsulinemic	_	
91-15	17107-17110	and	_	
91-16	17111-17123	hypoglycemia	_	
91-17	17123-17124	.	_	

#Text=GO annotations related to this gene include protein serine/threonine kinase activity and small GTPase regulator activity.
92-1	17125-17127	GO	_	
92-2	17128-17139	annotations	_	
92-3	17140-17147	related	_	
92-4	17148-17150	to	_	
92-5	17151-17155	this	_	
92-6	17156-17160	gene	_	
92-7	17161-17168	include	_	
92-8	17169-17176	protein	_	
92-9	17177-17183	serine	_	
92-10	17183-17184	/	_	
92-11	17184-17193	threonine	_	
92-12	17194-17200	kinase	_	
92-13	17201-17209	activity	_	
92-14	17210-17213	and	_	
92-15	17214-17219	small	_	
92-16	17220-17226	GTPase	_	
92-17	17227-17236	regulator	_	
92-18	17237-17245	activity	_	
92-19	17245-17246	.	_	

#Text=Previous studies did not denote any association between NRK and schizophrenia; however, an important paralog of this gene is TAOK2, which is essential for dendrite morphogenesis and has been associated with autism spectrum disorder.
93-1	17247-17255	Previous	_	
93-2	17256-17263	studies	_	
93-3	17264-17267	did	_	
93-4	17268-17271	not	_	
93-5	17272-17278	denote	_	
93-6	17279-17282	any	_	
93-7	17283-17294	association	_	
93-8	17295-17302	between	_	
93-9	17303-17306	NRK	_	
93-10	17307-17310	and	_	
93-11	17311-17324	schizophrenia	_	
93-12	17324-17325	;	_	
93-13	17326-17333	however	_	
93-14	17333-17334	,	_	
93-15	17335-17337	an	_	
93-16	17338-17347	important	_	
93-17	17348-17355	paralog	_	
93-18	17356-17358	of	_	
93-19	17359-17363	this	_	
93-20	17364-17368	gene	_	
93-21	17369-17371	is	_	
93-22	17372-17377	TAOK2	_	
93-23	17377-17378	,	_	
93-24	17379-17384	which	_	
93-25	17385-17387	is	_	
93-26	17388-17397	essential	_	
93-27	17398-17401	for	_	
93-28	17402-17410	dendrite	_	
93-29	17411-17424	morphogenesis	_	
93-30	17425-17428	and	_	
93-31	17429-17432	has	_	
93-32	17433-17437	been	_	
93-33	17438-17448	associated	_	
93-34	17449-17453	with	_	
93-35	17454-17460	autism	_	
93-36	17461-17469	spectrum	_	
93-37	17470-17478	disorder	_	
93-38	17478-17479	.	_	

#Text=Next, we adopted an alternative strategy in which we studied RDVs.
94-1	17480-17484	Next	_	
94-2	17484-17485	,	_	
94-3	17486-17488	we	_	
94-4	17489-17496	adopted	_	
94-5	17497-17499	an	_	
94-6	17500-17511	alternative	_	
94-7	17512-17520	strategy	_	
94-8	17521-17523	in	_	
94-9	17524-17529	which	_	
94-10	17530-17532	we	_	
94-11	17533-17540	studied	_	
94-12	17541-17545	RDVs	_	
94-13	17545-17546	.	_	

#Text=Previous reports have shown that RDVs have a higher likelihood of having a role in schizophrenia (Supplementary Information, section 5).
95-1	17547-17555	Previous	_	
95-2	17556-17563	reports	_	
95-3	17564-17568	have	_	
95-4	17569-17574	shown	_	
95-5	17575-17579	that	_	
95-6	17580-17584	RDVs	_	
95-7	17585-17589	have	_	
95-8	17590-17591	a	_	
95-9	17592-17598	higher	_	
95-10	17599-17609	likelihood	_	
95-11	17610-17612	of	_	
95-12	17613-17619	having	_	
95-13	17620-17621	a	_	
95-14	17622-17626	role	_	
95-15	17627-17629	in	_	
95-16	17630-17643	schizophrenia	_	
95-17	17644-17645	(	_	
95-18	17645-17658	Supplementary	_	
95-19	17659-17670	Information	_	
95-20	17670-17671	,	_	
95-21	17672-17679	section	_	
95-22	17680-17681	5	_	
95-23	17681-17682	)	_	
95-24	17682-17683	.	_	

#Text=After applying several filters (Supplementary Figure 1), 2895 mutations within 2442 genes in schizophrenic patients and 4484 mutations within 3481 genes in healthy controls were investigated with GO enrichment at the gene-based level using GeneMANIA.
96-1	17684-17689	After	_	
96-2	17690-17698	applying	_	
96-3	17699-17706	several	_	
96-4	17707-17714	filters	_	
96-5	17715-17716	(	_	
96-6	17716-17729	Supplementary	_	
96-7	17730-17736	Figure	_	
96-8	17737-17738	1	_	
96-9	17738-17739	)	_	
96-10	17739-17740	,	_	
96-11	17741-17745	2895	_	
96-12	17746-17755	mutations	_	
96-13	17756-17762	within	_	
96-14	17763-17767	2442	_	
96-15	17768-17773	genes	_	
96-16	17774-17776	in	_	
96-17	17777-17790	schizophrenic	_	
96-18	17791-17799	patients	_	
96-19	17800-17803	and	_	
96-20	17804-17808	4484	_	
96-21	17809-17818	mutations	_	
96-22	17819-17825	within	_	
96-23	17826-17830	3481	_	
96-24	17831-17836	genes	_	
96-25	17837-17839	in	_	
96-26	17840-17847	healthy	_	
96-27	17848-17856	controls	_	
96-28	17857-17861	were	_	
96-29	17862-17874	investigated	_	
96-30	17875-17879	with	_	
96-31	17880-17882	GO	_	
96-32	17883-17893	enrichment	_	
96-33	17894-17896	at	_	
96-34	17897-17900	the	_	
96-35	17901-17911	gene-based	_	
96-36	17912-17917	level	_	
96-37	17918-17923	using	_	
96-38	17924-17933	GeneMANIA	_	
96-39	17933-17934	.	_	

#Text=There were 505 and 952 pathway (or GO) terms enriched in cases and controls separately, but 56 RDVs in 42 genes within two pathways of DNA repair (GO: 0006281, 31 RDVs in 20 genes) and cell cycle (GO: 0007049, 25 RDVs in 22 genes) were present only in 39 schizophrenic patients (Supplementary Table 2 and Table 3), which also indicated a significant q-value.
97-1	17935-17940	There	_	
97-2	17941-17945	were	_	
97-3	17946-17949	505	_	
97-4	17950-17953	and	_	
97-5	17954-17957	952	_	
97-6	17958-17965	pathway	_	
97-7	17966-17967	(	_	
97-8	17967-17969	or	_	
97-9	17970-17972	GO	_	
97-10	17972-17973	)	_	
97-11	17974-17979	terms	_	
97-12	17980-17988	enriched	_	
97-13	17989-17991	in	_	
97-14	17992-17997	cases	_	
97-15	17998-18001	and	_	
97-16	18002-18010	controls	_	
97-17	18011-18021	separately	_	
97-18	18021-18022	,	_	
97-19	18023-18026	but	_	
97-20	18027-18029	56	_	
97-21	18030-18034	RDVs	_	
97-22	18035-18037	in	_	
97-23	18038-18040	42	_	
97-24	18041-18046	genes	_	
97-25	18047-18053	within	_	
97-26	18054-18057	two	_	
97-27	18058-18066	pathways	_	
97-28	18067-18069	of	_	
97-29	18070-18073	DNA	_	
97-30	18074-18080	repair	_	
97-31	18081-18082	(	_	
97-32	18082-18084	GO	_	
97-33	18084-18085	:	_	
97-34	18086-18093	0006281	_	
97-35	18093-18094	,	_	
97-36	18095-18097	31	_	
97-37	18098-18102	RDVs	_	
97-38	18103-18105	in	_	
97-39	18106-18108	20	_	
97-40	18109-18114	genes	_	
97-41	18114-18115	)	_	
97-42	18116-18119	and	_	
97-43	18120-18124	cell	_	
97-44	18125-18130	cycle	_	
97-45	18131-18132	(	_	
97-46	18132-18134	GO	_	
97-47	18134-18135	:	_	
97-48	18136-18143	0007049	_	
97-49	18143-18144	,	_	
97-50	18145-18147	25	_	
97-51	18148-18152	RDVs	_	
97-52	18153-18155	in	_	
97-53	18156-18158	22	_	
97-54	18159-18164	genes	_	
97-55	18164-18165	)	_	
97-56	18166-18170	were	_	
97-57	18171-18178	present	_	
97-58	18179-18183	only	_	
97-59	18184-18186	in	_	
97-60	18187-18189	39	_	
97-61	18190-18203	schizophrenic	_	
97-62	18204-18212	patients	_	
97-63	18213-18214	(	_	
97-64	18214-18227	Supplementary	_	
97-65	18228-18233	Table	_	
97-66	18234-18235	2	_	
97-67	18236-18239	and	_	
97-68	18240-18245	Table	_	
97-69	18246-18247	3	_	
97-70	18247-18248	)	_	
97-71	18248-18249	,	_	
97-72	18250-18255	which	_	
97-73	18256-18260	also	_	
97-74	18261-18270	indicated	_	
97-75	18271-18272	a	_	
97-76	18273-18284	significant	_	
97-77	18285-18292	q-value	_	
97-78	18292-18293	.	_	

#Text=There are 60 control-only categories that were not statistical significant.
98-1	18294-18299	There	_	
98-2	18300-18303	are	_	
98-3	18304-18306	60	_	
98-4	18307-18319	control-only	_	
98-5	18320-18330	categories	_	
98-6	18331-18335	that	_	
98-7	18336-18340	were	_	
98-8	18341-18344	not	_	
98-9	18345-18356	statistical	_	
98-10	18357-18368	significant	_	
98-11	18368-18369	.	_	

#Text=In the present study, we focused on pathways damaged in cases only.
99-1	18370-18372	In	_	
99-2	18373-18376	the	_	
99-3	18377-18384	present	_	
99-4	18385-18390	study	_	
99-5	18390-18391	,	_	
99-6	18392-18394	we	_	
99-7	18395-18402	focused	_	
99-8	18403-18405	on	_	
99-9	18406-18414	pathways	_	
99-10	18415-18422	damaged	_	
99-11	18423-18425	in	_	
99-12	18426-18431	cases	_	
99-13	18432-18436	only	_	
99-14	18436-18437	.	_	

#Text=We identified the developmental expression profile of 22 genes in cell cycle pathway and 20 genes in DNA repair pathway (Supplementary Information, section 6), which show high expression during the stage of brain development before birth, with a sharp decrease in expression after birth in hippocampus.
100-1	18438-18440	We	_	
100-2	18441-18451	identified	_	
100-3	18452-18455	the	_	
100-4	18456-18469	developmental	_	
100-5	18470-18480	expression	_	
100-6	18481-18488	profile	_	
100-7	18489-18491	of	_	
100-8	18492-18494	22	_	
100-9	18495-18500	genes	_	
100-10	18501-18503	in	_	
100-11	18504-18508	cell	_	
100-12	18509-18514	cycle	_	
100-13	18515-18522	pathway	_	
100-14	18523-18526	and	_	
100-15	18527-18529	20	_	
100-16	18530-18535	genes	_	
100-17	18536-18538	in	_	
100-18	18539-18542	DNA	_	
100-19	18543-18549	repair	_	
100-20	18550-18557	pathway	_	
100-21	18558-18559	(	_	
100-22	18559-18572	Supplementary	_	
100-23	18573-18584	Information	_	
100-24	18584-18585	,	_	
100-25	18586-18593	section	_	
100-26	18594-18595	6	_	
100-27	18595-18596	)	_	
100-28	18596-18597	,	_	
100-29	18598-18603	which	_	
100-30	18604-18608	show	_	
100-31	18609-18613	high	_	
100-32	18614-18624	expression	_	
100-33	18625-18631	during	_	
100-34	18632-18635	the	_	
100-35	18636-18641	stage	_	
100-36	18642-18644	of	_	
100-37	18645-18650	brain	_	
100-38	18651-18662	development	_	
100-39	18663-18669	before	_	
100-40	18670-18675	birth	_	
100-41	18675-18676	,	_	
100-42	18677-18681	with	_	
100-43	18682-18683	a	_	
100-44	18684-18689	sharp	_	
100-45	18690-18698	decrease	_	
100-46	18699-18701	in	_	
100-47	18702-18712	expression	_	
100-48	18713-18718	after	_	
100-49	18719-18724	birth	_	
100-50	18725-18727	in	_	
100-51	18728-18739	hippocampus	_	
100-52	18739-18740	.	_	

#Text=The expression profile obtained by WGCNA is presented in Figure 1.
101-1	18741-18744	The	_	
101-2	18745-18755	expression	_	
101-3	18756-18763	profile	_	
101-4	18764-18772	obtained	_	
101-5	18773-18775	by	_	
101-6	18776-18781	WGCNA	_	
101-7	18782-18784	is	_	
101-8	18785-18794	presented	_	
101-9	18795-18797	in	_	
101-10	18798-18804	Figure	_	
101-11	18805-18806	1	_	
101-12	18806-18807	.	_	

#Text=Clinical characterization and hippocampal characterization in schizophrenic patients with or without RDVs
#Text=Clinical characterization
#Text=Comparisons here focus on schizophrenic and healthy subjects as well as on the two genetic-based subgroups with schizophrenia, that is, patients with RDVs and those without RDVs.
102-1	18808-18816	Clinical	_	
102-2	18817-18833	characterization	_	
102-3	18834-18837	and	_	
102-4	18838-18849	hippocampal	_	
102-5	18850-18866	characterization	_	
102-6	18867-18869	in	_	
102-7	18870-18883	schizophrenic	_	
102-8	18884-18892	patients	_	
102-9	18893-18897	with	_	
102-10	18898-18900	or	_	
102-11	18901-18908	without	_	
102-12	18909-18913	RDVs	_	
102-13	18914-18922	Clinical	_	
102-14	18923-18939	characterization	_	
102-15	18940-18951	Comparisons	_	
102-16	18952-18956	here	_	
102-17	18957-18962	focus	_	
102-18	18963-18965	on	_	
102-19	18966-18979	schizophrenic	_	
102-20	18980-18983	and	_	
102-21	18984-18991	healthy	_	
102-22	18992-19000	subjects	_	
102-23	19001-19003	as	_	
102-24	19004-19008	well	_	
102-25	19009-19011	as	_	
102-26	19012-19014	on	_	
102-27	19015-19018	the	_	
102-28	19019-19022	two	_	
102-29	19023-19036	genetic-based	_	
102-30	19037-19046	subgroups	_	
102-31	19047-19051	with	_	
102-32	19052-19065	schizophrenia	_	
102-33	19065-19066	,	_	
102-34	19067-19071	that	_	
102-35	19072-19074	is	_	
102-36	19074-19075	,	_	
102-37	19076-19084	patients	_	
102-38	19085-19089	with	_	
102-39	19090-19094	RDVs	_	
102-40	19095-19098	and	_	
102-41	19099-19104	those	_	
102-42	19105-19112	without	_	
102-43	19113-19117	RDVs	_	
102-44	19117-19118	.	_	

#Text=There were no significant differences in age and sex among patients with RDVs, patients without RDVs and healthy controls (Table 4); however, the education years in patients without RDVs are significantly lower than those in patients with RDVs and controls.
103-1	19119-19124	There	_	
103-2	19125-19129	were	_	
103-3	19130-19132	no	_	
103-4	19133-19144	significant	_	
103-5	19145-19156	differences	_	
103-6	19157-19159	in	_	
103-7	19160-19163	age	_	
103-8	19164-19167	and	_	
103-9	19168-19171	sex	_	
103-10	19172-19177	among	_	
103-11	19178-19186	patients	_	
103-12	19187-19191	with	_	
103-13	19192-19196	RDVs	_	
103-14	19196-19197	,	_	
103-15	19198-19206	patients	_	
103-16	19207-19214	without	_	
103-17	19215-19219	RDVs	_	
103-18	19220-19223	and	_	
103-19	19224-19231	healthy	_	
103-20	19232-19240	controls	_	
103-21	19241-19242	(	_	
103-22	19242-19247	Table	_	
103-23	19248-19249	4	_	
103-24	19249-19250	)	_	
103-25	19250-19251	;	_	
103-26	19252-19259	however	_	
103-27	19259-19260	,	_	
103-28	19261-19264	the	_	
103-29	19265-19274	education	_	
103-30	19275-19280	years	_	
103-31	19281-19283	in	_	
103-32	19284-19292	patients	_	
103-33	19293-19300	without	_	
103-34	19301-19305	RDVs	_	
103-35	19306-19309	are	_	
103-36	19310-19323	significantly	_	
103-37	19324-19329	lower	_	
103-38	19330-19334	than	_	
103-39	19335-19340	those	_	
103-40	19341-19343	in	_	
103-41	19344-19352	patients	_	
103-42	19353-19357	with	_	
103-43	19358-19362	RDVs	_	
103-44	19363-19366	and	_	
103-45	19367-19375	controls	_	
103-46	19375-19376	.	_	

#Text=In addition, there were no significant differences in the duration of illnesses and severity of clinical symptoms between the two genetic-based patient subgroups.
#Text=rsFC of hippocampus
#Text=Functional connectivity of bilateral hippocampus
#Text=Using analysis of covariance with sex, age, education and the hippocampal volume as covariances, we found that left hippocampus showed significant difference in rsFC with left inferior parietal cortex (Montreal Neurological Institute (MNI) atlas coordinates: x=−36, y=−56, z=43; voxels=42), and the right cerebellar posterior lobe (MNI coordinate: x=9, y=−75, z=−45; voxels=40) between the three groups at P<0.05 (corrected for multiple comparisons based on Monte Carlo simulations; Figure 2a).
104-1	19377-19379	In	_	
104-2	19380-19388	addition	_	
104-3	19388-19389	,	_	
104-4	19390-19395	there	_	
104-5	19396-19400	were	_	
104-6	19401-19403	no	_	
104-7	19404-19415	significant	_	
104-8	19416-19427	differences	_	
104-9	19428-19430	in	_	
104-10	19431-19434	the	_	
104-11	19435-19443	duration	_	
104-12	19444-19446	of	_	
104-13	19447-19456	illnesses	_	
104-14	19457-19460	and	_	
104-15	19461-19469	severity	_	
104-16	19470-19472	of	_	
104-17	19473-19481	clinical	_	
104-18	19482-19490	symptoms	_	
104-19	19491-19498	between	_	
104-20	19499-19502	the	_	
104-21	19503-19506	two	_	
104-22	19507-19520	genetic-based	_	
104-23	19521-19528	patient	_	
104-24	19529-19538	subgroups	_	
104-25	19538-19539	.	_	
104-26	19540-19544	rsFC	_	
104-27	19545-19547	of	_	
104-28	19548-19559	hippocampus	_	
104-29	19560-19570	Functional	_	
104-30	19571-19583	connectivity	_	
104-31	19584-19586	of	_	
104-32	19587-19596	bilateral	_	
104-33	19597-19608	hippocampus	_	
104-34	19609-19614	Using	_	
104-35	19615-19623	analysis	_	
104-36	19624-19626	of	_	
104-37	19627-19637	covariance	_	
104-38	19638-19642	with	_	
104-39	19643-19646	sex	_	
104-40	19646-19647	,	_	
104-41	19648-19651	age	_	
104-42	19651-19652	,	_	
104-43	19653-19662	education	_	
104-44	19663-19666	and	_	
104-45	19667-19670	the	_	
104-46	19671-19682	hippocampal	_	
104-47	19683-19689	volume	_	
104-48	19690-19692	as	_	
104-49	19693-19704	covariances	_	
104-50	19704-19705	,	_	
104-51	19706-19708	we	_	
104-52	19709-19714	found	_	
104-53	19715-19719	that	_	
104-54	19720-19724	left	_	
104-55	19725-19736	hippocampus	_	
104-56	19737-19743	showed	_	
104-57	19744-19755	significant	_	
104-58	19756-19766	difference	_	
104-59	19767-19769	in	_	
104-60	19770-19774	rsFC	_	
104-61	19775-19779	with	_	
104-62	19780-19784	left	_	
104-63	19785-19793	inferior	_	
104-64	19794-19802	parietal	_	
104-65	19803-19809	cortex	_	
104-66	19810-19811	(	_	
104-67	19811-19819	Montreal	_	
104-68	19820-19832	Neurological	_	
104-69	19833-19842	Institute	_	
104-70	19843-19844	(	_	
104-71	19844-19847	MNI	_	
104-72	19847-19848	)	_	
104-73	19849-19854	atlas	_	
104-74	19855-19866	coordinates	_	
104-75	19866-19867	:	_	
104-76	19868-19869	x	_	
104-77	19869-19870	=	_	
104-78	19870-19871	−	_	
104-79	19871-19873	36	_	
104-80	19873-19874	,	_	
104-81	19875-19876	y	_	
104-82	19876-19877	=	_	
104-83	19877-19878	−	_	
104-84	19878-19880	56	_	
104-85	19880-19881	,	_	
104-86	19882-19883	z	_	
104-87	19883-19884	=	_	
104-88	19884-19886	43	_	
104-89	19886-19887	;	_	
104-90	19888-19894	voxels	_	
104-91	19894-19895	=	_	
104-92	19895-19897	42	_	
104-93	19897-19898	)	_	
104-94	19898-19899	,	_	
104-95	19900-19903	and	_	
104-96	19904-19907	the	_	
104-97	19908-19913	right	_	
104-98	19914-19924	cerebellar	_	
104-99	19925-19934	posterior	_	
104-100	19935-19939	lobe	_	
104-101	19940-19941	(	_	
104-102	19941-19944	MNI	_	
104-103	19945-19955	coordinate	_	
104-104	19955-19956	:	_	
104-105	19957-19958	x	_	
104-106	19958-19959	=	_	
104-107	19959-19960	9	_	
104-108	19960-19961	,	_	
104-109	19962-19963	y	_	
104-110	19963-19964	=	_	
104-111	19964-19965	−	_	
104-112	19965-19967	75	_	
104-113	19967-19968	,	_	
104-114	19969-19970	z	_	
104-115	19970-19971	=	_	
104-116	19971-19972	−	_	
104-117	19972-19974	45	_	
104-118	19974-19975	;	_	
104-119	19976-19982	voxels	_	
104-120	19982-19983	=	_	
104-121	19983-19985	40	_	
104-122	19985-19986	)	_	
104-123	19987-19994	between	_	
104-124	19995-19998	the	_	
104-125	19999-20004	three	_	
104-126	20005-20011	groups	_	
104-127	20012-20014	at	_	
104-128	20015-20016	P	_	
104-129	20016-20017	<	_	
104-130	20017-20021	0.05	_	
104-131	20022-20023	(	_	
104-132	20023-20032	corrected	_	
104-133	20033-20036	for	_	
104-134	20037-20045	multiple	_	
104-135	20046-20057	comparisons	_	
104-136	20058-20063	based	_	
104-137	20064-20066	on	_	
104-138	20067-20072	Monte	_	
104-139	20073-20078	Carlo	_	
104-140	20079-20090	simulations	_	
104-141	20090-20091	;	_	
104-142	20092-20098	Figure	_	
104-143	20099-20101	2a	_	
104-144	20101-20102	)	_	
104-145	20102-20103	.	_	

#Text=Post hoc test indicated that, compared with healthy controls and patients without RDVs, patients with RDVs demonstrated increased rsFC between left hippocampus and left inferior parietal cortex, as well as decreased rsFC between left hippocampus and right cerebellum posterior lobe.
105-1	20104-20108	Post	_	
105-2	20109-20112	hoc	_	
105-3	20113-20117	test	_	
105-4	20118-20127	indicated	_	
105-5	20128-20132	that	_	
105-6	20132-20133	,	_	
105-7	20134-20142	compared	_	
105-8	20143-20147	with	_	
105-9	20148-20155	healthy	_	
105-10	20156-20164	controls	_	
105-11	20165-20168	and	_	
105-12	20169-20177	patients	_	
105-13	20178-20185	without	_	
105-14	20186-20190	RDVs	_	
105-15	20190-20191	,	_	
105-16	20192-20200	patients	_	
105-17	20201-20205	with	_	
105-18	20206-20210	RDVs	_	
105-19	20211-20223	demonstrated	_	
105-20	20224-20233	increased	_	
105-21	20234-20238	rsFC	_	
105-22	20239-20246	between	_	
105-23	20247-20251	left	_	
105-24	20252-20263	hippocampus	_	
105-25	20264-20267	and	_	
105-26	20268-20272	left	_	
105-27	20273-20281	inferior	_	
105-28	20282-20290	parietal	_	
105-29	20291-20297	cortex	_	
105-30	20297-20298	,	_	
105-31	20299-20301	as	_	
105-32	20302-20306	well	_	
105-33	20307-20309	as	_	
105-34	20310-20319	decreased	_	
105-35	20320-20324	rsFC	_	
105-36	20325-20332	between	_	
105-37	20333-20337	left	_	
105-38	20338-20349	hippocampus	_	
105-39	20350-20353	and	_	
105-40	20354-20359	right	_	
105-41	20360-20370	cerebellum	_	
105-42	20371-20380	posterior	_	
105-43	20381-20385	lobe	_	
105-44	20385-20386	.	_	

#Text=In contrast, there was no significantly different rsFC between healthy controls and patients without RDVs (Figure 2b).
106-1	20387-20389	In	_	
106-2	20390-20398	contrast	_	
106-3	20398-20399	,	_	
106-4	20400-20405	there	_	
106-5	20406-20409	was	_	
106-6	20410-20412	no	_	
106-7	20413-20426	significantly	_	
106-8	20427-20436	different	_	
106-9	20437-20441	rsFC	_	
106-10	20442-20449	between	_	
106-11	20450-20457	healthy	_	
106-12	20458-20466	controls	_	
106-13	20467-20470	and	_	
106-14	20471-20479	patients	_	
106-15	20480-20487	without	_	
106-16	20488-20492	RDVs	_	
106-17	20493-20494	(	_	
106-18	20494-20500	Figure	_	
106-19	20501-20503	2b	_	
106-20	20503-20504	)	_	
106-21	20504-20505	.	_	

#Text=Unlike in the left hippocampus, there were no significant rsFC differences in the right hippocampus with other brain regions among the three groups.
#Text=rsFC of the six hippocampal subregions
#Text=Analysis of covariance showed significant differences in rsFC between the left dentate gyrus (DG) and left inferior parietal cortex (MNI coordinate: x=−36, y=−54, z=42; voxels=77), between right DG and left inferior parietal cortex (MNI coordinate: x=−48, y=−54, z=48; voxels=46) as well as posterior cingulate cortex (MNI coordinate: x=−6, y=−33, z=30; voxels=33), between left CA and right calcarine (MNI coordinate: x=24, y=−93, z=0; voxels=68), between right CA and right calcarine (MNI coordinate: x=21, y=−93, z=3; voxels=68) as well as left fusiform (MNI coordinate: x=−27, y=−54, z=−3; voxels=32), between left SC and orbital medial frontal cortex (MNI coordinate: x=3, y=30, z=−12; voxels=37) among the three groups at P<0.05 (corrected for multiple comparisons based on Monte Carlo simulations).
107-1	20506-20512	Unlike	_	
107-2	20513-20515	in	_	
107-3	20516-20519	the	_	
107-4	20520-20524	left	_	
107-5	20525-20536	hippocampus	_	
107-6	20536-20537	,	_	
107-7	20538-20543	there	_	
107-8	20544-20548	were	_	
107-9	20549-20551	no	_	
107-10	20552-20563	significant	_	
107-11	20564-20568	rsFC	_	
107-12	20569-20580	differences	_	
107-13	20581-20583	in	_	
107-14	20584-20587	the	_	
107-15	20588-20593	right	_	
107-16	20594-20605	hippocampus	_	
107-17	20606-20610	with	_	
107-18	20611-20616	other	_	
107-19	20617-20622	brain	_	
107-20	20623-20630	regions	_	
107-21	20631-20636	among	_	
107-22	20637-20640	the	_	
107-23	20641-20646	three	_	
107-24	20647-20653	groups	_	
107-25	20653-20654	.	_	
107-26	20655-20659	rsFC	_	
107-27	20660-20662	of	_	
107-28	20663-20666	the	_	
107-29	20667-20670	six	_	
107-30	20671-20682	hippocampal	_	
107-31	20683-20693	subregions	_	
107-32	20694-20702	Analysis	_	
107-33	20703-20705	of	_	
107-34	20706-20716	covariance	_	
107-35	20717-20723	showed	_	
107-36	20724-20735	significant	_	
107-37	20736-20747	differences	_	
107-38	20748-20750	in	_	
107-39	20751-20755	rsFC	_	
107-40	20756-20763	between	_	
107-41	20764-20767	the	_	
107-42	20768-20772	left	_	
107-43	20773-20780	dentate	_	
107-44	20781-20786	gyrus	_	
107-45	20787-20788	(	_	
107-46	20788-20790	DG	_	
107-47	20790-20791	)	_	
107-48	20792-20795	and	_	
107-49	20796-20800	left	_	
107-50	20801-20809	inferior	_	
107-51	20810-20818	parietal	_	
107-52	20819-20825	cortex	_	
107-53	20826-20827	(	_	
107-54	20827-20830	MNI	_	
107-55	20831-20841	coordinate	_	
107-56	20841-20842	:	_	
107-57	20843-20844	x	_	
107-58	20844-20845	=	_	
107-59	20845-20846	−	_	
107-60	20846-20848	36	_	
107-61	20848-20849	,	_	
107-62	20850-20851	y	_	
107-63	20851-20852	=	_	
107-64	20852-20853	−	_	
107-65	20853-20855	54	_	
107-66	20855-20856	,	_	
107-67	20857-20858	z	_	
107-68	20858-20859	=	_	
107-69	20859-20861	42	_	
107-70	20861-20862	;	_	
107-71	20863-20869	voxels	_	
107-72	20869-20870	=	_	
107-73	20870-20872	77	_	
107-74	20872-20873	)	_	
107-75	20873-20874	,	_	
107-76	20875-20882	between	_	
107-77	20883-20888	right	_	
107-78	20889-20891	DG	_	
107-79	20892-20895	and	_	
107-80	20896-20900	left	_	
107-81	20901-20909	inferior	_	
107-82	20910-20918	parietal	_	
107-83	20919-20925	cortex	_	
107-84	20926-20927	(	_	
107-85	20927-20930	MNI	_	
107-86	20931-20941	coordinate	_	
107-87	20941-20942	:	_	
107-88	20943-20944	x	_	
107-89	20944-20945	=	_	
107-90	20945-20946	−	_	
107-91	20946-20948	48	_	
107-92	20948-20949	,	_	
107-93	20950-20951	y	_	
107-94	20951-20952	=	_	
107-95	20952-20953	−	_	
107-96	20953-20955	54	_	
107-97	20955-20956	,	_	
107-98	20957-20958	z	_	
107-99	20958-20959	=	_	
107-100	20959-20961	48	_	
107-101	20961-20962	;	_	
107-102	20963-20969	voxels	_	
107-103	20969-20970	=	_	
107-104	20970-20972	46	_	
107-105	20972-20973	)	_	
107-106	20974-20976	as	_	
107-107	20977-20981	well	_	
107-108	20982-20984	as	_	
107-109	20985-20994	posterior	_	
107-110	20995-21004	cingulate	_	
107-111	21005-21011	cortex	_	
107-112	21012-21013	(	_	
107-113	21013-21016	MNI	_	
107-114	21017-21027	coordinate	_	
107-115	21027-21028	:	_	
107-116	21029-21030	x	_	
107-117	21030-21031	=	_	
107-118	21031-21032	−	_	
107-119	21032-21033	6	_	
107-120	21033-21034	,	_	
107-121	21035-21036	y	_	
107-122	21036-21037	=	_	
107-123	21037-21038	−	_	
107-124	21038-21040	33	_	
107-125	21040-21041	,	_	
107-126	21042-21043	z	_	
107-127	21043-21044	=	_	
107-128	21044-21046	30	_	
107-129	21046-21047	;	_	
107-130	21048-21054	voxels	_	
107-131	21054-21055	=	_	
107-132	21055-21057	33	_	
107-133	21057-21058	)	_	
107-134	21058-21059	,	_	
107-135	21060-21067	between	_	
107-136	21068-21072	left	_	
107-137	21073-21075	CA	_	
107-138	21076-21079	and	_	
107-139	21080-21085	right	_	
107-140	21086-21095	calcarine	_	
107-141	21096-21097	(	_	
107-142	21097-21100	MNI	_	
107-143	21101-21111	coordinate	_	
107-144	21111-21112	:	_	
107-145	21113-21114	x	_	
107-146	21114-21115	=	_	
107-147	21115-21117	24	_	
107-148	21117-21118	,	_	
107-149	21119-21120	y	_	
107-150	21120-21121	=	_	
107-151	21121-21122	−	_	
107-152	21122-21124	93	_	
107-153	21124-21125	,	_	
107-154	21126-21127	z	_	
107-155	21127-21128	=	_	
107-156	21128-21129	0	_	
107-157	21129-21130	;	_	
107-158	21131-21137	voxels	_	
107-159	21137-21138	=	_	
107-160	21138-21140	68	_	
107-161	21140-21141	)	_	
107-162	21141-21142	,	_	
107-163	21143-21150	between	_	
107-164	21151-21156	right	_	
107-165	21157-21159	CA	_	
107-166	21160-21163	and	_	
107-167	21164-21169	right	_	
107-168	21170-21179	calcarine	_	
107-169	21180-21181	(	_	
107-170	21181-21184	MNI	_	
107-171	21185-21195	coordinate	_	
107-172	21195-21196	:	_	
107-173	21197-21198	x	_	
107-174	21198-21199	=	_	
107-175	21199-21201	21	_	
107-176	21201-21202	,	_	
107-177	21203-21204	y	_	
107-178	21204-21205	=	_	
107-179	21205-21206	−	_	
107-180	21206-21208	93	_	
107-181	21208-21209	,	_	
107-182	21210-21211	z	_	
107-183	21211-21212	=	_	
107-184	21212-21213	3	_	
107-185	21213-21214	;	_	
107-186	21215-21221	voxels	_	
107-187	21221-21222	=	_	
107-188	21222-21224	68	_	
107-189	21224-21225	)	_	
107-190	21226-21228	as	_	
107-191	21229-21233	well	_	
107-192	21234-21236	as	_	
107-193	21237-21241	left	_	
107-194	21242-21250	fusiform	_	
107-195	21251-21252	(	_	
107-196	21252-21255	MNI	_	
107-197	21256-21266	coordinate	_	
107-198	21266-21267	:	_	
107-199	21268-21269	x	_	
107-200	21269-21270	=	_	
107-201	21270-21271	−	_	
107-202	21271-21273	27	_	
107-203	21273-21274	,	_	
107-204	21275-21276	y	_	
107-205	21276-21277	=	_	
107-206	21277-21278	−	_	
107-207	21278-21280	54	_	
107-208	21280-21281	,	_	
107-209	21282-21283	z	_	
107-210	21283-21284	=	_	
107-211	21284-21285	−	_	
107-212	21285-21286	3	_	
107-213	21286-21287	;	_	
107-214	21288-21294	voxels	_	
107-215	21294-21295	=	_	
107-216	21295-21297	32	_	
107-217	21297-21298	)	_	
107-218	21298-21299	,	_	
107-219	21300-21307	between	_	
107-220	21308-21312	left	_	
107-221	21313-21315	SC	_	
107-222	21316-21319	and	_	
107-223	21320-21327	orbital	_	
107-224	21328-21334	medial	_	
107-225	21335-21342	frontal	_	
107-226	21343-21349	cortex	_	
107-227	21350-21351	(	_	
107-228	21351-21354	MNI	_	
107-229	21355-21365	coordinate	_	
107-230	21365-21366	:	_	
107-231	21367-21368	x	_	
107-232	21368-21369	=	_	
107-233	21369-21370	3	_	
107-234	21370-21371	,	_	
107-235	21372-21373	y	_	
107-236	21373-21374	=	_	
107-237	21374-21376	30	_	
107-238	21376-21377	,	_	
107-239	21378-21379	z	_	
107-240	21379-21380	=	_	
107-241	21380-21381	−	_	
107-242	21381-21383	12	_	
107-243	21383-21384	;	_	
107-244	21385-21391	voxels	_	
107-245	21391-21392	=	_	
107-246	21392-21394	37	_	
107-247	21394-21395	)	_	
107-248	21396-21401	among	_	
107-249	21402-21405	the	_	
107-250	21406-21411	three	_	
107-251	21412-21418	groups	_	
107-252	21419-21421	at	_	
107-253	21422-21423	P	_	
107-254	21423-21424	<	_	
107-255	21424-21428	0.05	_	
107-256	21429-21430	(	_	
107-257	21430-21439	corrected	_	
107-258	21440-21443	for	_	
107-259	21444-21452	multiple	_	
107-260	21453-21464	comparisons	_	
107-261	21465-21470	based	_	
107-262	21471-21473	on	_	
107-263	21474-21479	Monte	_	
107-264	21480-21485	Carlo	_	
107-265	21486-21497	simulations	_	
107-266	21497-21498	)	_	
107-267	21498-21499	.	_	

#Text=Post hoc tests indicated that increased rsFC between left DG and left inferior parietal cortex was only found in patients with RDVs, whereas increased rsFC between right DG and left inferior parietal cortex as well as posterior cingulum was detected in both patients group. rsFC of CA was significantly decreased in patients without RDVs and a trend decreased in patients with RDVs.
108-1	21500-21504	Post	_	
108-2	21505-21508	hoc	_	
108-3	21509-21514	tests	_	
108-4	21515-21524	indicated	_	
108-5	21525-21529	that	_	
108-6	21530-21539	increased	_	
108-7	21540-21544	rsFC	_	
108-8	21545-21552	between	_	
108-9	21553-21557	left	_	
108-10	21558-21560	DG	_	
108-11	21561-21564	and	_	
108-12	21565-21569	left	_	
108-13	21570-21578	inferior	_	
108-14	21579-21587	parietal	_	
108-15	21588-21594	cortex	_	
108-16	21595-21598	was	_	
108-17	21599-21603	only	_	
108-18	21604-21609	found	_	
108-19	21610-21612	in	_	
108-20	21613-21621	patients	_	
108-21	21622-21626	with	_	
108-22	21627-21631	RDVs	_	
108-23	21631-21632	,	_	
108-24	21633-21640	whereas	_	
108-25	21641-21650	increased	_	
108-26	21651-21655	rsFC	_	
108-27	21656-21663	between	_	
108-28	21664-21669	right	_	
108-29	21670-21672	DG	_	
108-30	21673-21676	and	_	
108-31	21677-21681	left	_	
108-32	21682-21690	inferior	_	
108-33	21691-21699	parietal	_	
108-34	21700-21706	cortex	_	
108-35	21707-21709	as	_	
108-36	21710-21714	well	_	
108-37	21715-21717	as	_	
108-38	21718-21727	posterior	_	
108-39	21728-21736	cingulum	_	
108-40	21737-21740	was	_	
108-41	21741-21749	detected	_	
108-42	21750-21752	in	_	
108-43	21753-21757	both	_	
108-44	21758-21766	patients	_	
108-45	21767-21772	group	_	
108-46	21772-21773	.	_	
108-47	21774-21778	rsFC	_	
108-48	21779-21781	of	_	
108-49	21782-21784	CA	_	
108-50	21785-21788	was	_	
108-51	21789-21802	significantly	_	
108-52	21803-21812	decreased	_	
108-53	21813-21815	in	_	
108-54	21816-21824	patients	_	
108-55	21825-21832	without	_	
108-56	21833-21837	RDVs	_	
108-57	21838-21841	and	_	
108-58	21842-21843	a	_	
108-59	21844-21849	trend	_	
108-60	21850-21859	decreased	_	
108-61	21860-21862	in	_	
108-62	21863-21871	patients	_	
108-63	21872-21876	with	_	
108-64	21877-21881	RDVs	_	
108-65	21881-21882	.	_	

#Text=Decreased rsFC of left SC and orbital medial frontal cortex was found only in patients without RDVs (Table 3, Figure 3).
109-1	21883-21892	Decreased	_	
109-2	21893-21897	rsFC	_	
109-3	21898-21900	of	_	
109-4	21901-21905	left	_	
109-5	21906-21908	SC	_	
109-6	21909-21912	and	_	
109-7	21913-21920	orbital	_	
109-8	21921-21927	medial	_	
109-9	21928-21935	frontal	_	
109-10	21936-21942	cortex	_	
109-11	21943-21946	was	_	
109-12	21947-21952	found	_	
109-13	21953-21957	only	_	
109-14	21958-21960	in	_	
109-15	21961-21969	patients	_	
109-16	21970-21977	without	_	
109-17	21978-21982	RDVs	_	
109-18	21983-21984	(	_	
109-19	21984-21989	Table	_	
109-20	21990-21991	3	_	
109-21	21991-21992	,	_	
109-22	21993-21999	Figure	_	
109-23	22000-22001	3	_	
109-24	22001-22002	)	_	
109-25	22002-22003	.	_	

#Text=Relationships between hippocampal rsFC and memory
#Text=Compared with healthy controls, both patient groups showed significant impairments in SWM as well as in immediate and delayed logical memory (Supplementary Figure 4).
110-1	22004-22017	Relationships	_	
110-2	22018-22025	between	_	
110-3	22026-22037	hippocampal	_	
110-4	22038-22042	rsFC	_	
110-5	22043-22046	and	_	
110-6	22047-22053	memory	_	
110-7	22054-22062	Compared	_	
110-8	22063-22067	with	_	
110-9	22068-22075	healthy	_	
110-10	22076-22084	controls	_	
110-11	22084-22085	,	_	
110-12	22086-22090	both	_	
110-13	22091-22098	patient	_	
110-14	22099-22105	groups	_	
110-15	22106-22112	showed	_	
110-16	22113-22124	significant	_	
110-17	22125-22136	impairments	_	
110-18	22137-22139	in	_	
110-19	22140-22143	SWM	_	
110-20	22144-22146	as	_	
110-21	22147-22151	well	_	
110-22	22152-22154	as	_	
110-23	22155-22157	in	_	
110-24	22158-22167	immediate	_	
110-25	22168-22171	and	_	
110-26	22172-22179	delayed	_	
110-27	22180-22187	logical	_	
110-28	22188-22194	memory	_	
110-29	22195-22196	(	_	
110-30	22196-22209	Supplementary	_	
110-31	22210-22216	Figure	_	
110-32	22217-22218	4	_	
110-33	22218-22219	)	_	
110-34	22219-22220	.	_	

#Text=No significant differences in these measures were observed between the two genetic-based subgroups in schizophrenic patients, that is, with and without RDVs (Supplementary Figure 4).
111-1	22221-22223	No	_	
111-2	22224-22235	significant	_	
111-3	22236-22247	differences	_	
111-4	22248-22250	in	_	
111-5	22251-22256	these	_	
111-6	22257-22265	measures	_	
111-7	22266-22270	were	_	
111-8	22271-22279	observed	_	
111-9	22280-22287	between	_	
111-10	22288-22291	the	_	
111-11	22292-22295	two	_	
111-12	22296-22309	genetic-based	_	
111-13	22310-22319	subgroups	_	
111-14	22320-22322	in	_	
111-15	22323-22336	schizophrenic	_	
111-16	22337-22345	patients	_	
111-17	22345-22346	,	_	
111-18	22347-22351	that	_	
111-19	22352-22354	is	_	
111-20	22354-22355	,	_	
111-21	22356-22360	with	_	
111-22	22361-22364	and	_	
111-23	22365-22372	without	_	
111-24	22373-22377	RDVs	_	
111-25	22378-22379	(	_	
111-26	22379-22392	Supplementary	_	
111-27	22393-22399	Figure	_	
111-28	22400-22401	4	_	
111-29	22401-22402	)	_	
111-30	22402-22403	.	_	

#Text=Despite the lack of memory-related differences between the two genetic subgroups, we nevertheless observed different correlation patterns between rsFC and cognitive deficits.
112-1	22404-22411	Despite	_	
112-2	22412-22415	the	_	
112-3	22416-22420	lack	_	
112-4	22421-22423	of	_	
112-5	22424-22438	memory-related	_	
112-6	22439-22450	differences	_	
112-7	22451-22458	between	_	
112-8	22459-22462	the	_	
112-9	22463-22466	two	_	
112-10	22467-22474	genetic	_	
112-11	22475-22484	subgroups	_	
112-12	22484-22485	,	_	
112-13	22486-22488	we	_	
112-14	22489-22501	nevertheless	_	
112-15	22502-22510	observed	_	
112-16	22511-22520	different	_	
112-17	22521-22532	correlation	_	
112-18	22533-22541	patterns	_	
112-19	22542-22549	between	_	
112-20	22550-22554	rsFC	_	
112-21	22555-22558	and	_	
112-22	22559-22568	cognitive	_	
112-23	22569-22577	deficits	_	
112-24	22577-22578	.	_	

#Text=Errors in SWM were positively correlated to rsFC between left DG and left inferior parietal cortex in schizophrenic patients with RDVs (r=0.670, uncorrected P=0.034), whereas they were negatively correlated to rsFC between left DG and left inferior parietal cortex in healthy controls (r=−0.373, uncorrected P=0.032; Figure 4).
113-1	22579-22585	Errors	_	
113-2	22586-22588	in	_	
113-3	22589-22592	SWM	_	
113-4	22593-22597	were	_	
113-5	22598-22608	positively	_	
113-6	22609-22619	correlated	_	
113-7	22620-22622	to	_	
113-8	22623-22627	rsFC	_	
113-9	22628-22635	between	_	
113-10	22636-22640	left	_	
113-11	22641-22643	DG	_	
113-12	22644-22647	and	_	
113-13	22648-22652	left	_	
113-14	22653-22661	inferior	_	
113-15	22662-22670	parietal	_	
113-16	22671-22677	cortex	_	
113-17	22678-22680	in	_	
113-18	22681-22694	schizophrenic	_	
113-19	22695-22703	patients	_	
113-20	22704-22708	with	_	
113-21	22709-22713	RDVs	_	
113-22	22714-22715	(	_	
113-23	22715-22716	r	_	
113-24	22716-22717	=	_	
113-25	22717-22722	0.670	_	
113-26	22722-22723	,	_	
113-27	22724-22735	uncorrected	_	
113-28	22736-22737	P	_	
113-29	22737-22738	=	_	
113-30	22738-22743	0.034	_	
113-31	22743-22744	)	_	
113-32	22744-22745	,	_	
113-33	22746-22753	whereas	_	
113-34	22754-22758	they	_	
113-35	22759-22763	were	_	
113-36	22764-22774	negatively	_	
113-37	22775-22785	correlated	_	
113-38	22786-22788	to	_	
113-39	22789-22793	rsFC	_	
113-40	22794-22801	between	_	
113-41	22802-22806	left	_	
113-42	22807-22809	DG	_	
113-43	22810-22813	and	_	
113-44	22814-22818	left	_	
113-45	22819-22827	inferior	_	
113-46	22828-22836	parietal	_	
113-47	22837-22843	cortex	_	
113-48	22844-22846	in	_	
113-49	22847-22854	healthy	_	
113-50	22855-22863	controls	_	
113-51	22864-22865	(	_	
113-52	22865-22866	r	_	
113-53	22866-22867	=	_	
113-54	22867-22868	−	_	
113-55	22868-22873	0.373	_	
113-56	22873-22874	,	_	
113-57	22875-22886	uncorrected	_	
113-58	22887-22888	P	_	
113-59	22888-22889	=	_	
113-60	22889-22894	0.032	_	
113-61	22894-22895	;	_	
113-62	22896-22902	Figure	_	
113-63	22903-22904	4	_	
113-64	22904-22905	)	_	
113-65	22905-22906	.	_	

#Text=However, after correction for multiple tests, none of correlations above remains significant statistically, probably because of the small sample size.
114-1	22907-22914	However	_	
114-2	22914-22915	,	_	
114-3	22916-22921	after	_	
114-4	22922-22932	correction	_	
114-5	22933-22936	for	_	
114-6	22937-22945	multiple	_	
114-7	22946-22951	tests	_	
114-8	22951-22952	,	_	
114-9	22953-22957	none	_	
114-10	22958-22960	of	_	
114-11	22961-22973	correlations	_	
114-12	22974-22979	above	_	
114-13	22980-22987	remains	_	
114-14	22988-22999	significant	_	
114-15	23000-23013	statistically	_	
114-16	23013-23014	,	_	
114-17	23015-23023	probably	_	
114-18	23024-23031	because	_	
114-19	23032-23034	of	_	
114-20	23035-23038	the	_	
114-21	23039-23044	small	_	
114-22	23045-23051	sample	_	
114-23	23052-23056	size	_	
114-24	23056-23057	.	_	

#Text=No correlation was observed in schizophrenic patients without RDV (r=−0.102, uncorrected P=0.739).
115-1	23058-23060	No	_	
115-2	23061-23072	correlation	_	
115-3	23073-23076	was	_	
115-4	23077-23085	observed	_	
115-5	23086-23088	in	_	
115-6	23089-23102	schizophrenic	_	
115-7	23103-23111	patients	_	
115-8	23112-23119	without	_	
115-9	23120-23123	RDV	_	
115-10	23124-23125	(	_	
115-11	23125-23126	r	_	
115-12	23126-23127	=	_	
115-13	23127-23128	−	_	
115-14	23128-23133	0.102	_	
115-15	23133-23134	,	_	
115-16	23135-23146	uncorrected	_	
115-17	23147-23148	P	_	
115-18	23148-23149	=	_	
115-19	23149-23154	0.739	_	
115-20	23154-23155	)	_	
115-21	23155-23156	.	_	

#Text=We then compared the correlation coefficient between each of the two groups by using Z-test.
116-1	23157-23159	We	_	
116-2	23160-23164	then	_	
116-3	23165-23173	compared	_	
116-4	23174-23177	the	_	
116-5	23178-23189	correlation	_	
116-6	23190-23201	coefficient	_	
116-7	23202-23209	between	_	
116-8	23210-23214	each	_	
116-9	23215-23217	of	_	
116-10	23218-23221	the	_	
116-11	23222-23225	two	_	
116-12	23226-23232	groups	_	
116-13	23233-23235	by	_	
116-14	23236-23241	using	_	
116-15	23242-23248	Z-test	_	
116-16	23248-23249	.	_	

#Text=We found that the difference in correlations was statistically significant between schizophrenic patients with RDVs and healthy controls (Z=3.331, P=8.65 × 10−4), as well as between patients with RDVs and those without RDVs (Z=2.171, P=0.030) after Bonferroni correction.
117-1	23250-23252	We	_	
117-2	23253-23258	found	_	
117-3	23259-23263	that	_	
117-4	23264-23267	the	_	
117-5	23268-23278	difference	_	
117-6	23279-23281	in	_	
117-7	23282-23294	correlations	_	
117-8	23295-23298	was	_	
117-9	23299-23312	statistically	_	
117-10	23313-23324	significant	_	
117-11	23325-23332	between	_	
117-12	23333-23346	schizophrenic	_	
117-13	23347-23355	patients	_	
117-14	23356-23360	with	_	
117-15	23361-23365	RDVs	_	
117-16	23366-23369	and	_	
117-17	23370-23377	healthy	_	
117-18	23378-23386	controls	_	
117-19	23387-23388	(	_	
117-20	23388-23389	Z	_	
117-21	23389-23390	=	_	
117-22	23390-23395	3.331	_	
117-23	23395-23396	,	_	
117-24	23397-23398	P	_	
117-25	23398-23399	=	_	
117-26	23399-23403	8.65	_	
117-27	23404-23405	×	_	
117-28	23406-23408	10	_	
117-29	23408-23409	−	_	
117-30	23409-23410	4	_	
117-31	23410-23411	)	_	
117-32	23411-23412	,	_	
117-33	23413-23415	as	_	
117-34	23416-23420	well	_	
117-35	23421-23423	as	_	
117-36	23424-23431	between	_	
117-37	23432-23440	patients	_	
117-38	23441-23445	with	_	
117-39	23446-23450	RDVs	_	
117-40	23451-23454	and	_	
117-41	23455-23460	those	_	
117-42	23461-23468	without	_	
117-43	23469-23473	RDVs	_	
117-44	23474-23475	(	_	
117-45	23475-23476	Z	_	
117-46	23476-23477	=	_	
117-47	23477-23482	2.171	_	
117-48	23482-23483	,	_	
117-49	23484-23485	P	_	
117-50	23485-23486	=	_	
117-51	23486-23491	0.030	_	
117-52	23491-23492	)	_	
117-53	23493-23498	after	_	
117-54	23499-23509	Bonferroni	_	
117-55	23510-23520	correction	_	
117-56	23520-23521	.	_	

#Text=No significant difference was found between patients without RDVs and healthy controls (Z=0.884, P=0.377).
118-1	23522-23524	No	_	
118-2	23525-23536	significant	_	
118-3	23537-23547	difference	_	
118-4	23548-23551	was	_	
118-5	23552-23557	found	_	
118-6	23558-23565	between	_	
118-7	23566-23574	patients	_	
118-8	23575-23582	without	_	
118-9	23583-23587	RDVs	_	
118-10	23588-23591	and	_	
118-11	23592-23599	healthy	_	
118-12	23600-23608	controls	_	
118-13	23609-23610	(	_	
118-14	23610-23611	Z	_	
118-15	23611-23612	=	_	
118-16	23612-23617	0.884	_	
118-17	23617-23618	,	_	
118-18	23619-23620	P	_	
118-19	23620-23621	=	_	
118-20	23621-23626	0.377	_	
118-21	23626-23627	)	_	
118-22	23627-23628	.	_	

#Text=Discussion
#Text=Investigating a unique large sample of first-episode treatment-naive schizophrenic patients, we first identified that 56 RDVs in 42 genes within two pathways implicated in DNA repair and cell cycle were present only in a subgroup including 39 schizophrenic patients, whereas the remaining schizophrenic patients (that is, those without RDVs) as well as healthy subjects did not show these RDVs.
119-1	23629-23639	Discussion	_	
119-2	23640-23653	Investigating	_	
119-3	23654-23655	a	_	
119-4	23656-23662	unique	_	
119-5	23663-23668	large	_	
119-6	23669-23675	sample	_	
119-7	23676-23678	of	_	
119-8	23679-23692	first-episode	_	
119-9	23693-23708	treatment-naive	_	
119-10	23709-23722	schizophrenic	_	
119-11	23723-23731	patients	_	
119-12	23731-23732	,	_	
119-13	23733-23735	we	_	
119-14	23736-23741	first	_	
119-15	23742-23752	identified	_	
119-16	23753-23757	that	_	
119-17	23758-23760	56	_	
119-18	23761-23765	RDVs	_	
119-19	23766-23768	in	_	
119-20	23769-23771	42	_	
119-21	23772-23777	genes	_	
119-22	23778-23784	within	_	
119-23	23785-23788	two	_	
119-24	23789-23797	pathways	_	
119-25	23798-23808	implicated	_	
119-26	23809-23811	in	_	
119-27	23812-23815	DNA	_	
119-28	23816-23822	repair	_	
119-29	23823-23826	and	_	
119-30	23827-23831	cell	_	
119-31	23832-23837	cycle	_	
119-32	23838-23842	were	_	
119-33	23843-23850	present	_	
119-34	23851-23855	only	_	
119-35	23856-23858	in	_	
119-36	23859-23860	a	_	
119-37	23861-23869	subgroup	_	
119-38	23870-23879	including	_	
119-39	23880-23882	39	_	
119-40	23883-23896	schizophrenic	_	
119-41	23897-23905	patients	_	
119-42	23905-23906	,	_	
119-43	23907-23914	whereas	_	
119-44	23915-23918	the	_	
119-45	23919-23928	remaining	_	
119-46	23929-23942	schizophrenic	_	
119-47	23943-23951	patients	_	
119-48	23952-23953	(	_	
119-49	23953-23957	that	_	
119-50	23958-23960	is	_	
119-51	23960-23961	,	_	
119-52	23962-23967	those	_	
119-53	23968-23975	without	_	
119-54	23976-23980	RDVs	_	
119-55	23980-23981	)	_	
119-56	23982-23984	as	_	
119-57	23985-23989	well	_	
119-58	23990-23992	as	_	
119-59	23993-24000	healthy	_	
119-60	24001-24009	subjects	_	
119-61	24010-24013	did	_	
119-62	24014-24017	not	_	
119-63	24018-24022	show	_	
119-64	24023-24028	these	_	
119-65	24029-24033	RDVs	_	
119-66	24033-24034	.	_	

#Text=Further analysis revealed that these genes are highly expressed during the stage of brain development before birth, with a sharp decreased expression after birth in specifically the hippocampus.
120-1	24035-24042	Further	_	
120-2	24043-24051	analysis	_	
120-3	24052-24060	revealed	_	
120-4	24061-24065	that	_	
120-5	24066-24071	these	_	
120-6	24072-24077	genes	_	
120-7	24078-24081	are	_	
120-8	24082-24088	highly	_	
120-9	24089-24098	expressed	_	
120-10	24099-24105	during	_	
120-11	24106-24109	the	_	
120-12	24110-24115	stage	_	
120-13	24116-24118	of	_	
120-14	24119-24124	brain	_	
120-15	24125-24136	development	_	
120-16	24137-24143	before	_	
120-17	24144-24149	birth	_	
120-18	24149-24150	,	_	
120-19	24151-24155	with	_	
120-20	24156-24157	a	_	
120-21	24158-24163	sharp	_	
120-22	24164-24173	decreased	_	
120-23	24174-24184	expression	_	
120-24	24185-24190	after	_	
120-25	24191-24196	birth	_	
120-26	24197-24199	in	_	
120-27	24200-24212	specifically	_	
120-28	24213-24216	the	_	
120-29	24217-24228	hippocampus	_	
120-30	24228-24229	.	_	

#Text=Second, we identified a unique hippocampus rsFC pattern in schizophrenic patients with RDVs, that is, increased rsFC between left hippocampus (especially for left dentate gyrus) and left inferior parietal cortex, as well as decreased rsFC between the left hippocampus and cerebellum.
121-1	24230-24236	Second	_	
121-2	24236-24237	,	_	
121-3	24238-24240	we	_	
121-4	24241-24251	identified	_	
121-5	24252-24253	a	_	
121-6	24254-24260	unique	_	
121-7	24261-24272	hippocampus	_	
121-8	24273-24277	rsFC	_	
121-9	24278-24285	pattern	_	
121-10	24286-24288	in	_	
121-11	24289-24302	schizophrenic	_	
121-12	24303-24311	patients	_	
121-13	24312-24316	with	_	
121-14	24317-24321	RDVs	_	
121-15	24321-24322	,	_	
121-16	24323-24327	that	_	
121-17	24328-24330	is	_	
121-18	24330-24331	,	_	
121-19	24332-24341	increased	_	
121-20	24342-24346	rsFC	_	
121-21	24347-24354	between	_	
121-22	24355-24359	left	_	
121-23	24360-24371	hippocampus	_	
121-24	24372-24373	(	_	
121-25	24373-24383	especially	_	
121-26	24384-24387	for	_	
121-27	24388-24392	left	_	
121-28	24393-24400	dentate	_	
121-29	24401-24406	gyrus	_	
121-30	24406-24407	)	_	
121-31	24408-24411	and	_	
121-32	24412-24416	left	_	
121-33	24417-24425	inferior	_	
121-34	24426-24434	parietal	_	
121-35	24435-24441	cortex	_	
121-36	24441-24442	,	_	
121-37	24443-24445	as	_	
121-38	24446-24450	well	_	
121-39	24451-24453	as	_	
121-40	24454-24463	decreased	_	
121-41	24464-24468	rsFC	_	
121-42	24469-24476	between	_	
121-43	24477-24480	the	_	
121-44	24481-24485	left	_	
121-45	24486-24497	hippocampus	_	
121-46	24498-24501	and	_	
121-47	24502-24512	cerebellum	_	
121-48	24512-24513	.	_	

#Text=Subsequently, we found a tentative significant correlation of altered hippocampal rsFC with spatial memory deficits in schizophrenic patients with RDVs.
122-1	24514-24526	Subsequently	_	
122-2	24526-24527	,	_	
122-3	24528-24530	we	_	
122-4	24531-24536	found	_	
122-5	24537-24538	a	_	
122-6	24539-24548	tentative	_	
122-7	24549-24560	significant	_	
122-8	24561-24572	correlation	_	
122-9	24573-24575	of	_	
122-10	24576-24583	altered	_	
122-11	24584-24595	hippocampal	_	
122-12	24596-24600	rsFC	_	
122-13	24601-24605	with	_	
122-14	24606-24613	spatial	_	
122-15	24614-24620	memory	_	
122-16	24621-24629	deficits	_	
122-17	24630-24632	in	_	
122-18	24633-24646	schizophrenic	_	
122-19	24647-24655	patients	_	
122-20	24656-24660	with	_	
122-21	24661-24665	RDVs	_	
122-22	24665-24666	.	_	

#Text=Schizophrenic patients harbor more than threefolds rare DNA mutations, especially in those with early onset of illness.
123-1	24667-24680	Schizophrenic	_	
123-2	24681-24689	patients	_	
123-3	24690-24696	harbor	_	
123-4	24697-24701	more	_	
123-5	24702-24706	than	_	
123-6	24707-24717	threefolds	_	
123-7	24718-24722	rare	_	
123-8	24723-24726	DNA	_	
123-9	24727-24736	mutations	_	
123-10	24736-24737	,	_	
123-11	24738-24748	especially	_	
123-12	24749-24751	in	_	
123-13	24752-24757	those	_	
123-14	24758-24762	with	_	
123-15	24763-24768	early	_	
123-16	24769-24774	onset	_	
123-17	24775-24777	of	_	
123-18	24778-24785	illness	_	
123-19	24785-24786	.	_	

#Text=More de novo mutations were found recently at genomic hotspots, including chromosomes 1q21.1, 15q13.3, 16p13.1 and 22q11.2.
124-1	24787-24791	More	_	
124-2	24792-24794	de	_	
124-3	24795-24799	novo	_	
124-4	24800-24809	mutations	_	
124-5	24810-24814	were	_	
124-6	24815-24820	found	_	
124-7	24821-24829	recently	_	
124-8	24830-24832	at	_	
124-9	24833-24840	genomic	_	
124-10	24841-24849	hotspots	_	
124-11	24849-24850	,	_	
124-12	24851-24860	including	_	
124-13	24861-24872	chromosomes	_	
124-14	24873-24879	1q21.1	_	
124-15	24879-24880	,	_	
124-16	24881-24888	15q13.3	_	
124-17	24888-24889	,	_	
124-18	24890-24897	16p13.1	_	
124-19	24898-24901	and	_	
124-20	24902-24909	22q11.2	_	
124-21	24909-24910	.	_	

#Text=Studies in larger sample sets demonstrated a polygenic burden that increases the risk for schizophrenia, those genes primarily comprising many ultrarare nonsense mutations distributed across many genes, which mainly involved in neurodevelopment pathways.
125-1	24911-24918	Studies	_	
125-2	24919-24921	in	_	
125-3	24922-24928	larger	_	
125-4	24929-24935	sample	_	
125-5	24936-24940	sets	_	
125-6	24941-24953	demonstrated	_	
125-7	24954-24955	a	_	
125-8	24956-24965	polygenic	_	
125-9	24966-24972	burden	_	
125-10	24973-24977	that	_	
125-11	24978-24987	increases	_	
125-12	24988-24991	the	_	
125-13	24992-24996	risk	_	
125-14	24997-25000	for	_	
125-15	25001-25014	schizophrenia	_	
125-16	25014-25015	,	_	
125-17	25016-25021	those	_	
125-18	25022-25027	genes	_	
125-19	25028-25037	primarily	_	
125-20	25038-25048	comprising	_	
125-21	25049-25053	many	_	
125-22	25054-25063	ultrarare	_	
125-23	25064-25072	nonsense	_	
125-24	25073-25082	mutations	_	
125-25	25083-25094	distributed	_	
125-26	25095-25101	across	_	
125-27	25102-25106	many	_	
125-28	25107-25112	genes	_	
125-29	25112-25113	,	_	
125-30	25114-25119	which	_	
125-31	25120-25126	mainly	_	
125-32	25127-25135	involved	_	
125-33	25136-25138	in	_	
125-34	25139-25155	neurodevelopment	_	
125-35	25156-25164	pathways	_	
125-36	25164-25165	.	_	

#Text=Considering the low frequency and larger effect sizes of rare DNA mutations in current studies, we focused here on the case-unique RDVs, and found that these variants enriched in two pathways, for example, cell cycle regulation and DNA repair.
126-1	25166-25177	Considering	_	
126-2	25178-25181	the	_	
126-3	25182-25185	low	_	
126-4	25186-25195	frequency	_	
126-5	25196-25199	and	_	
126-6	25200-25206	larger	_	
126-7	25207-25213	effect	_	
126-8	25214-25219	sizes	_	
126-9	25220-25222	of	_	
126-10	25223-25227	rare	_	
126-11	25228-25231	DNA	_	
126-12	25232-25241	mutations	_	
126-13	25242-25244	in	_	
126-14	25245-25252	current	_	
126-15	25253-25260	studies	_	
126-16	25260-25261	,	_	
126-17	25262-25264	we	_	
126-18	25265-25272	focused	_	
126-19	25273-25277	here	_	
126-20	25278-25280	on	_	
126-21	25281-25284	the	_	
126-22	25285-25296	case-unique	_	
126-23	25297-25301	RDVs	_	
126-24	25301-25302	,	_	
126-25	25303-25306	and	_	
126-26	25307-25312	found	_	
126-27	25313-25317	that	_	
126-28	25318-25323	these	_	
126-29	25324-25332	variants	_	
126-30	25333-25341	enriched	_	
126-31	25342-25344	in	_	
126-32	25345-25348	two	_	
126-33	25349-25357	pathways	_	
126-34	25357-25358	,	_	
126-35	25359-25362	for	_	
126-36	25363-25370	example	_	
126-37	25370-25371	,	_	
126-38	25372-25376	cell	_	
126-39	25377-25382	cycle	_	
126-40	25383-25393	regulation	_	
126-41	25394-25397	and	_	
126-42	25398-25401	DNA	_	
126-43	25402-25408	repair	_	
126-44	25408-25409	.	_	

#Text=Our finding in current study supported that disturbances of cell cycle regulation and DNA repair in post-mitotic neurons have been implicated in development of psychotic disorders.
127-1	25410-25413	Our	_	
127-2	25414-25421	finding	_	
127-3	25422-25424	in	_	
127-4	25425-25432	current	_	
127-5	25433-25438	study	_	
127-6	25439-25448	supported	_	
127-7	25449-25453	that	_	
127-8	25454-25466	disturbances	_	
127-9	25467-25469	of	_	
127-10	25470-25474	cell	_	
127-11	25475-25480	cycle	_	
127-12	25481-25491	regulation	_	
127-13	25492-25495	and	_	
127-14	25496-25499	DNA	_	
127-15	25500-25506	repair	_	
127-16	25507-25509	in	_	
127-17	25510-25522	post-mitotic	_	
127-18	25523-25530	neurons	_	
127-19	25531-25535	have	_	
127-20	25536-25540	been	_	
127-21	25541-25551	implicated	_	
127-22	25552-25554	in	_	
127-23	25555-25566	development	_	
127-24	25567-25569	of	_	
127-25	25570-25579	psychotic	_	
127-26	25580-25589	disorders	_	
127-27	25589-25590	.	_	

#Text=Importantly, most of the genes enrichment in these two pathways was detected to be highly expressed in the hippocampus in the fetal stage, with the expression level sharply decreasing after birth.
128-1	25591-25602	Importantly	_	
128-2	25602-25603	,	_	
128-3	25604-25608	most	_	
128-4	25609-25611	of	_	
128-5	25612-25615	the	_	
128-6	25616-25621	genes	_	
128-7	25622-25632	enrichment	_	
128-8	25633-25635	in	_	
128-9	25636-25641	these	_	
128-10	25642-25645	two	_	
128-11	25646-25654	pathways	_	
128-12	25655-25658	was	_	
128-13	25659-25667	detected	_	
128-14	25668-25670	to	_	
128-15	25671-25673	be	_	
128-16	25674-25680	highly	_	
128-17	25681-25690	expressed	_	
128-18	25691-25693	in	_	
128-19	25694-25697	the	_	
128-20	25698-25709	hippocampus	_	
128-21	25710-25712	in	_	
128-22	25713-25716	the	_	
128-23	25717-25722	fetal	_	
128-24	25723-25728	stage	_	
128-25	25728-25729	,	_	
128-26	25730-25734	with	_	
128-27	25735-25738	the	_	
128-28	25739-25749	expression	_	
128-29	25750-25755	level	_	
128-30	25756-25763	sharply	_	
128-31	25764-25774	decreasing	_	
128-32	25775-25780	after	_	
128-33	25781-25786	birth	_	
128-34	25786-25787	.	_	

#Text=On the basis of this finding, we could hypothesize that individuals possessing mutations in these two particular pathways may be more prone to develop schizophrenia later on because of the critical gene expressions during their fetal development.
129-1	25788-25790	On	_	
129-2	25791-25794	the	_	
129-3	25795-25800	basis	_	
129-4	25801-25803	of	_	
129-5	25804-25808	this	_	
129-6	25809-25816	finding	_	
129-7	25816-25817	,	_	
129-8	25818-25820	we	_	
129-9	25821-25826	could	_	
129-10	25827-25838	hypothesize	_	
129-11	25839-25843	that	_	
129-12	25844-25855	individuals	_	
129-13	25856-25866	possessing	_	
129-14	25867-25876	mutations	_	
129-15	25877-25879	in	_	
129-16	25880-25885	these	_	
129-17	25886-25889	two	_	
129-18	25890-25900	particular	_	
129-19	25901-25909	pathways	_	
129-20	25910-25913	may	_	
129-21	25914-25916	be	_	
129-22	25917-25921	more	_	
129-23	25922-25927	prone	_	
129-24	25928-25930	to	_	
129-25	25931-25938	develop	_	
129-26	25939-25952	schizophrenia	_	
129-27	25953-25958	later	_	
129-28	25959-25961	on	_	
129-29	25962-25969	because	_	
129-30	25970-25972	of	_	
129-31	25973-25976	the	_	
129-32	25977-25985	critical	_	
129-33	25986-25990	gene	_	
129-34	25991-26002	expressions	_	
129-35	26003-26009	during	_	
129-36	26010-26015	their	_	
129-37	26016-26021	fetal	_	
129-38	26022-26033	development	_	
129-39	26033-26034	.	_	

#Text=More interestingly, such hypothesis genetically specifies and conforms well with the neurodevelopmental model that emphasizes insults as early as late-first or early-second trimester as central for pathological activation of neural circuits in schizophrenia
#Text=Our finding of the RDVs in these two pathways hints upon alterations in cell cycle regulation and the DNA repair in schizophrenic patients during embryogenesis, although the underlying mechanisms are still in explicit.
130-1	26035-26039	More	_	
130-2	26040-26053	interestingly	_	
130-3	26053-26054	,	_	
130-4	26055-26059	such	_	
130-5	26060-26070	hypothesis	_	
130-6	26071-26082	genetically	_	
130-7	26083-26092	specifies	_	
130-8	26093-26096	and	_	
130-9	26097-26105	conforms	_	
130-10	26106-26110	well	_	
130-11	26111-26115	with	_	
130-12	26116-26119	the	_	
130-13	26120-26138	neurodevelopmental	_	
130-14	26139-26144	model	_	
130-15	26145-26149	that	_	
130-16	26150-26160	emphasizes	_	
130-17	26161-26168	insults	_	
130-18	26169-26171	as	_	
130-19	26172-26177	early	_	
130-20	26178-26180	as	_	
130-21	26181-26191	late-first	_	
130-22	26192-26194	or	_	
130-23	26195-26207	early-second	_	
130-24	26208-26217	trimester	_	
130-25	26218-26220	as	_	
130-26	26221-26228	central	_	
130-27	26229-26232	for	_	
130-28	26233-26245	pathological	_	
130-29	26246-26256	activation	_	
130-30	26257-26259	of	_	
130-31	26260-26266	neural	_	
130-32	26267-26275	circuits	_	
130-33	26276-26278	in	_	
130-34	26279-26292	schizophrenia	_	
130-35	26293-26296	Our	_	
130-36	26297-26304	finding	_	
130-37	26305-26307	of	_	
130-38	26308-26311	the	_	
130-39	26312-26316	RDVs	_	
130-40	26317-26319	in	_	
130-41	26320-26325	these	_	
130-42	26326-26329	two	_	
130-43	26330-26338	pathways	_	
130-44	26339-26344	hints	_	
130-45	26345-26349	upon	_	
130-46	26350-26361	alterations	_	
130-47	26362-26364	in	_	
130-48	26365-26369	cell	_	
130-49	26370-26375	cycle	_	
130-50	26376-26386	regulation	_	
130-51	26387-26390	and	_	
130-52	26391-26394	the	_	
130-53	26395-26398	DNA	_	
130-54	26399-26405	repair	_	
130-55	26406-26408	in	_	
130-56	26409-26422	schizophrenic	_	
130-57	26423-26431	patients	_	
130-58	26432-26438	during	_	
130-59	26439-26452	embryogenesis	_	
130-60	26452-26453	,	_	
130-61	26454-26462	although	_	
130-62	26463-26466	the	_	
130-63	26467-26477	underlying	_	
130-64	26478-26488	mechanisms	_	
130-65	26489-26492	are	_	
130-66	26493-26498	still	_	
130-67	26499-26501	in	_	
130-68	26502-26510	explicit	_	
130-69	26510-26511	.	_	

#Text=Study from Katsel et al. suggested abnormal patterns of cell cycle gene and protein expression in schizophrenia, which may contribute to the oligodendroglial deficits observed in schizophrenia.
131-1	26512-26517	Study	_	
131-2	26518-26522	from	_	
131-3	26523-26529	Katsel	_	
131-4	26530-26532	et	_	
131-5	26533-26535	al	_	
131-6	26535-26536	.	_	
131-7	26537-26546	suggested	_	
131-8	26547-26555	abnormal	_	
131-9	26556-26564	patterns	_	
131-10	26565-26567	of	_	
131-11	26568-26572	cell	_	
131-12	26573-26578	cycle	_	
131-13	26579-26583	gene	_	
131-14	26584-26587	and	_	
131-15	26588-26595	protein	_	
131-16	26596-26606	expression	_	
131-17	26607-26609	in	_	
131-18	26610-26623	schizophrenia	_	
131-19	26623-26624	,	_	
131-20	26625-26630	which	_	
131-21	26631-26634	may	_	
131-22	26635-26645	contribute	_	
131-23	26646-26648	to	_	
131-24	26649-26652	the	_	
131-25	26653-26669	oligodendroglial	_	
131-26	26670-26678	deficits	_	
131-27	26679-26687	observed	_	
131-28	26688-26690	in	_	
131-29	26691-26704	schizophrenia	_	
131-30	26704-26705	.	_	

#Text=This could lead to changes in brain development and make the brain more susceptible to environmental risk factors, with downstream effects on neural progenitor proliferation and differentiation.
132-1	26706-26710	This	_	
132-2	26711-26716	could	_	
132-3	26717-26721	lead	_	
132-4	26722-26724	to	_	
132-5	26725-26732	changes	_	
132-6	26733-26735	in	_	
132-7	26736-26741	brain	_	
132-8	26742-26753	development	_	
132-9	26754-26757	and	_	
132-10	26758-26762	make	_	
132-11	26763-26766	the	_	
132-12	26767-26772	brain	_	
132-13	26773-26777	more	_	
132-14	26778-26789	susceptible	_	
132-15	26790-26792	to	_	
132-16	26793-26806	environmental	_	
132-17	26807-26811	risk	_	
132-18	26812-26819	factors	_	
132-19	26819-26820	,	_	
132-20	26821-26825	with	_	
132-21	26826-26836	downstream	_	
132-22	26837-26844	effects	_	
132-23	26845-26847	on	_	
132-24	26848-26854	neural	_	
132-25	26855-26865	progenitor	_	
132-26	26866-26879	proliferation	_	
132-27	26880-26883	and	_	
132-28	26884-26899	differentiation	_	
132-29	26899-26900	.	_	

#Text=In the present study, we detected aberrant functional connectivity of left hippocampus with inferior parietal lobe, posterior cingulate cortex, visual cortex and medial frontal gyrus in schizophrenic patients with RDVs.
133-1	26901-26903	In	_	
133-2	26904-26907	the	_	
133-3	26908-26915	present	_	
133-4	26916-26921	study	_	
133-5	26921-26922	,	_	
133-6	26923-26925	we	_	
133-7	26926-26934	detected	_	
133-8	26935-26943	aberrant	_	
133-9	26944-26954	functional	_	
133-10	26955-26967	connectivity	_	
133-11	26968-26970	of	_	
133-12	26971-26975	left	_	
133-13	26976-26987	hippocampus	_	
133-14	26988-26992	with	_	
133-15	26993-27001	inferior	_	
133-16	27002-27010	parietal	_	
133-17	27011-27015	lobe	_	
133-18	27015-27016	,	_	
133-19	27017-27026	posterior	_	
133-20	27027-27036	cingulate	_	
133-21	27037-27043	cortex	_	
133-22	27043-27044	,	_	
133-23	27045-27051	visual	_	
133-24	27052-27058	cortex	_	
133-25	27059-27062	and	_	
133-26	27063-27069	medial	_	
133-27	27070-27077	frontal	_	
133-28	27078-27083	gyrus	_	
133-29	27084-27086	in	_	
133-30	27087-27100	schizophrenic	_	
133-31	27101-27109	patients	_	
133-32	27110-27114	with	_	
133-33	27115-27119	RDVs	_	
133-34	27119-27120	.	_	

#Text=In contrast, schizophrenic patients without RDVs did not show such pattern.
134-1	27121-27123	In	_	
134-2	27124-27132	contrast	_	
134-3	27132-27133	,	_	
134-4	27134-27147	schizophrenic	_	
134-5	27148-27156	patients	_	
134-6	27157-27164	without	_	
134-7	27165-27169	RDVs	_	
134-8	27170-27173	did	_	
134-9	27174-27177	not	_	
134-10	27178-27182	show	_	
134-11	27183-27187	such	_	
134-12	27188-27195	pattern	_	
134-13	27195-27196	.	_	

#Text=This suggests that the aberrant resting-state functional connections of left hippocampus in schizophrenia might likely be of neurodevelopmental origin (rather than of neurodegenerative origin or affected by antipsychotics with the latter being excluded here anyway because of the fact that our sample of treatment-naive).
135-1	27197-27201	This	_	
135-2	27202-27210	suggests	_	
135-3	27211-27215	that	_	
135-4	27216-27219	the	_	
135-5	27220-27228	aberrant	_	
135-6	27229-27242	resting-state	_	
135-7	27243-27253	functional	_	
135-8	27254-27265	connections	_	
135-9	27266-27268	of	_	
135-10	27269-27273	left	_	
135-11	27274-27285	hippocampus	_	
135-12	27286-27288	in	_	
135-13	27289-27302	schizophrenia	_	
135-14	27303-27308	might	_	
135-15	27309-27315	likely	_	
135-16	27316-27318	be	_	
135-17	27319-27321	of	_	
135-18	27322-27340	neurodevelopmental	_	
135-19	27341-27347	origin	_	
135-20	27348-27349	(	_	
135-21	27349-27355	rather	_	
135-22	27356-27360	than	_	
135-23	27361-27363	of	_	
135-24	27364-27381	neurodegenerative	_	
135-25	27382-27388	origin	_	
135-26	27389-27391	or	_	
135-27	27392-27400	affected	_	
135-28	27401-27403	by	_	
135-29	27404-27418	antipsychotics	_	
135-30	27419-27423	with	_	
135-31	27424-27427	the	_	
135-32	27428-27434	latter	_	
135-33	27435-27440	being	_	
135-34	27441-27449	excluded	_	
135-35	27450-27454	here	_	
135-36	27455-27461	anyway	_	
135-37	27462-27469	because	_	
135-38	27470-27472	of	_	
135-39	27473-27476	the	_	
135-40	27477-27481	fact	_	
135-41	27482-27486	that	_	
135-42	27487-27490	our	_	
135-43	27491-27497	sample	_	
135-44	27498-27500	of	_	
135-45	27501-27516	treatment-naive	_	
135-46	27516-27517	)	_	
135-47	27517-27518	.	_	

#Text=Most interesting, we found that increased functional connectivity of left hippocampus (especially for the dentate gyrus) with left inferior parietal cortex and decreased FC between left hippocampus and cerebellum were only found in schizophrenic patients with RDVs.
136-1	27519-27523	Most	_	
136-2	27524-27535	interesting	_	
136-3	27535-27536	,	_	
136-4	27537-27539	we	_	
136-5	27540-27545	found	_	
136-6	27546-27550	that	_	
136-7	27551-27560	increased	_	
136-8	27561-27571	functional	_	
136-9	27572-27584	connectivity	_	
136-10	27585-27587	of	_	
136-11	27588-27592	left	_	
136-12	27593-27604	hippocampus	_	
136-13	27605-27606	(	_	
136-14	27606-27616	especially	_	
136-15	27617-27620	for	_	
136-16	27621-27624	the	_	
136-17	27625-27632	dentate	_	
136-18	27633-27638	gyrus	_	
136-19	27638-27639	)	_	
136-20	27640-27644	with	_	
136-21	27645-27649	left	_	
136-22	27650-27658	inferior	_	
136-23	27659-27667	parietal	_	
136-24	27668-27674	cortex	_	
136-25	27675-27678	and	_	
136-26	27679-27688	decreased	_	
136-27	27689-27691	FC	_	
136-28	27692-27699	between	_	
136-29	27700-27704	left	_	
136-30	27705-27716	hippocampus	_	
136-31	27717-27720	and	_	
136-32	27721-27731	cerebellum	_	
136-33	27732-27736	were	_	
136-34	27737-27741	only	_	
136-35	27742-27747	found	_	
136-36	27748-27750	in	_	
136-37	27751-27764	schizophrenic	_	
136-38	27765-27773	patients	_	
136-39	27774-27778	with	_	
136-40	27779-27783	RDVs	_	
136-41	27783-27784	.	_	

#Text=This further underlines the neurodevelopmental impact of RDV on phenotypic makers like the left hippocampal rsFC and its high relevance for schizophrenia.
137-1	27785-27789	This	_	
137-2	27790-27797	further	_	
137-3	27798-27808	underlines	_	
137-4	27809-27812	the	_	
137-5	27813-27831	neurodevelopmental	_	
137-6	27832-27838	impact	_	
137-7	27839-27841	of	_	
137-8	27842-27845	RDV	_	
137-9	27846-27848	on	_	
137-10	27849-27859	phenotypic	_	
137-11	27860-27866	makers	_	
137-12	27867-27871	like	_	
137-13	27872-27875	the	_	
137-14	27876-27880	left	_	
137-15	27881-27892	hippocampal	_	
137-16	27893-27897	rsFC	_	
137-17	27898-27901	and	_	
137-18	27902-27905	its	_	
137-19	27906-27910	high	_	
137-20	27911-27920	relevance	_	
137-21	27921-27924	for	_	
137-22	27925-27938	schizophrenia	_	
137-23	27938-27939	.	_	

#Text=The exact mechanisms mediating the transition from early prenatal RDVs' occurrence to hippocampal rsFC abnormalities during the later outbreak of schizophrenia remain unclear though.
138-1	27940-27943	The	_	
138-2	27944-27949	exact	_	
138-3	27950-27960	mechanisms	_	
138-4	27961-27970	mediating	_	
138-5	27971-27974	the	_	
138-6	27975-27985	transition	_	
138-7	27986-27990	from	_	
138-8	27991-27996	early	_	
138-9	27997-28005	prenatal	_	
138-10	28006-28010	RDVs	_	
138-11	28010-28011	'	_	
138-12	28012-28022	occurrence	_	
138-13	28023-28025	to	_	
138-14	28026-28037	hippocampal	_	
138-15	28038-28042	rsFC	_	
138-16	28043-28056	abnormalities	_	
138-17	28057-28063	during	_	
138-18	28064-28067	the	_	
138-19	28068-28073	later	_	
138-20	28074-28082	outbreak	_	
138-21	28083-28085	of	_	
138-22	28086-28099	schizophrenia	_	
138-23	28100-28106	remain	_	
138-24	28107-28114	unclear	_	
138-25	28115-28121	though	_	
138-26	28121-28122	.	_	

#Text=Increased functional connectivity between left dentate gyrus and left inferior parietal cortex was correlated with more errors of SWM in schizophrenic patients with RDVs, whereas no such correlation was found in schizophrenic patients without RDVs (and opposite, that is, negative) and in healthy subjects.
139-1	28123-28132	Increased	_	
139-2	28133-28143	functional	_	
139-3	28144-28156	connectivity	_	
139-4	28157-28164	between	_	
139-5	28165-28169	left	_	
139-6	28170-28177	dentate	_	
139-7	28178-28183	gyrus	_	
139-8	28184-28187	and	_	
139-9	28188-28192	left	_	
139-10	28193-28201	inferior	_	
139-11	28202-28210	parietal	_	
139-12	28211-28217	cortex	_	
139-13	28218-28221	was	_	
139-14	28222-28232	correlated	_	
139-15	28233-28237	with	_	
139-16	28238-28242	more	_	
139-17	28243-28249	errors	_	
139-18	28250-28252	of	_	
139-19	28253-28256	SWM	_	
139-20	28257-28259	in	_	
139-21	28260-28273	schizophrenic	_	
139-22	28274-28282	patients	_	
139-23	28283-28287	with	_	
139-24	28288-28292	RDVs	_	
139-25	28292-28293	,	_	
139-26	28294-28301	whereas	_	
139-27	28302-28304	no	_	
139-28	28305-28309	such	_	
139-29	28310-28321	correlation	_	
139-30	28322-28325	was	_	
139-31	28326-28331	found	_	
139-32	28332-28334	in	_	
139-33	28335-28348	schizophrenic	_	
139-34	28349-28357	patients	_	
139-35	28358-28365	without	_	
139-36	28366-28370	RDVs	_	
139-37	28371-28372	(	_	
139-38	28372-28375	and	_	
139-39	28376-28384	opposite	_	
139-40	28384-28385	,	_	
139-41	28386-28390	that	_	
139-42	28391-28393	is	_	
139-43	28393-28394	,	_	
139-44	28395-28403	negative	_	
139-45	28403-28404	)	_	
139-46	28405-28408	and	_	
139-47	28409-28411	in	_	
139-48	28412-28419	healthy	_	
139-49	28420-28428	subjects	_	
139-50	28428-28429	.	_	

#Text=The dentate gyrus has been regarded as one of a few brain structures owning high rates of adult neurogenesis and has a critical role in resolving new memories and spatial memory.
140-1	28430-28433	The	_	
140-2	28434-28441	dentate	_	
140-3	28442-28447	gyrus	_	
140-4	28448-28451	has	_	
140-5	28452-28456	been	_	
140-6	28457-28465	regarded	_	
140-7	28466-28468	as	_	
140-8	28469-28472	one	_	
140-9	28473-28475	of	_	
140-10	28476-28477	a	_	
140-11	28478-28481	few	_	
140-12	28482-28487	brain	_	
140-13	28488-28498	structures	_	
140-14	28499-28505	owning	_	
140-15	28506-28510	high	_	
140-16	28511-28516	rates	_	
140-17	28517-28519	of	_	
140-18	28520-28525	adult	_	
140-19	28526-28538	neurogenesis	_	
140-20	28539-28542	and	_	
140-21	28543-28546	has	_	
140-22	28547-28548	a	_	
140-23	28549-28557	critical	_	
140-24	28558-28562	role	_	
140-25	28563-28565	in	_	
140-26	28566-28575	resolving	_	
140-27	28576-28579	new	_	
140-28	28580-28588	memories	_	
140-29	28589-28592	and	_	
140-30	28593-28600	spatial	_	
140-31	28601-28607	memory	_	
140-32	28607-28608	.	_	

#Text=A recent study demonstrated that the inferior parietal cortex is involved in spatial perception and spatial orientation in particular and spatial functions in general (the ‘where').
141-1	28609-28610	A	_	
141-2	28611-28617	recent	_	
141-3	28618-28623	study	_	
141-4	28624-28636	demonstrated	_	
141-5	28637-28641	that	_	
141-6	28642-28645	the	_	
141-7	28646-28654	inferior	_	
141-8	28655-28663	parietal	_	
141-9	28664-28670	cortex	_	
141-10	28671-28673	is	_	
141-11	28674-28682	involved	_	
141-12	28683-28685	in	_	
141-13	28686-28693	spatial	_	
141-14	28694-28704	perception	_	
141-15	28705-28708	and	_	
141-16	28709-28716	spatial	_	
141-17	28717-28728	orientation	_	
141-18	28729-28731	in	_	
141-19	28732-28742	particular	_	
141-20	28743-28746	and	_	
141-21	28747-28754	spatial	_	
141-22	28755-28764	functions	_	
141-23	28765-28767	in	_	
141-24	28768-28775	general	_	
141-25	28776-28777	(	_	
141-26	28777-28780	the	_	
141-27	28781-28782	‘	_	
141-28	28782-28787	where	_	
141-29	28787-28788	'	_	
141-30	28788-28789	)	_	
141-31	28789-28790	.	_	

#Text=In addition, the inferior parietal cortex is also the target of output from hippocampus.
142-1	28791-28793	In	_	
142-2	28794-28802	addition	_	
142-3	28802-28803	,	_	
142-4	28804-28807	the	_	
142-5	28808-28816	inferior	_	
142-6	28817-28825	parietal	_	
142-7	28826-28832	cortex	_	
142-8	28833-28835	is	_	
142-9	28836-28840	also	_	
142-10	28841-28844	the	_	
142-11	28845-28851	target	_	
142-12	28852-28854	of	_	
142-13	28855-28861	output	_	
142-14	28862-28866	from	_	
142-15	28867-28878	hippocampus	_	
142-16	28878-28879	.	_	

#Text=The findings in the present study thus provided direct evidence that aberrant increased FC of left dentate gyrus with inferior parietal cortex might contribute to the severity of SWM deficits in schizophrenic patients with RDVs.
143-1	28880-28883	The	_	
143-2	28884-28892	findings	_	
143-3	28893-28895	in	_	
143-4	28896-28899	the	_	
143-5	28900-28907	present	_	
143-6	28908-28913	study	_	
143-7	28914-28918	thus	_	
143-8	28919-28927	provided	_	
143-9	28928-28934	direct	_	
143-10	28935-28943	evidence	_	
143-11	28944-28948	that	_	
143-12	28949-28957	aberrant	_	
143-13	28958-28967	increased	_	
143-14	28968-28970	FC	_	
143-15	28971-28973	of	_	
143-16	28974-28978	left	_	
143-17	28979-28986	dentate	_	
143-18	28987-28992	gyrus	_	
143-19	28993-28997	with	_	
143-20	28998-29006	inferior	_	
143-21	29007-29015	parietal	_	
143-22	29016-29022	cortex	_	
143-23	29023-29028	might	_	
143-24	29029-29039	contribute	_	
143-25	29040-29042	to	_	
143-26	29043-29046	the	_	
143-27	29047-29055	severity	_	
143-28	29056-29058	of	_	
143-29	29059-29062	SWM	_	
143-30	29063-29071	deficits	_	
143-31	29072-29074	in	_	
143-32	29075-29088	schizophrenic	_	
143-33	29089-29097	patients	_	
143-34	29098-29102	with	_	
143-35	29103-29107	RDVs	_	
143-36	29107-29108	.	_	

#Text=Above all, our results provide a link among RDVs, dentate gyrus dysfunctional resting-state connectivity and SWM deficits in a genetic-based neurodevelopmental subgroup of patients with schizophrenia.
144-1	29109-29114	Above	_	
144-2	29115-29118	all	_	
144-3	29118-29119	,	_	
144-4	29120-29123	our	_	
144-5	29124-29131	results	_	
144-6	29132-29139	provide	_	
144-7	29140-29141	a	_	
144-8	29142-29146	link	_	
144-9	29147-29152	among	_	
144-10	29153-29157	RDVs	_	
144-11	29157-29158	,	_	
144-12	29159-29166	dentate	_	
144-13	29167-29172	gyrus	_	
144-14	29173-29186	dysfunctional	_	
144-15	29187-29200	resting-state	_	
144-16	29201-29213	connectivity	_	
144-17	29214-29217	and	_	
144-18	29218-29221	SWM	_	
144-19	29222-29230	deficits	_	
144-20	29231-29233	in	_	
144-21	29234-29235	a	_	
144-22	29236-29249	genetic-based	_	
144-23	29250-29268	neurodevelopmental	_	
144-24	29269-29277	subgroup	_	
144-25	29278-29280	of	_	
144-26	29281-29289	patients	_	
144-27	29290-29294	with	_	
144-28	29295-29308	schizophrenia	_	
144-29	29308-29309	.	_	

#Text=However, several limitations must be born in mind when interpreting our results.
145-1	29310-29317	However	_	
145-2	29317-29318	,	_	
145-3	29319-29326	several	_	
145-4	29327-29338	limitations	_	
145-5	29339-29343	must	_	
145-6	29344-29346	be	_	
145-7	29347-29351	born	_	
145-8	29352-29354	in	_	
145-9	29355-29359	mind	_	
145-10	29360-29364	when	_	
145-11	29365-29377	interpreting	_	
145-12	29378-29381	our	_	
145-13	29382-29389	results	_	
145-14	29389-29390	.	_	

#Text=First, the sample size of the present study is relatively small for genetic study, which might be lack of the power to detect significant association signal between cases and controls.
146-1	29391-29396	First	_	
146-2	29396-29397	,	_	
146-3	29398-29401	the	_	
146-4	29402-29408	sample	_	
146-5	29409-29413	size	_	
146-6	29414-29416	of	_	
146-7	29417-29420	the	_	
146-8	29421-29428	present	_	
146-9	29429-29434	study	_	
146-10	29435-29437	is	_	
146-11	29438-29448	relatively	_	
146-12	29449-29454	small	_	
146-13	29455-29458	for	_	
146-14	29459-29466	genetic	_	
146-15	29467-29472	study	_	
146-16	29472-29473	,	_	
146-17	29474-29479	which	_	
146-18	29480-29485	might	_	
146-19	29486-29488	be	_	
146-20	29489-29493	lack	_	
146-21	29494-29496	of	_	
146-22	29497-29500	the	_	
146-23	29501-29506	power	_	
146-24	29507-29509	to	_	
146-25	29510-29516	detect	_	
146-26	29517-29528	significant	_	
146-27	29529-29540	association	_	
146-28	29541-29547	signal	_	
146-29	29548-29555	between	_	
146-30	29556-29561	cases	_	
146-31	29562-29565	and	_	
146-32	29566-29574	controls	_	
146-33	29574-29575	.	_	

#Text=However, we adopt an alternative strategy for filtering rare variants and then enrich to find two special pathways.
147-1	29576-29583	However	_	
147-2	29583-29584	,	_	
147-3	29585-29587	we	_	
147-4	29588-29593	adopt	_	
147-5	29594-29596	an	_	
147-6	29597-29608	alternative	_	
147-7	29609-29617	strategy	_	
147-8	29618-29621	for	_	
147-9	29622-29631	filtering	_	
147-10	29632-29636	rare	_	
147-11	29637-29645	variants	_	
147-12	29646-29649	and	_	
147-13	29650-29654	then	_	
147-14	29655-29661	enrich	_	
147-15	29662-29664	to	_	
147-16	29665-29669	find	_	
147-17	29670-29673	two	_	
147-18	29674-29681	special	_	
147-19	29682-29690	pathways	_	
147-20	29690-29691	.	_	

#Text=Second, not all the subjects underwent the memory test in both the two-patient groups, which could have affected the results of correlation analysis between imaging and cognitive data.
148-1	29692-29698	Second	_	
148-2	29698-29699	,	_	
148-3	29700-29703	not	_	
148-4	29704-29707	all	_	
148-5	29708-29711	the	_	
148-6	29712-29720	subjects	_	
148-7	29721-29730	underwent	_	
148-8	29731-29734	the	_	
148-9	29735-29741	memory	_	
148-10	29742-29746	test	_	
148-11	29747-29749	in	_	
148-12	29750-29754	both	_	
148-13	29755-29758	the	_	
148-14	29759-29770	two-patient	_	
148-15	29771-29777	groups	_	
148-16	29777-29778	,	_	
148-17	29779-29784	which	_	
148-18	29785-29790	could	_	
148-19	29791-29795	have	_	
148-20	29796-29804	affected	_	
148-21	29805-29808	the	_	
148-22	29809-29816	results	_	
148-23	29817-29819	of	_	
148-24	29820-29831	correlation	_	
148-25	29832-29840	analysis	_	
148-26	29841-29848	between	_	
148-27	29849-29856	imaging	_	
148-28	29857-29860	and	_	
148-29	29861-29870	cognitive	_	
148-30	29871-29875	data	_	
148-31	29875-29876	.	_	

#Text=Fortunately, there were no significant differences in clinical profiles between patients with RDVs who underwent cognitive tests and those who did not within both groups.
149-1	29877-29888	Fortunately	_	
149-2	29888-29889	,	_	
149-3	29890-29895	there	_	
149-4	29896-29900	were	_	
149-5	29901-29903	no	_	
149-6	29904-29915	significant	_	
149-7	29916-29927	differences	_	
149-8	29928-29930	in	_	
149-9	29931-29939	clinical	_	
149-10	29940-29948	profiles	_	
149-11	29949-29956	between	_	
149-12	29957-29965	patients	_	
149-13	29966-29970	with	_	
149-14	29971-29975	RDVs	_	
149-15	29976-29979	who	_	
149-16	29980-29989	underwent	_	
149-17	29990-29999	cognitive	_	
149-18	30000-30005	tests	_	
149-19	30006-30009	and	_	
149-20	30010-30015	those	_	
149-21	30016-30019	who	_	
149-22	30020-30023	did	_	
149-23	30024-30027	not	_	
149-24	30028-30034	within	_	
149-25	30035-30039	both	_	
149-26	30040-30046	groups	_	
149-27	30046-30047	.	_	

#Text=Third, considering the small sample size of patients who underwent the cognitive tasks, the correlation analysis between neuroimaging and neurocognition remained uncorrected for multiple comparisons, which might lead to false-positive results.
150-1	30048-30053	Third	_	
150-2	30053-30054	,	_	
150-3	30055-30066	considering	_	
150-4	30067-30070	the	_	
150-5	30071-30076	small	_	
150-6	30077-30083	sample	_	
150-7	30084-30088	size	_	
150-8	30089-30091	of	_	
150-9	30092-30100	patients	_	
150-10	30101-30104	who	_	
150-11	30105-30114	underwent	_	
150-12	30115-30118	the	_	
150-13	30119-30128	cognitive	_	
150-14	30129-30134	tasks	_	
150-15	30134-30135	,	_	
150-16	30136-30139	the	_	
150-17	30140-30151	correlation	_	
150-18	30152-30160	analysis	_	
150-19	30161-30168	between	_	
150-20	30169-30181	neuroimaging	_	
150-21	30182-30185	and	_	
150-22	30186-30200	neurocognition	_	
150-23	30201-30209	remained	_	
150-24	30210-30221	uncorrected	_	
150-25	30222-30225	for	_	
150-26	30226-30234	multiple	_	
150-27	30235-30246	comparisons	_	
150-28	30246-30247	,	_	
150-29	30248-30253	which	_	
150-30	30254-30259	might	_	
150-31	30260-30264	lead	_	
150-32	30265-30267	to	_	
150-33	30268-30282	false-positive	_	
150-34	30283-30290	results	_	
150-35	30290-30291	.	_	

#Text=In sum, to our knowledge, our findings demonstrate for the first time the presence of genes implicated in DNA repair and cell cycle pathways and related specifically to hippocampal development in a subgroup of first-episode treatment-naive schizophrenic patients.
151-1	30292-30294	In	_	
151-2	30295-30298	sum	_	
151-3	30298-30299	,	_	
151-4	30300-30302	to	_	
151-5	30303-30306	our	_	
151-6	30307-30316	knowledge	_	
151-7	30316-30317	,	_	
151-8	30318-30321	our	_	
151-9	30322-30330	findings	_	
151-10	30331-30342	demonstrate	_	
151-11	30343-30346	for	_	
151-12	30347-30350	the	_	
151-13	30351-30356	first	_	
151-14	30357-30361	time	_	
151-15	30362-30365	the	_	
151-16	30366-30374	presence	_	
151-17	30375-30377	of	_	
151-18	30378-30383	genes	_	
151-19	30384-30394	implicated	_	
151-20	30395-30397	in	_	
151-21	30398-30401	DNA	_	
151-22	30402-30408	repair	_	
151-23	30409-30412	and	_	
151-24	30413-30417	cell	_	
151-25	30418-30423	cycle	_	
151-26	30424-30432	pathways	_	
151-27	30433-30436	and	_	
151-28	30437-30444	related	_	
151-29	30445-30457	specifically	_	
151-30	30458-30460	to	_	
151-31	30461-30472	hippocampal	_	
151-32	30473-30484	development	_	
151-33	30485-30487	in	_	
151-34	30488-30489	a	_	
151-35	30490-30498	subgroup	_	
151-36	30499-30501	of	_	
151-37	30502-30515	first-episode	_	
151-38	30516-30531	treatment-naive	_	
151-39	30532-30545	schizophrenic	_	
151-40	30546-30554	patients	_	
151-41	30554-30555	.	_	

#Text=Importantly, the presence of these genes directly had an impact on or modulated phenotypic expression as hippocampal rsFC and related spatial memory function in this subgroup.
152-1	30556-30567	Importantly	_	
152-2	30567-30568	,	_	
152-3	30569-30572	the	_	
152-4	30573-30581	presence	_	
152-5	30582-30584	of	_	
152-6	30585-30590	these	_	
152-7	30591-30596	genes	_	
152-8	30597-30605	directly	_	
152-9	30606-30609	had	_	
152-10	30610-30612	an	_	
152-11	30613-30619	impact	_	
152-12	30620-30622	on	_	
152-13	30623-30625	or	_	
152-14	30626-30635	modulated	_	
152-15	30636-30646	phenotypic	_	
152-16	30647-30657	expression	_	
152-17	30658-30660	as	_	
152-18	30661-30672	hippocampal	_	
152-19	30673-30677	rsFC	_	
152-20	30678-30681	and	_	
152-21	30682-30689	related	_	
152-22	30690-30697	spatial	_	
152-23	30698-30704	memory	_	
152-24	30705-30713	function	_	
152-25	30714-30716	in	_	
152-26	30717-30721	this	_	
152-27	30722-30730	subgroup	_	
152-28	30730-30731	.	_	

#Text=Hence, our findings bridge the gap from genes regulating hippocampal development before birth to corresponding phenotypical markers like rsFC of hippocampus and associated cognitive, that is, SWM function at the outbreak of first-episode schizophrenia.
153-1	30732-30737	Hence	_	
153-2	30737-30738	,	_	
153-3	30739-30742	our	_	
153-4	30743-30751	findings	_	
153-5	30752-30758	bridge	_	
153-6	30759-30762	the	_	
153-7	30763-30766	gap	_	
153-8	30767-30771	from	_	
153-9	30772-30777	genes	_	
153-10	30778-30788	regulating	_	
153-11	30789-30800	hippocampal	_	
153-12	30801-30812	development	_	
153-13	30813-30819	before	_	
153-14	30820-30825	birth	_	
153-15	30826-30828	to	_	
153-16	30829-30842	corresponding	_	
153-17	30843-30855	phenotypical	_	
153-18	30856-30863	markers	_	
153-19	30864-30868	like	_	
153-20	30869-30873	rsFC	_	
153-21	30874-30876	of	_	
153-22	30877-30888	hippocampus	_	
153-23	30889-30892	and	_	
153-24	30893-30903	associated	_	
153-25	30904-30913	cognitive	_	
153-26	30913-30914	,	_	
153-27	30915-30919	that	_	
153-28	30920-30922	is	_	
153-29	30922-30923	,	_	
153-30	30924-30927	SWM	_	
153-31	30928-30936	function	_	
153-32	30937-30939	at	_	
153-33	30940-30943	the	_	
153-34	30944-30952	outbreak	_	
153-35	30953-30955	of	_	
153-36	30956-30969	first-episode	_	
153-37	30970-30983	schizophrenia	_	
153-38	30983-30984	.	_	

#Text=Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)
#Text=The authors declare no conflict of interest.
154-1	30985-30998	Supplementary	_	
154-2	30999-31010	Information	_	
154-3	31011-31022	accompanies	_	
154-4	31023-31026	the	_	
154-5	31027-31032	paper	_	
154-6	31033-31035	on	_	
154-7	31036-31039	the	_	
154-8	31040-31053	Translational	_	
154-9	31054-31064	Psychiatry	_	
154-10	31065-31072	website	_	
154-11	31073-31074	(	_	
154-12	31074-31078	http	_	
154-13	31078-31079	:	_	
154-14	31079-31080	/	_	
154-15	31080-31081	/	_	
154-16	31081-31095	www.nature.com	_	
154-17	31095-31096	/	_	
154-18	31096-31098	tp	_	
154-19	31098-31099	)	_	
154-20	31100-31103	The	_	
154-21	31104-31111	authors	_	
154-22	31112-31119	declare	_	
154-23	31120-31122	no	_	
154-24	31123-31131	conflict	_	
154-25	31132-31134	of	_	
154-26	31135-31143	interest	_	
154-27	31143-31144	.	_	

#Text=Genes, environment and schizophrenia
#Text=Implications of normal brain development for the pathogenesis of schizophrenia
#Text=Is schizophrenia a neurodevelopmental disorder
#Text=The heritability of schizophrenia and schizoaffective disorder: a family study
#Text=The Roscommon family study: I.
155-1	31145-31150	Genes	_	
155-2	31150-31151	,	_	
155-3	31152-31163	environment	_	
155-4	31164-31167	and	_	
155-5	31168-31181	schizophrenia	_	
155-6	31182-31194	Implications	_	
155-7	31195-31197	of	_	
155-8	31198-31204	normal	_	
155-9	31205-31210	brain	_	
155-10	31211-31222	development	_	
155-11	31223-31226	for	_	
155-12	31227-31230	the	_	
155-13	31231-31243	pathogenesis	_	
155-14	31244-31246	of	_	
155-15	31247-31260	schizophrenia	_	
155-16	31261-31263	Is	_	
155-17	31264-31277	schizophrenia	_	
155-18	31278-31279	a	_	
155-19	31280-31298	neurodevelopmental	_	
155-20	31299-31307	disorder	_	
155-21	31308-31311	The	_	
155-22	31312-31324	heritability	_	
155-23	31325-31327	of	_	
155-24	31328-31341	schizophrenia	_	
155-25	31342-31345	and	_	
155-26	31346-31361	schizoaffective	_	
155-27	31362-31370	disorder	_	
155-28	31370-31371	:	_	
155-29	31372-31373	a	_	
155-30	31374-31380	family	_	
155-31	31381-31386	study	_	
155-32	31387-31390	The	_	
155-33	31391-31400	Roscommon	_	
155-34	31401-31407	family	_	
155-35	31408-31413	study	_	
155-36	31413-31414	:	_	
155-37	31415-31416	I	_	
155-38	31416-31417	.	_	

#Text=Methods, diagnosis of probands, and risk of schizophrenia in relatives
#Text=Gottesman II.
156-1	31418-31425	Methods	_	
156-2	31425-31426	,	_	
156-3	31427-31436	diagnosis	_	
156-4	31437-31439	of	_	
156-5	31440-31448	probands	_	
156-6	31448-31449	,	_	
156-7	31450-31453	and	_	
156-8	31454-31458	risk	_	
156-9	31459-31461	of	_	
156-10	31462-31475	schizophrenia	_	
156-11	31476-31478	in	_	
156-12	31479-31488	relatives	_	
156-13	31489-31498	Gottesman	_	
156-14	31499-31501	II	_	
156-15	31501-31502	.	_	

#Text=The genetic epidemiology of schizophrenia and the design of linkage studies
#Text=Biological insights from 108 schizophrenia-associated genetic loci
#Text=Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network
#Text=De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia
#Text=High frequencies of de novo CNVs in bipolar disorder and schizophrenia
#Text=De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia
#Text=De novo mutations in schizophrenia implicate synaptic networks
#Text=A polygenic burden of rare disruptive mutations in schizophrenia
#Text=Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia
#Text=De novo mutations in schizophrenia implicate chromatin remodeling and support a genetic overlap with autism and intellectual disability
#Text=The hippocampal formation in schizophrenia
#Text=Neuroimaging studies of the hippocampus in schizophrenia
#Text=The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications
#Text=Altered resting-state functional connectivity and anatomical connectivity of hippocampus in schizophrenia
#Text=Functional integration between the posterior hippocampus and prefrontal cortex is impaired in both first episode schizophrenia and the at risk mental state
#Text=Prevalence of depression in patients with hypertension: a systematic review and meta-analysis
#Text=Neurocognitive deficits in first-episode schizophrenic patients and their first-degree relatives
#Text=Factor structures of the neurocognitive assessments and familial analysis in first-episode schizophrenia patients, their relatives and controls
#Text=DNA repair and mutant frequency in schizophrenia
#Text=Genetic polymorphism in the DNA repair gene XRCC1 and susceptibility to schizophrenia
#Text=Abnormal indices of cell cycle activity in schizophrenia and their potential association with oligodendrocytes
#Text=Schizophrenia is associated with dysregulation of a Cdk5 activator that regulates synaptic protein expression and cognition
#Text=Cell cycle regulatory failure in neurones: causes and consequences
#Text=The human hippocampus and spatial and episodic memory
#Text=Major depressive disorder
#Text=Prevalence of depression and depressive symptoms among resident physicians: a systematic review and meta-analysis
#Text=
#Text=The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
#Text=
#Text=Fast and accurate short read alignment with Burrows–Wheeler transform
#Text=The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data
#Text=PLINK: a tool set for whole-genome association and population-based linkage analyses
#Text=A comprehensive framework for prioritizing variants in exome sequencing studies of Mendelian diseases
#Text=A general framework for weighted gene co-expression network analysis
#Text=WGCNA: an R package for weighted correlation network analysis
#Text=Spatio-temporal transcriptome of the human brain
#Text=Accurate whole human genome sequencing using reversible terminator chemistry
#Text=Testing for an unusual distribution of rare variants
#Text=A versatile gene-based test for genome-wide association studies
#Text=Autism spectrum disorder susceptibility gene TAOK2 affects basal dendrite formation in the neocortex
#Text=Large recurrent microdeletions associated with schizophrenia
#Text=Relationship of GAD(67) regulation to cell cycle and DNA repair in GABA neurons in the adult hippocampus: bipolar disorder versus schizophrenia
#Text=Regulation of cell cycle and DNA repair in post-mitotic GABA neurons in psychotic disorders
#Text=Site-specific regulation of cell cycle and DNA repair in post-mitotic GABA cells in schizophrenic versus bipolars
#Text=The neurodevelopmental model of schizophrenia: update 2005
#Text=Neurodevelopmental hypothesis of schizophrenia
#Text=Inferior parietal lobule function in spatial perception and visuomotor integration
#Text=Abnormal indices of cell cycle activity in schizophrenia and their potential association with oligodendrocytes
#Text=Adult neurogenesis produces a large pool of new granule cells in the dentate gyrus
#Text=Resolving new memories: a critical look at the dentate gyrus, adult neurogenesis, and pattern separation
#Text=Could adult hippocampal neurogenesis be relevant for human behavior
#Text=The inferior parietal lobule is the target of output from the superior colliculus, hippocampus, and cerebellum
#Text=Supplementary Material
#Text=The developmental expression profile of 22 genes in the cell cycle pathway and 20 genes in the DNA repair pathway in hippocampus.
157-1	31503-31506	The	_	
157-2	31507-31514	genetic	_	
157-3	31515-31527	epidemiology	_	
157-4	31528-31530	of	_	
157-5	31531-31544	schizophrenia	_	
157-6	31545-31548	and	_	
157-7	31549-31552	the	_	
157-8	31553-31559	design	_	
157-9	31560-31562	of	_	
157-10	31563-31570	linkage	_	
157-11	31571-31578	studies	_	
157-12	31579-31589	Biological	_	
157-13	31590-31598	insights	_	
157-14	31599-31603	from	_	
157-15	31604-31607	108	_	
157-16	31608-31632	schizophrenia-associated	_	
157-17	31633-31640	genetic	_	
157-18	31641-31645	loci	_	
157-19	31646-31653	Spatial	_	
157-20	31654-31657	and	_	
157-21	31658-31666	temporal	_	
157-22	31667-31674	mapping	_	
157-23	31675-31677	of	_	
157-24	31678-31680	de	_	
157-25	31681-31685	novo	_	
157-26	31686-31695	mutations	_	
157-27	31696-31698	in	_	
157-28	31699-31712	schizophrenia	_	
157-29	31713-31715	to	_	
157-30	31716-31717	a	_	
157-31	31718-31723	fetal	_	
157-32	31724-31734	prefrontal	_	
157-33	31735-31743	cortical	_	
157-34	31744-31751	network	_	
157-35	31752-31754	De	_	
157-36	31755-31759	novo	_	
157-37	31760-31763	CNV	_	
157-38	31764-31772	analysis	_	
157-39	31773-31783	implicates	_	
157-40	31784-31792	specific	_	
157-41	31793-31806	abnormalities	_	
157-42	31807-31809	of	_	
157-43	31810-31822	postsynaptic	_	
157-44	31823-31833	signalling	_	
157-45	31834-31843	complexes	_	
157-46	31844-31846	in	_	
157-47	31847-31850	the	_	
157-48	31851-31863	pathogenesis	_	
157-49	31864-31866	of	_	
157-50	31867-31880	schizophrenia	_	
157-51	31881-31885	High	_	
157-52	31886-31897	frequencies	_	
157-53	31898-31900	of	_	
157-54	31901-31903	de	_	
157-55	31904-31908	novo	_	
157-56	31909-31913	CNVs	_	
157-57	31914-31916	in	_	
157-58	31917-31924	bipolar	_	
157-59	31925-31933	disorder	_	
157-60	31934-31937	and	_	
157-61	31938-31951	schizophrenia	_	
157-62	31952-31954	De	_	
157-63	31955-31959	novo	_	
157-64	31960-31964	gene	_	
157-65	31965-31974	mutations	_	
157-66	31975-31984	highlight	_	
157-67	31985-31993	patterns	_	
157-68	31994-31996	of	_	
157-69	31997-32004	genetic	_	
157-70	32005-32008	and	_	
157-71	32009-32015	neural	_	
157-72	32016-32026	complexity	_	
157-73	32027-32029	in	_	
157-74	32030-32043	schizophrenia	_	
157-75	32044-32046	De	_	
157-76	32047-32051	novo	_	
157-77	32052-32061	mutations	_	
157-78	32062-32064	in	_	
157-79	32065-32078	schizophrenia	_	
157-80	32079-32088	implicate	_	
157-81	32089-32097	synaptic	_	
157-82	32098-32106	networks	_	
157-83	32107-32108	A	_	
157-84	32109-32118	polygenic	_	
157-85	32119-32125	burden	_	
157-86	32126-32128	of	_	
157-87	32129-32133	rare	_	
157-88	32134-32144	disruptive	_	
157-89	32145-32154	mutations	_	
157-90	32155-32157	in	_	
157-91	32158-32171	schizophrenia	_	
157-92	32172-32176	Rare	_	
157-93	32177-32187	structural	_	
157-94	32188-32196	variants	_	
157-95	32197-32204	disrupt	_	
157-96	32205-32213	multiple	_	
157-97	32214-32219	genes	_	
157-98	32220-32222	in	_	
157-99	32223-32241	neurodevelopmental	_	
157-100	32242-32250	pathways	_	
157-101	32251-32253	in	_	
157-102	32254-32267	schizophrenia	_	
157-103	32268-32270	De	_	
157-104	32271-32275	novo	_	
157-105	32276-32285	mutations	_	
157-106	32286-32288	in	_	
157-107	32289-32302	schizophrenia	_	
157-108	32303-32312	implicate	_	
157-109	32313-32322	chromatin	_	
157-110	32323-32333	remodeling	_	
157-111	32334-32337	and	_	
157-112	32338-32345	support	_	
157-113	32346-32347	a	_	
157-114	32348-32355	genetic	_	
157-115	32356-32363	overlap	_	
157-116	32364-32368	with	_	
157-117	32369-32375	autism	_	
157-118	32376-32379	and	_	
157-119	32380-32392	intellectual	_	
157-120	32393-32403	disability	_	
157-121	32404-32407	The	_	
157-122	32408-32419	hippocampal	_	
157-123	32420-32429	formation	_	
157-124	32430-32432	in	_	
157-125	32433-32446	schizophrenia	_	
157-126	32447-32459	Neuroimaging	_	
157-127	32460-32467	studies	_	
157-128	32468-32470	of	_	
157-129	32471-32474	the	_	
157-130	32475-32486	hippocampus	_	
157-131	32487-32489	in	_	
157-132	32490-32503	schizophrenia	_	
157-133	32504-32507	The	_	
157-134	32508-32519	hippocampus	_	
157-135	32520-32522	in	_	
157-136	32523-32536	schizophrenia	_	
157-137	32536-32537	:	_	
157-138	32538-32539	a	_	
157-139	32540-32546	review	_	
157-140	32547-32549	of	_	
157-141	32550-32553	the	_	
157-142	32554-32571	neuropathological	_	
157-143	32572-32580	evidence	_	
157-144	32581-32584	and	_	
157-145	32585-32588	its	_	
157-146	32589-32607	pathophysiological	_	
157-147	32608-32620	implications	_	
157-148	32621-32628	Altered	_	
157-149	32629-32642	resting-state	_	
157-150	32643-32653	functional	_	
157-151	32654-32666	connectivity	_	
157-152	32667-32670	and	_	
157-153	32671-32681	anatomical	_	
157-154	32682-32694	connectivity	_	
157-155	32695-32697	of	_	
157-156	32698-32709	hippocampus	_	
157-157	32710-32712	in	_	
157-158	32713-32726	schizophrenia	_	
157-159	32727-32737	Functional	_	
157-160	32738-32749	integration	_	
157-161	32750-32757	between	_	
157-162	32758-32761	the	_	
157-163	32762-32771	posterior	_	
157-164	32772-32783	hippocampus	_	
157-165	32784-32787	and	_	
157-166	32788-32798	prefrontal	_	
157-167	32799-32805	cortex	_	
157-168	32806-32808	is	_	
157-169	32809-32817	impaired	_	
157-170	32818-32820	in	_	
157-171	32821-32825	both	_	
157-172	32826-32831	first	_	
157-173	32832-32839	episode	_	
157-174	32840-32853	schizophrenia	_	
157-175	32854-32857	and	_	
157-176	32858-32861	the	_	
157-177	32862-32864	at	_	
157-178	32865-32869	risk	_	
157-179	32870-32876	mental	_	
157-180	32877-32882	state	_	
157-181	32883-32893	Prevalence	_	
157-182	32894-32896	of	_	
157-183	32897-32907	depression	_	
157-184	32908-32910	in	_	
157-185	32911-32919	patients	_	
157-186	32920-32924	with	_	
157-187	32925-32937	hypertension	_	
157-188	32937-32938	:	_	
157-189	32939-32940	a	_	
157-190	32941-32951	systematic	_	
157-191	32952-32958	review	_	
157-192	32959-32962	and	_	
157-193	32963-32976	meta-analysis	_	
157-194	32977-32991	Neurocognitive	_	
157-195	32992-33000	deficits	_	
157-196	33001-33003	in	_	
157-197	33004-33017	first-episode	_	
157-198	33018-33031	schizophrenic	_	
157-199	33032-33040	patients	_	
157-200	33041-33044	and	_	
157-201	33045-33050	their	_	
157-202	33051-33063	first-degree	_	
157-203	33064-33073	relatives	_	
157-204	33074-33080	Factor	_	
157-205	33081-33091	structures	_	
157-206	33092-33094	of	_	
157-207	33095-33098	the	_	
157-208	33099-33113	neurocognitive	_	
157-209	33114-33125	assessments	_	
157-210	33126-33129	and	_	
157-211	33130-33138	familial	_	
157-212	33139-33147	analysis	_	
157-213	33148-33150	in	_	
157-214	33151-33164	first-episode	_	
157-215	33165-33178	schizophrenia	_	
157-216	33179-33187	patients	_	
157-217	33187-33188	,	_	
157-218	33189-33194	their	_	
157-219	33195-33204	relatives	_	
157-220	33205-33208	and	_	
157-221	33209-33217	controls	_	
157-222	33218-33221	DNA	_	
157-223	33222-33228	repair	_	
157-224	33229-33232	and	_	
157-225	33233-33239	mutant	_	
157-226	33240-33249	frequency	_	
157-227	33250-33252	in	_	
157-228	33253-33266	schizophrenia	_	
157-229	33267-33274	Genetic	_	
157-230	33275-33287	polymorphism	_	
157-231	33288-33290	in	_	
157-232	33291-33294	the	_	
157-233	33295-33298	DNA	_	
157-234	33299-33305	repair	_	
157-235	33306-33310	gene	_	
157-236	33311-33316	XRCC1	_	
157-237	33317-33320	and	_	
157-238	33321-33335	susceptibility	_	
157-239	33336-33338	to	_	
157-240	33339-33352	schizophrenia	_	
157-241	33353-33361	Abnormal	_	
157-242	33362-33369	indices	_	
157-243	33370-33372	of	_	
157-244	33373-33377	cell	_	
157-245	33378-33383	cycle	_	
157-246	33384-33392	activity	_	
157-247	33393-33395	in	_	
157-248	33396-33409	schizophrenia	_	
157-249	33410-33413	and	_	
157-250	33414-33419	their	_	
157-251	33420-33429	potential	_	
157-252	33430-33441	association	_	
157-253	33442-33446	with	_	
157-254	33447-33463	oligodendrocytes	_	
157-255	33464-33477	Schizophrenia	_	
157-256	33478-33480	is	_	
157-257	33481-33491	associated	_	
157-258	33492-33496	with	_	
157-259	33497-33510	dysregulation	_	
157-260	33511-33513	of	_	
157-261	33514-33515	a	_	
157-262	33516-33520	Cdk5	_	
157-263	33521-33530	activator	_	
157-264	33531-33535	that	_	
157-265	33536-33545	regulates	_	
157-266	33546-33554	synaptic	_	
157-267	33555-33562	protein	_	
157-268	33563-33573	expression	_	
157-269	33574-33577	and	_	
157-270	33578-33587	cognition	_	
157-271	33588-33592	Cell	_	
157-272	33593-33598	cycle	_	
157-273	33599-33609	regulatory	_	
157-274	33610-33617	failure	_	
157-275	33618-33620	in	_	
157-276	33621-33629	neurones	_	
157-277	33629-33630	:	_	
157-278	33631-33637	causes	_	
157-279	33638-33641	and	_	
157-280	33642-33654	consequences	_	
157-281	33655-33658	The	_	
157-282	33659-33664	human	_	
157-283	33665-33676	hippocampus	_	
157-284	33677-33680	and	_	
157-285	33681-33688	spatial	_	
157-286	33689-33692	and	_	
157-287	33693-33701	episodic	_	
157-288	33702-33708	memory	_	
157-289	33709-33714	Major	_	
157-290	33715-33725	depressive	_	
157-291	33726-33734	disorder	_	
157-292	33735-33745	Prevalence	_	
157-293	33746-33748	of	_	
157-294	33749-33759	depression	_	
157-295	33760-33763	and	_	
157-296	33764-33774	depressive	_	
157-297	33775-33783	symptoms	_	
157-298	33784-33789	among	_	
157-299	33790-33798	resident	_	
157-300	33799-33809	physicians	_	
157-301	33809-33810	:	_	
157-302	33811-33812	a	_	
157-303	33813-33823	systematic	_	
157-304	33824-33830	review	_	
157-305	33831-33834	and	_	
157-306	33835-33848	meta-analysis	_	
157-307	33850-33853	The	_	
157-308	33854-33862	Positive	_	
157-309	33863-33866	and	_	
157-310	33867-33875	Negative	_	
157-311	33876-33884	Syndrome	_	
157-312	33885-33890	Scale	_	
157-313	33891-33892	(	_	
157-314	33892-33897	PANSS	_	
157-315	33897-33898	)	_	
157-316	33899-33902	for	_	
157-317	33903-33916	schizophrenia	_	
157-318	33918-33922	Fast	_	
157-319	33923-33926	and	_	
157-320	33927-33935	accurate	_	
157-321	33936-33941	short	_	
157-322	33942-33946	read	_	
157-323	33947-33956	alignment	_	
157-324	33957-33961	with	_	
157-325	33962-33977	Burrows–Wheeler	_	
157-326	33978-33987	transform	_	
157-327	33988-33991	The	_	
157-328	33992-33998	Genome	_	
157-329	33999-34007	Analysis	_	
157-330	34008-34015	Toolkit	_	
157-331	34015-34016	:	_	
157-332	34017-34018	a	_	
157-333	34019-34028	MapReduce	_	
157-334	34029-34038	framework	_	
157-335	34039-34042	for	_	
157-336	34043-34052	analyzing	_	
157-337	34053-34068	next-generation	_	
157-338	34069-34072	DNA	_	
157-339	34073-34083	sequencing	_	
157-340	34084-34088	data	_	
157-341	34089-34094	PLINK	_	
157-342	34094-34095	:	_	
157-343	34096-34097	a	_	
157-344	34098-34102	tool	_	
157-345	34103-34106	set	_	
157-346	34107-34110	for	_	
157-347	34111-34123	whole-genome	_	
157-348	34124-34135	association	_	
157-349	34136-34139	and	_	
157-350	34140-34156	population-based	_	
157-351	34157-34164	linkage	_	
157-352	34165-34173	analyses	_	
157-353	34174-34175	A	_	
157-354	34176-34189	comprehensive	_	
157-355	34190-34199	framework	_	
157-356	34200-34203	for	_	
157-357	34204-34216	prioritizing	_	
157-358	34217-34225	variants	_	
157-359	34226-34228	in	_	
157-360	34229-34234	exome	_	
157-361	34235-34245	sequencing	_	
157-362	34246-34253	studies	_	
157-363	34254-34256	of	_	
157-364	34257-34266	Mendelian	_	
157-365	34267-34275	diseases	_	
157-366	34276-34277	A	_	
157-367	34278-34285	general	_	
157-368	34286-34295	framework	_	
157-369	34296-34299	for	_	
157-370	34300-34308	weighted	_	
157-371	34309-34313	gene	_	
157-372	34314-34327	co-expression	_	
157-373	34328-34335	network	_	
157-374	34336-34344	analysis	_	
157-375	34345-34350	WGCNA	_	
157-376	34350-34351	:	_	
157-377	34352-34354	an	_	
157-378	34355-34356	R	_	
157-379	34357-34364	package	_	
157-380	34365-34368	for	_	
157-381	34369-34377	weighted	_	
157-382	34378-34389	correlation	_	
157-383	34390-34397	network	_	
157-384	34398-34406	analysis	_	
157-385	34407-34422	Spatio-temporal	_	
157-386	34423-34436	transcriptome	_	
157-387	34437-34439	of	_	
157-388	34440-34443	the	_	
157-389	34444-34449	human	_	
157-390	34450-34455	brain	_	
157-391	34456-34464	Accurate	_	
157-392	34465-34470	whole	_	
157-393	34471-34476	human	_	
157-394	34477-34483	genome	_	
157-395	34484-34494	sequencing	_	
157-396	34495-34500	using	_	
157-397	34501-34511	reversible	_	
157-398	34512-34522	terminator	_	
157-399	34523-34532	chemistry	_	
157-400	34533-34540	Testing	_	
157-401	34541-34544	for	_	
157-402	34545-34547	an	_	
157-403	34548-34555	unusual	_	
157-404	34556-34568	distribution	_	
157-405	34569-34571	of	_	
157-406	34572-34576	rare	_	
157-407	34577-34585	variants	_	
157-408	34586-34587	A	_	
157-409	34588-34597	versatile	_	
157-410	34598-34608	gene-based	_	
157-411	34609-34613	test	_	
157-412	34614-34617	for	_	
157-413	34618-34629	genome-wide	_	
157-414	34630-34641	association	_	
157-415	34642-34649	studies	_	
157-416	34650-34656	Autism	_	
157-417	34657-34665	spectrum	_	
157-418	34666-34674	disorder	_	
157-419	34675-34689	susceptibility	_	
157-420	34690-34694	gene	_	
157-421	34695-34700	TAOK2	_	
157-422	34701-34708	affects	_	
157-423	34709-34714	basal	_	
157-424	34715-34723	dendrite	_	
157-425	34724-34733	formation	_	
157-426	34734-34736	in	_	
157-427	34737-34740	the	_	
157-428	34741-34750	neocortex	_	
157-429	34751-34756	Large	_	
157-430	34757-34766	recurrent	_	
157-431	34767-34781	microdeletions	_	
157-432	34782-34792	associated	_	
157-433	34793-34797	with	_	
157-434	34798-34811	schizophrenia	_	
157-435	34812-34824	Relationship	_	
157-436	34825-34827	of	_	
157-437	34828-34831	GAD	_	
157-438	34831-34832	(	_	
157-439	34832-34834	67	_	
157-440	34834-34835	)	_	
157-441	34836-34846	regulation	_	
157-442	34847-34849	to	_	
157-443	34850-34854	cell	_	
157-444	34855-34860	cycle	_	
157-445	34861-34864	and	_	
157-446	34865-34868	DNA	_	
157-447	34869-34875	repair	_	
157-448	34876-34878	in	_	
157-449	34879-34883	GABA	_	
157-450	34884-34891	neurons	_	
157-451	34892-34894	in	_	
157-452	34895-34898	the	_	
157-453	34899-34904	adult	_	
157-454	34905-34916	hippocampus	_	
157-455	34916-34917	:	_	
157-456	34918-34925	bipolar	_	
157-457	34926-34934	disorder	_	
157-458	34935-34941	versus	_	
157-459	34942-34955	schizophrenia	_	
157-460	34956-34966	Regulation	_	
157-461	34967-34969	of	_	
157-462	34970-34974	cell	_	
157-463	34975-34980	cycle	_	
157-464	34981-34984	and	_	
157-465	34985-34988	DNA	_	
157-466	34989-34995	repair	_	
157-467	34996-34998	in	_	
157-468	34999-35011	post-mitotic	_	
157-469	35012-35016	GABA	_	
157-470	35017-35024	neurons	_	
157-471	35025-35027	in	_	
157-472	35028-35037	psychotic	_	
157-473	35038-35047	disorders	_	
157-474	35048-35061	Site-specific	_	
157-475	35062-35072	regulation	_	
157-476	35073-35075	of	_	
157-477	35076-35080	cell	_	
157-478	35081-35086	cycle	_	
157-479	35087-35090	and	_	
157-480	35091-35094	DNA	_	
157-481	35095-35101	repair	_	
157-482	35102-35104	in	_	
157-483	35105-35117	post-mitotic	_	
157-484	35118-35122	GABA	_	
157-485	35123-35128	cells	_	
157-486	35129-35131	in	_	
157-487	35132-35145	schizophrenic	_	
157-488	35146-35152	versus	_	
157-489	35153-35161	bipolars	_	
157-490	35162-35165	The	_	
157-491	35166-35184	neurodevelopmental	_	
157-492	35185-35190	model	_	
157-493	35191-35193	of	_	
157-494	35194-35207	schizophrenia	_	
157-495	35207-35208	:	_	
157-496	35209-35215	update	_	
157-497	35216-35220	2005	_	
157-498	35221-35239	Neurodevelopmental	_	
157-499	35240-35250	hypothesis	_	
157-500	35251-35253	of	_	
157-501	35254-35267	schizophrenia	_	
157-502	35268-35276	Inferior	_	
157-503	35277-35285	parietal	_	
157-504	35286-35292	lobule	_	
157-505	35293-35301	function	_	
157-506	35302-35304	in	_	
157-507	35305-35312	spatial	_	
157-508	35313-35323	perception	_	
157-509	35324-35327	and	_	
157-510	35328-35338	visuomotor	_	
157-511	35339-35350	integration	_	
157-512	35351-35359	Abnormal	_	
157-513	35360-35367	indices	_	
157-514	35368-35370	of	_	
157-515	35371-35375	cell	_	
157-516	35376-35381	cycle	_	
157-517	35382-35390	activity	_	
157-518	35391-35393	in	_	
157-519	35394-35407	schizophrenia	_	
157-520	35408-35411	and	_	
157-521	35412-35417	their	_	
157-522	35418-35427	potential	_	
157-523	35428-35439	association	_	
157-524	35440-35444	with	_	
157-525	35445-35461	oligodendrocytes	_	
157-526	35462-35467	Adult	_	
157-527	35468-35480	neurogenesis	_	
157-528	35481-35489	produces	_	
157-529	35490-35491	a	_	
157-530	35492-35497	large	_	
157-531	35498-35502	pool	_	
157-532	35503-35505	of	_	
157-533	35506-35509	new	_	
157-534	35510-35517	granule	_	
157-535	35518-35523	cells	_	
157-536	35524-35526	in	_	
157-537	35527-35530	the	_	
157-538	35531-35538	dentate	_	
157-539	35539-35544	gyrus	_	
157-540	35545-35554	Resolving	_	
157-541	35555-35558	new	_	
157-542	35559-35567	memories	_	
157-543	35567-35568	:	_	
157-544	35569-35570	a	_	
157-545	35571-35579	critical	_	
157-546	35580-35584	look	_	
157-547	35585-35587	at	_	
157-548	35588-35591	the	_	
157-549	35592-35599	dentate	_	
157-550	35600-35605	gyrus	_	
157-551	35605-35606	,	_	
157-552	35607-35612	adult	_	
157-553	35613-35625	neurogenesis	_	
157-554	35625-35626	,	_	
157-555	35627-35630	and	_	
157-556	35631-35638	pattern	_	
157-557	35639-35649	separation	_	
157-558	35650-35655	Could	_	
157-559	35656-35661	adult	_	
157-560	35662-35673	hippocampal	_	
157-561	35674-35686	neurogenesis	_	
157-562	35687-35689	be	_	
157-563	35690-35698	relevant	_	
157-564	35699-35702	for	_	
157-565	35703-35708	human	_	
157-566	35709-35717	behavior	_	
157-567	35718-35721	The	_	
157-568	35722-35730	inferior	_	
157-569	35731-35739	parietal	_	
157-570	35740-35746	lobule	_	
157-571	35747-35749	is	_	
157-572	35750-35753	the	_	
157-573	35754-35760	target	_	
157-574	35761-35763	of	_	
157-575	35764-35770	output	_	
157-576	35771-35775	from	_	
157-577	35776-35779	the	_	
157-578	35780-35788	superior	_	
157-579	35789-35799	colliculus	_	
157-580	35799-35800	,	_	
157-581	35801-35812	hippocampus	_	
157-582	35812-35813	,	_	
157-583	35814-35817	and	_	
157-584	35818-35828	cerebellum	_	
157-585	35829-35842	Supplementary	_	
157-586	35843-35851	Material	_	
157-587	35852-35855	The	_	
157-588	35856-35869	developmental	_	
157-589	35870-35880	expression	_	
157-590	35881-35888	profile	_	
157-591	35889-35891	of	_	
157-592	35892-35894	22	_	
157-593	35895-35900	genes	_	
157-594	35901-35903	in	_	
157-595	35904-35907	the	_	
157-596	35908-35912	cell	_	
157-597	35913-35918	cycle	_	
157-598	35919-35926	pathway	_	
157-599	35927-35930	and	_	
157-600	35931-35933	20	_	
157-601	35934-35939	genes	_	
157-602	35940-35942	in	_	
157-603	35943-35946	the	_	
157-604	35947-35950	DNA	_	
157-605	35951-35957	repair	_	
157-606	35958-35965	pathway	_	
157-607	35966-35968	in	_	
157-608	35969-35980	hippocampus	_	
157-609	35980-35981	.	_	

#Text=Following colors for different Gene Ontology (GO) categories were used: red for DNA repair and blue for cell cycle, and a smooth curve with confidence interval (gray range).
158-1	35982-35991	Following	_	
158-2	35992-35998	colors	_	
158-3	35999-36002	for	_	
158-4	36003-36012	different	_	
158-5	36013-36017	Gene	_	
158-6	36018-36026	Ontology	_	
158-7	36027-36028	(	_	
158-8	36028-36030	GO	_	
158-9	36030-36031	)	_	
158-10	36032-36042	categories	_	
158-11	36043-36047	were	_	
158-12	36048-36052	used	_	
158-13	36052-36053	:	_	
158-14	36054-36057	red	_	
158-15	36058-36061	for	_	
158-16	36062-36065	DNA	_	
158-17	36066-36072	repair	_	
158-18	36073-36076	and	_	
158-19	36077-36081	blue	_	
158-20	36082-36085	for	_	
158-21	36086-36090	cell	_	
158-22	36091-36096	cycle	_	
158-23	36096-36097	,	_	
158-24	36098-36101	and	_	
158-25	36102-36103	a	_	
158-26	36104-36110	smooth	_	
158-27	36111-36116	curve	_	
158-28	36117-36121	with	_	
158-29	36122-36132	confidence	_	
158-30	36133-36141	interval	_	
158-31	36142-36143	(	_	
158-32	36143-36147	gray	_	
158-33	36148-36153	range	_	
158-34	36153-36154	)	_	
158-35	36154-36155	.	_	

#Text=The expression profiles show high expression during the stage of brain development before birth, with a sharp decrease in expression after birth.
159-1	36156-36159	The	_	
159-2	36160-36170	expression	_	
159-3	36171-36179	profiles	_	
159-4	36180-36184	show	_	
159-5	36185-36189	high	_	
159-6	36190-36200	expression	_	
159-7	36201-36207	during	_	
159-8	36208-36211	the	_	
159-9	36212-36217	stage	_	
159-10	36218-36220	of	_	
159-11	36221-36226	brain	_	
159-12	36227-36238	development	_	
159-13	36239-36245	before	_	
159-14	36246-36251	birth	_	
159-15	36251-36252	,	_	
159-16	36253-36257	with	_	
159-17	36258-36259	a	_	
159-18	36260-36265	sharp	_	
159-19	36266-36274	decrease	_	
159-20	36275-36277	in	_	
159-21	36278-36288	expression	_	
159-22	36289-36294	after	_	
159-23	36295-36300	birth	_	
159-24	36300-36301	.	_	

#Text=Aberrant resting-state functional connectivity (rsFC) of the left hippocampus among three groups.
160-1	36302-36310	Aberrant	_	
160-2	36311-36324	resting-state	_	
160-3	36325-36335	functional	_	
160-4	36336-36348	connectivity	_	
160-5	36349-36350	(	_	
160-6	36350-36354	rsFC	_	
160-7	36354-36355	)	_	
160-8	36356-36358	of	_	
160-9	36359-36362	the	_	
160-10	36363-36367	left	_	
160-11	36368-36379	hippocampus	_	
160-12	36380-36385	among	_	
160-13	36386-36391	three	_	
160-14	36392-36398	groups	_	
160-15	36398-36399	.	_	

#Text=(a) Left inferior parietal cortex and right cerebellum posterior lobe showed significantly different rsFC with left hippocampus among three groups.
161-1	36400-36401	(	_	
161-2	36401-36402	a	_	
161-3	36402-36403	)	_	
161-4	36404-36408	Left	_	
161-5	36409-36417	inferior	_	
161-6	36418-36426	parietal	_	
161-7	36427-36433	cortex	_	
161-8	36434-36437	and	_	
161-9	36438-36443	right	_	
161-10	36444-36454	cerebellum	_	
161-11	36455-36464	posterior	_	
161-12	36465-36469	lobe	_	
161-13	36470-36476	showed	_	
161-14	36477-36490	significantly	_	
161-15	36491-36500	different	_	
161-16	36501-36505	rsFC	_	
161-17	36506-36510	with	_	
161-18	36511-36515	left	_	
161-19	36516-36527	hippocampus	_	
161-20	36528-36533	among	_	
161-21	36534-36539	three	_	
161-22	36540-36546	groups	_	
161-23	36546-36547	.	_	

#Text=The statistical significance threshold was set at P<0.05 and corrected for multiple comparisons based on Monte Carlo simulations, for main effect for diagnosis of functional connectivity (FC) of left hippocampus.
162-1	36548-36551	The	_	
162-2	36552-36563	statistical	_	
162-3	36564-36576	significance	_	
162-4	36577-36586	threshold	_	
162-5	36587-36590	was	_	
162-6	36591-36594	set	_	
162-7	36595-36597	at	_	
162-8	36598-36599	P	_	
162-9	36599-36600	<	_	
162-10	36600-36604	0.05	_	
162-11	36605-36608	and	_	
162-12	36609-36618	corrected	_	
162-13	36619-36622	for	_	
162-14	36623-36631	multiple	_	
162-15	36632-36643	comparisons	_	
162-16	36644-36649	based	_	
162-17	36650-36652	on	_	
162-18	36653-36658	Monte	_	
162-19	36659-36664	Carlo	_	
162-20	36665-36676	simulations	_	
162-21	36676-36677	,	_	
162-22	36678-36681	for	_	
162-23	36682-36686	main	_	
162-24	36687-36693	effect	_	
162-25	36694-36697	for	_	
162-26	36698-36707	diagnosis	_	
162-27	36708-36710	of	_	
162-28	36711-36721	functional	_	
162-29	36722-36734	connectivity	_	
162-30	36735-36736	(	_	
162-31	36736-36738	FC	_	
162-32	36738-36739	)	_	
162-33	36740-36742	of	_	
162-34	36743-36747	left	_	
162-35	36748-36759	hippocampus	_	
162-36	36759-36760	.	_	

#Text=(b) ANCOVA with sex, age, education and the hippocampal volume as covariances. rsFC between left hippocampus and left inferior parietal cortex is increased, whereas rsFC between left hippocampus and cerebellum is decreased only in schizophrenic patients with rare damage variants (RDVs).
163-1	36761-36762	(	_	
163-2	36762-36763	b	_	
163-3	36763-36764	)	_	
163-4	36765-36771	ANCOVA	_	
163-5	36772-36776	with	_	
163-6	36777-36780	sex	_	
163-7	36780-36781	,	_	
163-8	36782-36785	age	_	
163-9	36785-36786	,	_	
163-10	36787-36796	education	_	
163-11	36797-36800	and	_	
163-12	36801-36804	the	_	
163-13	36805-36816	hippocampal	_	
163-14	36817-36823	volume	_	
163-15	36824-36826	as	_	
163-16	36827-36838	covariances	_	
163-17	36838-36839	.	_	
163-18	36840-36844	rsFC	_	
163-19	36845-36852	between	_	
163-20	36853-36857	left	_	
163-21	36858-36869	hippocampus	_	
163-22	36870-36873	and	_	
163-23	36874-36878	left	_	
163-24	36879-36887	inferior	_	
163-25	36888-36896	parietal	_	
163-26	36897-36903	cortex	_	
163-27	36904-36906	is	_	
163-28	36907-36916	increased	_	
163-29	36916-36917	,	_	
163-30	36918-36925	whereas	_	
163-31	36926-36930	rsFC	_	
163-32	36931-36938	between	_	
163-33	36939-36943	left	_	
163-34	36944-36955	hippocampus	_	
163-35	36956-36959	and	_	
163-36	36960-36970	cerebellum	_	
163-37	36971-36973	is	_	
163-38	36974-36983	decreased	_	
163-39	36984-36988	only	_	
163-40	36989-36991	in	_	
163-41	36992-37005	schizophrenic	_	
163-42	37006-37014	patients	_	
163-43	37015-37019	with	_	
163-44	37020-37024	rare	_	
163-45	37025-37031	damage	_	
163-46	37032-37040	variants	_	
163-47	37041-37042	(	_	
163-48	37042-37046	RDVs	_	
163-49	37046-37047	)	_	
163-50	37047-37048	.	_	

#Text=The statistical significance threshold was set at P<0.05, post hoc test by least significant difference.
164-1	37049-37052	The	_	
164-2	37053-37064	statistical	_	
164-3	37065-37077	significance	_	
164-4	37078-37087	threshold	_	
164-5	37088-37091	was	_	
164-6	37092-37095	set	_	
164-7	37096-37098	at	_	
164-8	37099-37100	P	_	
164-9	37100-37101	<	_	
164-10	37101-37105	0.05	_	
164-11	37105-37106	,	_	
164-12	37107-37111	post	_	
164-13	37112-37115	hoc	_	
164-14	37116-37120	test	_	
164-15	37121-37123	by	_	
164-16	37124-37129	least	_	
164-17	37130-37141	significant	_	
164-18	37142-37152	difference	_	
164-19	37152-37153	.	_	

#Text=ANCOVA, analysis of covariance; HIP, hippocampus; IPL, inferior parietal cortex; L, left; PCL, cerebellum posterior lobe; R, right.
165-1	37154-37160	ANCOVA	_	
165-2	37160-37161	,	_	
165-3	37162-37170	analysis	_	
165-4	37171-37173	of	_	
165-5	37174-37184	covariance	_	
165-6	37184-37185	;	_	
165-7	37186-37189	HIP	_	
165-8	37189-37190	,	_	
165-9	37191-37202	hippocampus	_	
165-10	37202-37203	;	_	
165-11	37204-37207	IPL	_	
165-12	37207-37208	,	_	
165-13	37209-37217	inferior	_	
165-14	37218-37226	parietal	_	
165-15	37227-37233	cortex	_	
165-16	37233-37234	;	_	
165-17	37235-37236	L	_	
165-18	37236-37237	,	_	
165-19	37238-37242	left	_	
165-20	37242-37243	;	_	
165-21	37244-37247	PCL	_	
165-22	37247-37248	,	_	
165-23	37249-37259	cerebellum	_	
165-24	37260-37269	posterior	_	
165-25	37270-37274	lobe	_	
165-26	37274-37275	;	_	
165-27	37276-37277	R	_	
165-28	37277-37278	,	_	
165-29	37279-37284	right	_	
165-30	37284-37285	.	_	

#Text=Notes: s.e. for all figures.
166-1	37286-37291	Notes	_	
166-2	37291-37292	:	_	
166-3	37293-37296	s.e	_	
166-4	37296-37297	.	_	
166-5	37298-37301	for	_	
166-6	37302-37305	all	_	
166-7	37306-37313	figures	_	
166-8	37313-37314	.	_	

#Text=Aberrant resting-state functional connectivity (rsFC) of hippocampal subregions.
167-1	37315-37323	Aberrant	_	
167-2	37324-37337	resting-state	_	
167-3	37338-37348	functional	_	
167-4	37349-37361	connectivity	_	
167-5	37362-37363	(	_	
167-6	37363-37367	rsFC	_	
167-7	37367-37368	)	_	
167-8	37369-37371	of	_	
167-9	37372-37383	hippocampal	_	
167-10	37384-37394	subregions	_	
167-11	37394-37395	.	_	

#Text=(a) The brain map of aberrant rsFC with hippocampal subregions among three groups.
168-1	37396-37397	(	_	
168-2	37397-37398	a	_	
168-3	37398-37399	)	_	
168-4	37400-37403	The	_	
168-5	37404-37409	brain	_	
168-6	37410-37413	map	_	
168-7	37414-37416	of	_	
168-8	37417-37425	aberrant	_	
168-9	37426-37430	rsFC	_	
168-10	37431-37435	with	_	
168-11	37436-37447	hippocampal	_	
168-12	37448-37458	subregions	_	
168-13	37459-37464	among	_	
168-14	37465-37470	three	_	
168-15	37471-37477	groups	_	
168-16	37477-37478	.	_	

#Text=The statistical significance threshold was set at P<0.05, corrected for multiple comparisons based on Monte Carlo simulations, for main effect for diagnosis of functional connectivity (FC) of the different hippocampal subregions.
169-1	37479-37482	The	_	
169-2	37483-37494	statistical	_	
169-3	37495-37507	significance	_	
169-4	37508-37517	threshold	_	
169-5	37518-37521	was	_	
169-6	37522-37525	set	_	
169-7	37526-37528	at	_	
169-8	37529-37530	P	_	
169-9	37530-37531	<	_	
169-10	37531-37535	0.05	_	
169-11	37535-37536	,	_	
169-12	37537-37546	corrected	_	
169-13	37547-37550	for	_	
169-14	37551-37559	multiple	_	
169-15	37560-37571	comparisons	_	
169-16	37572-37577	based	_	
169-17	37578-37580	on	_	
169-18	37581-37586	Monte	_	
169-19	37587-37592	Carlo	_	
169-20	37593-37604	simulations	_	
169-21	37604-37605	,	_	
169-22	37606-37609	for	_	
169-23	37610-37614	main	_	
169-24	37615-37621	effect	_	
169-25	37622-37625	for	_	
169-26	37626-37635	diagnosis	_	
169-27	37636-37638	of	_	
169-28	37639-37649	functional	_	
169-29	37650-37662	connectivity	_	
169-30	37663-37664	(	_	
169-31	37664-37666	FC	_	
169-32	37666-37667	)	_	
169-33	37668-37670	of	_	
169-34	37671-37674	the	_	
169-35	37675-37684	different	_	
169-36	37685-37696	hippocampal	_	
169-37	37697-37707	subregions	_	
169-38	37707-37708	.	_	

#Text=(b) rsFC between left DG and left IPL increased only in schizophrenic patients with rare damage variants, whereas decreased rsFC of left SC with MFG was only found in schizophrenic patients without rare damage variants.
170-1	37709-37710	(	_	
170-2	37710-37711	b	_	
170-3	37711-37712	)	_	
170-4	37713-37717	rsFC	_	
170-5	37718-37725	between	_	
170-6	37726-37730	left	_	
170-7	37731-37733	DG	_	
170-8	37734-37737	and	_	
170-9	37738-37742	left	_	
170-10	37743-37746	IPL	_	
170-11	37747-37756	increased	_	
170-12	37757-37761	only	_	
170-13	37762-37764	in	_	
170-14	37765-37778	schizophrenic	_	
170-15	37779-37787	patients	_	
170-16	37788-37792	with	_	
170-17	37793-37797	rare	_	
170-18	37798-37804	damage	_	
170-19	37805-37813	variants	_	
170-20	37813-37814	,	_	
170-21	37815-37822	whereas	_	
170-22	37823-37832	decreased	_	
170-23	37833-37837	rsFC	_	
170-24	37838-37840	of	_	
170-25	37841-37845	left	_	
170-26	37846-37848	SC	_	
170-27	37849-37853	with	_	
170-28	37854-37857	MFG	_	
170-29	37858-37861	was	_	
170-30	37862-37866	only	_	
170-31	37867-37872	found	_	
170-32	37873-37875	in	_	
170-33	37876-37889	schizophrenic	_	
170-34	37890-37898	patients	_	
170-35	37899-37906	without	_	
170-36	37907-37911	rare	_	
170-37	37912-37918	damage	_	
170-38	37919-37927	variants	_	
170-39	37927-37928	.	_	

#Text=The statistical significance threshold was set at P<0.05, post hoc test by least significant difference.
171-1	37929-37932	The	_	
171-2	37933-37944	statistical	_	
171-3	37945-37957	significance	_	
171-4	37958-37967	threshold	_	
171-5	37968-37971	was	_	
171-6	37972-37975	set	_	
171-7	37976-37978	at	_	
171-8	37979-37980	P	_	
171-9	37980-37981	<	_	
171-10	37981-37985	0.05	_	
171-11	37985-37986	,	_	
171-12	37987-37991	post	_	
171-13	37992-37995	hoc	_	
171-14	37996-38000	test	_	
171-15	38001-38003	by	_	
171-16	38004-38009	least	_	
171-17	38010-38021	significant	_	
171-18	38022-38032	difference	_	
171-19	38032-38033	.	_	

#Text=CA, cornuammonis; Cal, calcarine; DG, dentate gyrus; Fus, fusiform; IPL, inferior parietal cortex; L, left; MFG, medial frontal cortex; PCC, posterior cingulate cortex; R, right; RDV, rare damaging variant; SC, subicular complex.
172-1	38034-38036	CA	_	
172-2	38036-38037	,	_	
172-3	38038-38050	cornuammonis	_	
172-4	38050-38051	;	_	
172-5	38052-38055	Cal	_	
172-6	38055-38056	,	_	
172-7	38057-38066	calcarine	_	
172-8	38066-38067	;	_	
172-9	38068-38070	DG	_	
172-10	38070-38071	,	_	
172-11	38072-38079	dentate	_	
172-12	38080-38085	gyrus	_	
172-13	38085-38086	;	_	
172-14	38087-38090	Fus	_	
172-15	38090-38091	,	_	
172-16	38092-38100	fusiform	_	
172-17	38100-38101	;	_	
172-18	38102-38105	IPL	_	
172-19	38105-38106	,	_	
172-20	38107-38115	inferior	_	
172-21	38116-38124	parietal	_	
172-22	38125-38131	cortex	_	
172-23	38131-38132	;	_	
172-24	38133-38134	L	_	
172-25	38134-38135	,	_	
172-26	38136-38140	left	_	
172-27	38140-38141	;	_	
172-28	38142-38145	MFG	_	
172-29	38145-38146	,	_	
172-30	38147-38153	medial	_	
172-31	38154-38161	frontal	_	
172-32	38162-38168	cortex	_	
172-33	38168-38169	;	_	
172-34	38170-38173	PCC	_	
172-35	38173-38174	,	_	
172-36	38175-38184	posterior	_	
172-37	38185-38194	cingulate	_	
172-38	38195-38201	cortex	_	
172-39	38201-38202	;	_	
172-40	38203-38204	R	_	
172-41	38204-38205	,	_	
172-42	38206-38211	right	_	
172-43	38211-38212	;	_	
172-44	38213-38216	RDV	_	
172-45	38216-38217	,	_	
172-46	38218-38222	rare	_	
172-47	38223-38231	damaging	_	
172-48	38232-38239	variant	_	
172-49	38239-38240	;	_	
172-50	38241-38243	SC	_	
172-51	38243-38244	,	_	
172-52	38245-38254	subicular	_	
172-53	38255-38262	complex	_	
172-54	38262-38263	.	_	

#Text=Notes: s.e. for all figures.
173-1	38264-38269	Notes	_	
173-2	38269-38270	:	_	
173-3	38271-38274	s.e	_	
173-4	38274-38275	.	_	
173-5	38276-38279	for	_	
173-6	38280-38283	all	_	
173-7	38284-38291	figures	_	
173-8	38291-38292	.	_	

#Text=Relationships between resting-state functional connectivity (rsFC) of hippocampus and spatial working memory.
174-1	38293-38306	Relationships	_	
174-2	38307-38314	between	_	
174-3	38315-38328	resting-state	_	
174-4	38329-38339	functional	_	
174-5	38340-38352	connectivity	_	
174-6	38353-38354	(	_	
174-7	38354-38358	rsFC	_	
174-8	38358-38359	)	_	
174-9	38360-38362	of	_	
174-10	38363-38374	hippocampus	_	
174-11	38375-38378	and	_	
174-12	38379-38386	spatial	_	
174-13	38387-38394	working	_	
174-14	38395-38401	memory	_	
174-15	38401-38402	.	_	

#Text=Increased rsFC between left dentate gyrus and left inferior parietal cortex was positively related to number of errors of spatial working memory in schizophrenic patients with rare damaging variants and negatively related to number of errors of spatial working memory in healthy controls, uncorrected P<0.05.
175-1	38403-38412	Increased	_	
175-2	38413-38417	rsFC	_	
175-3	38418-38425	between	_	
175-4	38426-38430	left	_	
175-5	38431-38438	dentate	_	
175-6	38439-38444	gyrus	_	
175-7	38445-38448	and	_	
175-8	38449-38453	left	_	
175-9	38454-38462	inferior	_	
175-10	38463-38471	parietal	_	
175-11	38472-38478	cortex	_	
175-12	38479-38482	was	_	
175-13	38483-38493	positively	_	
175-14	38494-38501	related	_	
175-15	38502-38504	to	_	
175-16	38505-38511	number	_	
175-17	38512-38514	of	_	
175-18	38515-38521	errors	_	
175-19	38522-38524	of	_	
175-20	38525-38532	spatial	_	
175-21	38533-38540	working	_	
175-22	38541-38547	memory	_	
175-23	38548-38550	in	_	
175-24	38551-38564	schizophrenic	_	
175-25	38565-38573	patients	_	
175-26	38574-38578	with	_	
175-27	38579-38583	rare	_	
175-28	38584-38592	damaging	_	
175-29	38593-38601	variants	_	
175-30	38602-38605	and	_	
175-31	38606-38616	negatively	_	
175-32	38617-38624	related	_	
175-33	38625-38627	to	_	
175-34	38628-38634	number	_	
175-35	38635-38637	of	_	
175-36	38638-38644	errors	_	
175-37	38645-38647	of	_	
175-38	38648-38655	spatial	_	
175-39	38656-38663	working	_	
175-40	38664-38670	memory	_	
175-41	38671-38673	in	_	
175-42	38674-38681	healthy	_	
175-43	38682-38690	controls	_	
175-44	38690-38691	,	_	
175-45	38692-38703	uncorrected	_	
175-46	38704-38705	P	_	
175-47	38705-38706	<	_	
175-48	38706-38710	0.05	_	
175-49	38710-38711	.	_	

#Text=The difference in the degree of correlation was statistically significant between schizophrenic patients with RDVs and healthy controls (Z=3.331, P=8.65 × 10−4) after the Bonferroni correction, and a trend toward significance between patients with RDVs and patients without RDVs (Z=2.171, P=0.030 before Bonferroni correction), but not significant between patients without RDVs and healthy controls (Z=0.884, P=0.377).
176-1	38712-38715	The	_	
176-2	38716-38726	difference	_	
176-3	38727-38729	in	_	
176-4	38730-38733	the	_	
176-5	38734-38740	degree	_	
176-6	38741-38743	of	_	
176-7	38744-38755	correlation	_	
176-8	38756-38759	was	_	
176-9	38760-38773	statistically	_	
176-10	38774-38785	significant	_	
176-11	38786-38793	between	_	
176-12	38794-38807	schizophrenic	_	
176-13	38808-38816	patients	_	
176-14	38817-38821	with	_	
176-15	38822-38826	RDVs	_	
176-16	38827-38830	and	_	
176-17	38831-38838	healthy	_	
176-18	38839-38847	controls	_	
176-19	38848-38849	(	_	
176-20	38849-38850	Z	_	
176-21	38850-38851	=	_	
176-22	38851-38856	3.331	_	
176-23	38856-38857	,	_	
176-24	38858-38859	P	_	
176-25	38859-38860	=	_	
176-26	38860-38864	8.65	_	
176-27	38865-38866	×	_	
176-28	38867-38869	10	_	
176-29	38869-38870	−	_	
176-30	38870-38871	4	_	
176-31	38871-38872	)	_	
176-32	38873-38878	after	_	
176-33	38879-38882	the	_	
176-34	38883-38893	Bonferroni	_	
176-35	38894-38904	correction	_	
176-36	38904-38905	,	_	
176-37	38906-38909	and	_	
176-38	38910-38911	a	_	
176-39	38912-38917	trend	_	
176-40	38918-38924	toward	_	
176-41	38925-38937	significance	_	
176-42	38938-38945	between	_	
176-43	38946-38954	patients	_	
176-44	38955-38959	with	_	
176-45	38960-38964	RDVs	_	
176-46	38965-38968	and	_	
176-47	38969-38977	patients	_	
176-48	38978-38985	without	_	
176-49	38986-38990	RDVs	_	
176-50	38991-38992	(	_	
176-51	38992-38993	Z	_	
176-52	38993-38994	=	_	
176-53	38994-38999	2.171	_	
176-54	38999-39000	,	_	
176-55	39001-39002	P	_	
176-56	39002-39003	=	_	
176-57	39003-39008	0.030	_	
176-58	39009-39015	before	_	
176-59	39016-39026	Bonferroni	_	
176-60	39027-39037	correction	_	
176-61	39037-39038	)	_	
176-62	39038-39039	,	_	
176-63	39040-39043	but	_	
176-64	39044-39047	not	_	
176-65	39048-39059	significant	_	
176-66	39060-39067	between	_	
176-67	39068-39076	patients	_	
176-68	39077-39084	without	_	
176-69	39085-39089	RDVs	_	
176-70	39090-39093	and	_	
176-71	39094-39101	healthy	_	
176-72	39102-39110	controls	_	
176-73	39111-39112	(	_	
176-74	39112-39113	Z	_	
176-75	39113-39114	=	_	
176-76	39114-39119	0.884	_	
176-77	39119-39120	,	_	
176-78	39121-39122	P	_	
176-79	39122-39123	=	_	
176-80	39123-39128	0.377	_	
176-81	39128-39129	)	_	
176-82	39129-39130	.	_	

#Text=DG, dentate gyrus; IPL, inferior parietal cortex; NoE, number of error; L, left; RDV, rare damaging variant.
177-1	39131-39133	DG	_	
177-2	39133-39134	,	_	
177-3	39135-39142	dentate	_	
177-4	39143-39148	gyrus	_	
177-5	39148-39149	;	_	
177-6	39150-39153	IPL	_	
177-7	39153-39154	,	_	
177-8	39155-39163	inferior	_	
177-9	39164-39172	parietal	_	
177-10	39173-39179	cortex	_	
177-11	39179-39180	;	_	
177-12	39181-39184	NoE	_	
177-13	39184-39185	,	_	
177-14	39186-39192	number	_	
177-15	39193-39195	of	_	
177-16	39196-39201	error	_	
177-17	39201-39202	;	_	
177-18	39203-39204	L	_	
177-19	39204-39205	,	_	
177-20	39206-39210	left	_	
177-21	39210-39211	;	_	
177-22	39212-39215	RDV	_	
177-23	39215-39216	,	_	
177-24	39217-39221	rare	_	
177-25	39222-39230	damaging	_	
177-26	39231-39238	variant	_	
177-27	39238-39239	.	_	

#Text=Note: partial correlation analysis was used to analyze the relationship between rsFC of hippocampus and spatial working memory with age, sex and educations and structural hippocampal volume as covariates.
178-1	39240-39244	Note	_	
178-2	39244-39245	:	_	
178-3	39246-39253	partial	_	
178-4	39254-39265	correlation	_	
178-5	39266-39274	analysis	_	
178-6	39275-39278	was	_	
178-7	39279-39283	used	_	
178-8	39284-39286	to	_	
178-9	39287-39294	analyze	_	
178-10	39295-39298	the	_	
178-11	39299-39311	relationship	_	
178-12	39312-39319	between	_	
178-13	39320-39324	rsFC	_	
178-14	39325-39327	of	_	
178-15	39328-39339	hippocampus	_	
178-16	39340-39343	and	_	
178-17	39344-39351	spatial	_	
178-18	39352-39359	working	_	
178-19	39360-39366	memory	_	
178-20	39367-39371	with	_	
178-21	39372-39375	age	_	
178-22	39375-39376	,	_	
178-23	39377-39380	sex	_	
178-24	39381-39384	and	_	
178-25	39385-39395	educations	_	
178-26	39396-39399	and	_	
178-27	39400-39410	structural	_	
178-28	39411-39422	hippocampal	_	
178-29	39423-39429	volume	_	
178-30	39430-39432	as	_	
178-31	39433-39443	covariates	_	
178-32	39443-39444	.	_	

#Text=Statistic of demographic data for all samples
#Text= \tCase (N=94)\tControl (N=134)\tP-value\t \tGender (male/female)\t46/48\t71/63\t0.64\t \tAge (mean±s.d)\t23.94±6.92\t24.39±10.95\t0.37\t \tEducation (mean±s.d)\t12.79±3.15\t13.50±2.89\t0.07\t \t
#Text=Summary for sequencing quality
#Text= \tTotal (N=228)\tCase (N=94)\tControl (N=134)\tP-value\t \tTotal reads\t75 918 287\t76 078 777\t75 805 704\t0.45\t \tTotal yield (bp)\t7 667 746 978\t7 683 956 451\t7 656 376 154\t0.45\t \tInitial mappable reads (%)\t75 731 958 (99.75%)\t75 897 153 (99.76%)\t75 616 076 (99.75%)\t0.44\t \t1 ×, Target genotypes (%)\t58 570 040 (94.34%)\t58 500 027 (94.23%)\t58 619 153 (94.42%)\t0.08\t \t10 ×, Target genotypes (%)\t55 003 180 (88.60%)\t54 965 986 (88.53%)\t55 029 271 (88.64%)\t0.33\t \tMean target depth\t44.95\t46.54\t43.84\t0.009\t \tSNPs\t74 413\t74501\t74351\t0.25\t \tCoding SNPs\t20 229\t20157\t20280\t<0.001\t \tSynonymous SNPs\t10 491\t10457\t10516\t0.001\t \tNonsynonymous SNPs\t9220\t9185\t9245\t<0.001\t \tIndels\t7645\t7664\t7632\t0.19\t \tCoding indels\t383\t378\t386\t<0.001\t \t
#Text=Abbreviation: SNP, single-nucleotide polymorphism.
179-1	39445-39454	Statistic	_	
179-2	39455-39457	of	_	
179-3	39458-39469	demographic	_	
179-4	39470-39474	data	_	
179-5	39475-39478	for	_	
179-6	39479-39482	all	_	
179-7	39483-39490	samples	_	
179-8	39491-39492	 	_	
179-9	39493-39497	Case	_	
179-10	39498-39499	(	_	
179-11	39499-39500	N	_	
179-12	39500-39501	=	_	
179-13	39501-39503	94	_	
179-14	39503-39504	)	_	
179-15	39505-39512	Control	_	
179-16	39513-39514	(	_	
179-17	39514-39515	N	_	
179-18	39515-39516	=	_	
179-19	39516-39519	134	_	
179-20	39519-39520	)	_	
179-21	39521-39528	P-value	_	
179-22	39531-39537	Gender	_	
179-23	39538-39539	(	_	
179-24	39539-39543	male	_	
179-25	39543-39544	/	_	
179-26	39544-39550	female	_	
179-27	39550-39551	)	_	
179-28	39552-39554	46	_	
179-29	39554-39555	/	_	
179-30	39555-39557	48	_	
179-31	39558-39560	71	_	
179-32	39560-39561	/	_	
179-33	39561-39563	63	_	
179-34	39564-39568	0.64	_	
179-35	39571-39574	Age	_	
179-36	39575-39576	(	_	
179-37	39576-39580	mean	_	
179-38	39580-39581	±	_	
179-39	39581-39584	s.d	_	
179-40	39584-39585	)	_	
179-41	39586-39591	23.94	_	
179-42	39591-39592	±	_	
179-43	39592-39596	6.92	_	
179-44	39597-39602	24.39	_	
179-45	39602-39603	±	_	
179-46	39603-39608	10.95	_	
179-47	39609-39613	0.37	_	
179-48	39616-39625	Education	_	
179-49	39626-39627	(	_	
179-50	39627-39631	mean	_	
179-51	39631-39632	±	_	
179-52	39632-39635	s.d	_	
179-53	39635-39636	)	_	
179-54	39637-39642	12.79	_	
179-55	39642-39643	±	_	
179-56	39643-39647	3.15	_	
179-57	39648-39653	13.50	_	
179-58	39653-39654	±	_	
179-59	39654-39658	2.89	_	
179-60	39659-39663	0.07	_	
179-61	39667-39674	Summary	_	
179-62	39675-39678	for	_	
179-63	39679-39689	sequencing	_	
179-64	39690-39697	quality	_	
179-65	39698-39699	 	_	
179-66	39700-39705	Total	_	
179-67	39706-39707	(	_	
179-68	39707-39708	N	_	
179-69	39708-39709	=	_	
179-70	39709-39712	228	_	
179-71	39712-39713	)	_	
179-72	39714-39718	Case	_	
179-73	39719-39720	(	_	
179-74	39720-39721	N	_	
179-75	39721-39722	=	_	
179-76	39722-39724	94	_	
179-77	39724-39725	)	_	
179-78	39726-39733	Control	_	
179-79	39734-39735	(	_	
179-80	39735-39736	N	_	
179-81	39736-39737	=	_	
179-82	39737-39740	134	_	
179-83	39740-39741	)	_	
179-84	39742-39749	P-value	_	
179-85	39752-39757	Total	_	
179-86	39758-39763	reads	_	
179-87	39764-39766	75	_	
179-88	39767-39770	918	_	
179-89	39771-39774	287	_	
179-90	39775-39777	76	_	
179-91	39778-39781	078	_	
179-92	39782-39785	777	_	
179-93	39786-39788	75	_	
179-94	39789-39792	805	_	
179-95	39793-39796	704	_	
179-96	39797-39801	0.45	_	
179-97	39804-39809	Total	_	
179-98	39810-39815	yield	_	
179-99	39816-39817	(	_	
179-100	39817-39819	bp	_	
179-101	39819-39820	)	_	
179-102	39821-39822	7	_	
179-103	39823-39826	667	_	
179-104	39827-39830	746	_	
179-105	39831-39834	978	_	
179-106	39835-39836	7	_	
179-107	39837-39840	683	_	
179-108	39841-39844	956	_	
179-109	39845-39848	451	_	
179-110	39849-39850	7	_	
179-111	39851-39854	656	_	
179-112	39855-39858	376	_	
179-113	39859-39862	154	_	
179-114	39863-39867	0.45	_	
179-115	39870-39877	Initial	_	
179-116	39878-39886	mappable	_	
179-117	39887-39892	reads	_	
179-118	39893-39894	(	_	
179-119	39894-39895	%	_	
179-120	39895-39896	)	_	
179-121	39897-39899	75	_	
179-122	39900-39903	731	_	
179-123	39904-39907	958	_	
179-124	39908-39909	(	_	
179-125	39909-39915	99.75%	_	
179-126	39915-39916	)	_	
179-127	39917-39919	75	_	
179-128	39920-39923	897	_	
179-129	39924-39927	153	_	
179-130	39928-39929	(	_	
179-131	39929-39935	99.76%	_	
179-132	39935-39936	)	_	
179-133	39937-39939	75	_	
179-134	39940-39943	616	_	
179-135	39944-39947	076	_	
179-136	39948-39949	(	_	
179-137	39949-39955	99.75%	_	
179-138	39955-39956	)	_	
179-139	39957-39961	0.44	_	
179-140	39964-39965	1	_	
179-141	39966-39967	×	_	
179-142	39967-39968	,	_	
179-143	39969-39975	Target	_	
179-144	39976-39985	genotypes	_	
179-145	39986-39987	(	_	
179-146	39987-39988	%	_	
179-147	39988-39989	)	_	
179-148	39990-39992	58	_	
179-149	39993-39996	570	_	
179-150	39997-40000	040	_	
179-151	40001-40002	(	_	
179-152	40002-40008	94.34%	_	
179-153	40008-40009	)	_	
179-154	40010-40012	58	_	
179-155	40013-40016	500	_	
179-156	40017-40020	027	_	
179-157	40021-40022	(	_	
179-158	40022-40028	94.23%	_	
179-159	40028-40029	)	_	
179-160	40030-40032	58	_	
179-161	40033-40036	619	_	
179-162	40037-40040	153	_	
179-163	40041-40042	(	_	
179-164	40042-40048	94.42%	_	
179-165	40048-40049	)	_	
179-166	40050-40054	0.08	_	
179-167	40057-40059	10	_	
179-168	40060-40061	×	_	
179-169	40061-40062	,	_	
179-170	40063-40069	Target	_	
179-171	40070-40079	genotypes	_	
179-172	40080-40081	(	_	
179-173	40081-40082	%	_	
179-174	40082-40083	)	_	
179-175	40084-40086	55	_	
179-176	40087-40090	003	_	
179-177	40091-40094	180	_	
179-178	40095-40096	(	_	
179-179	40096-40102	88.60%	_	
179-180	40102-40103	)	_	
179-181	40104-40106	54	_	
179-182	40107-40110	965	_	
179-183	40111-40114	986	_	
179-184	40115-40116	(	_	
179-185	40116-40122	88.53%	_	
179-186	40122-40123	)	_	
179-187	40124-40126	55	_	
179-188	40127-40130	029	_	
179-189	40131-40134	271	_	
179-190	40135-40136	(	_	
179-191	40136-40142	88.64%	_	
179-192	40142-40143	)	_	
179-193	40144-40148	0.33	_	
179-194	40151-40155	Mean	_	
179-195	40156-40162	target	_	
179-196	40163-40168	depth	_	
179-197	40169-40174	44.95	_	
179-198	40175-40180	46.54	_	
179-199	40181-40186	43.84	_	
179-200	40187-40192	0.009	_	
179-201	40195-40199	SNPs	_	
179-202	40200-40202	74	_	
179-203	40203-40206	413	_	
179-204	40207-40212	74501	_	
179-205	40213-40218	74351	_	
179-206	40219-40223	0.25	_	
179-207	40226-40232	Coding	_	
179-208	40233-40237	SNPs	_	
179-209	40238-40240	20	_	
179-210	40241-40244	229	_	
179-211	40245-40250	20157	_	
179-212	40251-40256	20280	_	
179-213	40257-40258	<	_	
179-214	40258-40263	0.001	_	
179-215	40266-40276	Synonymous	_	
179-216	40277-40281	SNPs	_	
179-217	40282-40284	10	_	
179-218	40285-40288	491	_	
179-219	40289-40294	10457	_	
179-220	40295-40300	10516	_	
179-221	40301-40306	0.001	_	
179-222	40309-40322	Nonsynonymous	_	
179-223	40323-40327	SNPs	_	
179-224	40328-40332	9220	_	
179-225	40333-40337	9185	_	
179-226	40338-40342	9245	_	
179-227	40343-40344	<	_	
179-228	40344-40349	0.001	_	
179-229	40352-40358	Indels	_	
179-230	40359-40363	7645	_	
179-231	40364-40368	7664	_	
179-232	40369-40373	7632	_	
179-233	40374-40378	0.19	_	
179-234	40381-40387	Coding	_	
179-235	40388-40394	indels	_	
179-236	40395-40398	383	_	
179-237	40399-40402	378	_	
179-238	40403-40406	386	_	
179-239	40407-40408	<	_	
179-240	40408-40413	0.001	_	
179-241	40417-40429	Abbreviation	_	
179-242	40429-40430	:	_	
179-243	40431-40434	SNP	_	
179-244	40434-40435	,	_	
179-245	40436-40453	single-nucleotide	_	
179-246	40454-40466	polymorphism	_	
179-247	40466-40467	.	_	

#Text=Bold values show significant statistic difference.
180-1	40468-40472	Bold	_	
180-2	40473-40479	values	_	
180-3	40480-40484	show	_	
180-4	40485-40496	significant	_	
180-5	40497-40506	statistic	_	
180-6	40507-40517	difference	_	
180-7	40517-40518	.	_	

#Text=Aberrant functional connectivity of hippocampus and hippocampal subregions in patients group
#Text= \tBrain region\tPeak MNI (x y z)\tPeak Z-score\tCluster size\t \tHippocampus_L\tInferior parietal lobule_L\t−36 −56 43\t6.8463\t42\t \t \tCerebellar posterior lobe\t9 −75 −45\t7.3691\t40\t \t \t \t \t \t \t \tHippocampal subregions\t \t DG_L\tInferior parietal lobule_L\t−36 −54 42\t10.7382\t77\t \t DG_R\tInferior parietal lobule_L\t−48 −54 48\t8.2654\t46\t \t \tPosterior cingulate cortex\t−6 −33 30\t7.0922\t33\t \t CA_L\tCalcarine_R\t24 −93 0\t11.1746\t68\t \t CA_R\tCalcarine_R\t21 −93 3\t13.0346\t97\t \t \tFusiform extent to lingual_L\t−27 −54 −3\t9.205\t32\t \t SUB_L\tMedial frontal cortex\t3 30 −12\t7.1874\t37\t \t
#Text=Abbreviations: CA, cornuammonis; DG, dentate gyrus; L, left; MNI, Montreal Neurological Institute; SC, subicular complex; R, right.
181-1	40519-40527	Aberrant	_	
181-2	40528-40538	functional	_	
181-3	40539-40551	connectivity	_	
181-4	40552-40554	of	_	
181-5	40555-40566	hippocampus	_	
181-6	40567-40570	and	_	
181-7	40571-40582	hippocampal	_	
181-8	40583-40593	subregions	_	
181-9	40594-40596	in	_	
181-10	40597-40605	patients	_	
181-11	40606-40611	group	_	
181-12	40612-40613	 	_	
181-13	40614-40619	Brain	_	
181-14	40620-40626	region	_	
181-15	40627-40631	Peak	_	
181-16	40632-40635	MNI	_	
181-17	40636-40637	(	_	
181-18	40637-40638	x	_	
181-19	40639-40640	y	_	
181-20	40641-40642	z	_	
181-21	40642-40643	)	_	
181-22	40644-40648	Peak	_	
181-23	40649-40656	Z-score	_	
181-24	40657-40664	Cluster	_	
181-25	40665-40669	size	_	
181-26	40672-40685	Hippocampus_L	_	
181-27	40686-40694	Inferior	_	
181-28	40695-40703	parietal	_	
181-29	40704-40712	lobule_L	_	
181-30	40713-40714	−	_	
181-31	40714-40716	36	_	
181-32	40717-40718	−	_	
181-33	40718-40720	56	_	
181-34	40721-40723	43	_	
181-35	40724-40730	6.8463	_	
181-36	40731-40733	42	_	
181-37	40736-40737	 	_	
181-38	40738-40748	Cerebellar	_	
181-39	40749-40758	posterior	_	
181-40	40759-40763	lobe	_	
181-41	40764-40765	9	_	
181-42	40766-40767	−	_	
181-43	40767-40769	75	_	
181-44	40770-40771	−	_	
181-45	40771-40773	45	_	
181-46	40774-40780	7.3691	_	
181-47	40781-40783	40	_	
181-48	40786-40795	 	 	 	 	 	_	
181-49	40798-40809	Hippocampal	_	
181-50	40810-40820	subregions	_	
181-51	40824-40828	DG_L	_	
181-52	40829-40837	Inferior	_	
181-53	40838-40846	parietal	_	
181-54	40847-40855	lobule_L	_	
181-55	40856-40857	−	_	
181-56	40857-40859	36	_	
181-57	40860-40861	−	_	
181-58	40861-40863	54	_	
181-59	40864-40866	42	_	
181-60	40867-40874	10.7382	_	
181-61	40875-40877	77	_	
181-62	40881-40885	DG_R	_	
181-63	40886-40894	Inferior	_	
181-64	40895-40903	parietal	_	
181-65	40904-40912	lobule_L	_	
181-66	40913-40914	−	_	
181-67	40914-40916	48	_	
181-68	40917-40918	−	_	
181-69	40918-40920	54	_	
181-70	40921-40923	48	_	
181-71	40924-40930	8.2654	_	
181-72	40931-40933	46	_	
181-73	40936-40937	 	_	
181-74	40938-40947	Posterior	_	
181-75	40948-40957	cingulate	_	
181-76	40958-40964	cortex	_	
181-77	40965-40966	−	_	
181-78	40966-40967	6	_	
181-79	40968-40969	−	_	
181-80	40969-40971	33	_	
181-81	40972-40974	30	_	
181-82	40975-40981	7.0922	_	
181-83	40982-40984	33	_	
181-84	40988-40992	CA_L	_	
181-85	40993-41004	Calcarine_R	_	
181-86	41005-41007	24	_	
181-87	41008-41009	−	_	
181-88	41009-41011	93	_	
181-89	41012-41013	0	_	
181-90	41014-41021	11.1746	_	
181-91	41022-41024	68	_	
181-92	41028-41032	CA_R	_	
181-93	41033-41044	Calcarine_R	_	
181-94	41045-41047	21	_	
181-95	41048-41049	−	_	
181-96	41049-41051	93	_	
181-97	41052-41053	3	_	
181-98	41054-41061	13.0346	_	
181-99	41062-41064	97	_	
181-100	41067-41068	 	_	
181-101	41069-41077	Fusiform	_	
181-102	41078-41084	extent	_	
181-103	41085-41087	to	_	
181-104	41088-41097	lingual_L	_	
181-105	41098-41099	−	_	
181-106	41099-41101	27	_	
181-107	41102-41103	−	_	
181-108	41103-41105	54	_	
181-109	41106-41107	−	_	
181-110	41107-41108	3	_	
181-111	41109-41114	9.205	_	
181-112	41115-41117	32	_	
181-113	41121-41126	SUB_L	_	
181-114	41127-41133	Medial	_	
181-115	41134-41141	frontal	_	
181-116	41142-41148	cortex	_	
181-117	41149-41150	3	_	
181-118	41151-41153	30	_	
181-119	41154-41155	−	_	
181-120	41155-41157	12	_	
181-121	41158-41164	7.1874	_	
181-122	41165-41167	37	_	
181-123	41171-41184	Abbreviations	_	
181-124	41184-41185	:	_	
181-125	41186-41188	CA	_	
181-126	41188-41189	,	_	
181-127	41190-41202	cornuammonis	_	
181-128	41202-41203	;	_	
181-129	41204-41206	DG	_	
181-130	41206-41207	,	_	
181-131	41208-41215	dentate	_	
181-132	41216-41221	gyrus	_	
181-133	41221-41222	;	_	
181-134	41223-41224	L	_	
181-135	41224-41225	,	_	
181-136	41226-41230	left	_	
181-137	41230-41231	;	_	
181-138	41232-41235	MNI	_	
181-139	41235-41236	,	_	
181-140	41237-41245	Montreal	_	
181-141	41246-41258	Neurological	_	
181-142	41259-41268	Institute	_	
181-143	41268-41269	;	_	
181-144	41270-41272	SC	_	
181-145	41272-41273	,	_	
181-146	41274-41283	subicular	_	
181-147	41284-41291	complex	_	
181-148	41291-41292	;	_	
181-149	41293-41294	R	_	
181-150	41294-41295	,	_	
181-151	41296-41301	right	_	
181-152	41301-41302	.	_	

#Text=Note: The statistical significance threshold for main effect for diagnosis of functional connectivity of each hippocampal subregions was set at P<0.05, corrected for multiple comparisons based on Monte Carlo simulations.
182-1	41303-41307	Note	_	
182-2	41307-41308	:	_	
182-3	41309-41312	The	_	
182-4	41313-41324	statistical	_	
182-5	41325-41337	significance	_	
182-6	41338-41347	threshold	_	
182-7	41348-41351	for	_	
182-8	41352-41356	main	_	
182-9	41357-41363	effect	_	
182-10	41364-41367	for	_	
182-11	41368-41377	diagnosis	_	
182-12	41378-41380	of	_	
182-13	41381-41391	functional	_	
182-14	41392-41404	connectivity	_	
182-15	41405-41407	of	_	
182-16	41408-41412	each	_	
182-17	41413-41424	hippocampal	_	
182-18	41425-41435	subregions	_	
182-19	41436-41439	was	_	
182-20	41440-41443	set	_	
182-21	41444-41446	at	_	
182-22	41447-41448	P	_	
182-23	41448-41449	<	_	
182-24	41449-41453	0.05	_	
182-25	41453-41454	,	_	
182-26	41455-41464	corrected	_	
182-27	41465-41468	for	_	
182-28	41469-41477	multiple	_	
182-29	41478-41489	comparisons	_	
182-30	41490-41495	based	_	
182-31	41496-41498	on	_	
182-32	41499-41504	Monte	_	
182-33	41505-41510	Carlo	_	
182-34	41511-41522	simulations	_	
182-35	41522-41523	.	_	

#Text=Sample summary and test scores for imaging
#Text=Category (mean±s.d.)
183-1	41524-41530	Sample	_	
183-2	41531-41538	summary	_	
183-3	41539-41542	and	_	
183-4	41543-41547	test	_	
183-5	41548-41554	scores	_	
183-6	41555-41558	for	_	
183-7	41559-41566	imaging	_	
183-8	41567-41575	Category	_	
183-9	41576-41577	(	_	
183-10	41577-41581	mean	_	
183-11	41581-41582	±	_	
183-12	41582-41585	s.d	_	
183-13	41585-41586	.	_	
183-14	41586-41587	)	_	

#Text=Cases with RDVs (n=26)\tCases without RDVs (n=48)\tControl (n=74)\tdf\tF/t/λ/value\tP-value\t \tAge (years)\t25.69±7.2\t23.00±6.92\t23.23±6.52\t2\t1.54\t0.22\t \tGender (male/female)\t13/13\t24/24\t41/33\t2\t0.43\t0.81\t \tYears of education\t13.42±3.19\t11.90±3.08\t13.44±3.24\t2\t3.72\t0.03\t \tDuration of disease\t3.5\t2\t \t72\t0.57\t0.57\t \tPANSS total\t87.08±17.16\t88.06±12.55\t \t71\t−0.28\t0.78\t \tPANSS positive\t23.65±8.27\t24.34±5.55\t \t37.72\t−0.38\t0.71\t \tPANSS negative\t18.69±8.50\t18.87±6.75\t \t42.68\t−0.09\t0.93\t \tPANSS general psychopathology\t44.73±8.84\t44.85±7.47\t \t71\t−0.06\t0.95\t \tLogical memory immediate\t6.16±3.31\t7.84±4.62\t12.94±3.89\t2\t45.47\t<0.001\t \tLogical memory delay\t4.09±3.19\t5.65±4.39\t11.02±4.12\t2\t44.51\t<0.001\t \tHippocampus L milliliter\t2534.70±291.31\t2512.42±239.22\t2722.55±301.57\t2\t7.42\t0.001\t \tHippocampus R milliliter\t2573.12±305.71\t2559.78±262.83\t2741.44±289.61\t2\t5.63\t0.004\t \t
#Text=Abbreviations: L, left; PANSS, Positive and Negative Syndrome Scale; R, right; RDV, rare damage variant.
184-1	41588-41593	Cases	_	
184-2	41594-41598	with	_	
184-3	41599-41603	RDVs	_	
184-4	41604-41605	(	_	
184-5	41605-41606	n	_	
184-6	41606-41607	=	_	
184-7	41607-41609	26	_	
184-8	41609-41610	)	_	
184-9	41611-41616	Cases	_	
184-10	41617-41624	without	_	
184-11	41625-41629	RDVs	_	
184-12	41630-41631	(	_	
184-13	41631-41632	n	_	
184-14	41632-41633	=	_	
184-15	41633-41635	48	_	
184-16	41635-41636	)	_	
184-17	41637-41644	Control	_	
184-18	41645-41646	(	_	
184-19	41646-41647	n	_	
184-20	41647-41648	=	_	
184-21	41648-41650	74	_	
184-22	41650-41651	)	_	
184-23	41652-41654	df	_	
184-24	41655-41656	F	_	
184-25	41656-41657	/	_	
184-26	41657-41658	t	_	
184-27	41658-41659	/	_	
184-28	41659-41660	λ	_	
184-29	41660-41661	/	_	
184-30	41661-41666	value	_	
184-31	41667-41674	P-value	_	
184-32	41677-41680	Age	_	
184-33	41681-41682	(	_	
184-34	41682-41687	years	_	
184-35	41687-41688	)	_	
184-36	41689-41694	25.69	_	
184-37	41694-41695	±	_	
184-38	41695-41698	7.2	_	
184-39	41699-41704	23.00	_	
184-40	41704-41705	±	_	
184-41	41705-41709	6.92	_	
184-42	41710-41715	23.23	_	
184-43	41715-41716	±	_	
184-44	41716-41720	6.52	_	
184-45	41721-41722	2	_	
184-46	41723-41727	1.54	_	
184-47	41728-41732	0.22	_	
184-48	41735-41741	Gender	_	
184-49	41742-41743	(	_	
184-50	41743-41747	male	_	
184-51	41747-41748	/	_	
184-52	41748-41754	female	_	
184-53	41754-41755	)	_	
184-54	41756-41758	13	_	
184-55	41758-41759	/	_	
184-56	41759-41761	13	_	
184-57	41762-41764	24	_	
184-58	41764-41765	/	_	
184-59	41765-41767	24	_	
184-60	41768-41770	41	_	
184-61	41770-41771	/	_	
184-62	41771-41773	33	_	
184-63	41774-41775	2	_	
184-64	41776-41780	0.43	_	
184-65	41781-41785	0.81	_	
184-66	41788-41793	Years	_	
184-67	41794-41796	of	_	
184-68	41797-41806	education	_	
184-69	41807-41812	13.42	_	
184-70	41812-41813	±	_	
184-71	41813-41817	3.19	_	
184-72	41818-41823	11.90	_	
184-73	41823-41824	±	_	
184-74	41824-41828	3.08	_	
184-75	41829-41834	13.44	_	
184-76	41834-41835	±	_	
184-77	41835-41839	3.24	_	
184-78	41840-41841	2	_	
184-79	41842-41846	3.72	_	
184-80	41847-41851	0.03	_	
184-81	41854-41862	Duration	_	
184-82	41863-41865	of	_	
184-83	41866-41873	disease	_	
184-84	41874-41877	3.5	_	
184-85	41878-41879	2	_	
184-86	41880-41881	 	_	
184-87	41882-41884	72	_	
184-88	41885-41889	0.57	_	
184-89	41890-41894	0.57	_	
184-90	41897-41902	PANSS	_	
184-91	41903-41908	total	_	
184-92	41909-41914	87.08	_	
184-93	41914-41915	±	_	
184-94	41915-41920	17.16	_	
184-95	41921-41926	88.06	_	
184-96	41926-41927	±	_	
184-97	41927-41932	12.55	_	
184-98	41933-41934	 	_	
184-99	41935-41937	71	_	
184-100	41938-41939	−	_	
184-101	41939-41943	0.28	_	
184-102	41944-41948	0.78	_	
184-103	41951-41956	PANSS	_	
184-104	41957-41965	positive	_	
184-105	41966-41971	23.65	_	
184-106	41971-41972	±	_	
184-107	41972-41976	8.27	_	
184-108	41977-41982	24.34	_	
184-109	41982-41983	±	_	
184-110	41983-41987	5.55	_	
184-111	41988-41989	 	_	
184-112	41990-41995	37.72	_	
184-113	41996-41997	−	_	
184-114	41997-42001	0.38	_	
184-115	42002-42006	0.71	_	
184-116	42009-42014	PANSS	_	
184-117	42015-42023	negative	_	
184-118	42024-42029	18.69	_	
184-119	42029-42030	±	_	
184-120	42030-42034	8.50	_	
184-121	42035-42040	18.87	_	
184-122	42040-42041	±	_	
184-123	42041-42045	6.75	_	
184-124	42046-42047	 	_	
184-125	42048-42053	42.68	_	
184-126	42054-42055	−	_	
184-127	42055-42059	0.09	_	
184-128	42060-42064	0.93	_	
184-129	42067-42072	PANSS	_	
184-130	42073-42080	general	_	
184-131	42081-42096	psychopathology	_	
184-132	42097-42102	44.73	_	
184-133	42102-42103	±	_	
184-134	42103-42107	8.84	_	
184-135	42108-42113	44.85	_	
184-136	42113-42114	±	_	
184-137	42114-42118	7.47	_	
184-138	42119-42120	 	_	
184-139	42121-42123	71	_	
184-140	42124-42125	−	_	
184-141	42125-42129	0.06	_	
184-142	42130-42134	0.95	_	
184-143	42137-42144	Logical	_	
184-144	42145-42151	memory	_	
184-145	42152-42161	immediate	_	
184-146	42162-42166	6.16	_	
184-147	42166-42167	±	_	
184-148	42167-42171	3.31	_	
184-149	42172-42176	7.84	_	
184-150	42176-42177	±	_	
184-151	42177-42181	4.62	_	
184-152	42182-42187	12.94	_	
184-153	42187-42188	±	_	
184-154	42188-42192	3.89	_	
184-155	42193-42194	2	_	
184-156	42195-42200	45.47	_	
184-157	42201-42202	<	_	
184-158	42202-42207	0.001	_	
184-159	42210-42217	Logical	_	
184-160	42218-42224	memory	_	
184-161	42225-42230	delay	_	
184-162	42231-42235	4.09	_	
184-163	42235-42236	±	_	
184-164	42236-42240	3.19	_	
184-165	42241-42245	5.65	_	
184-166	42245-42246	±	_	
184-167	42246-42250	4.39	_	
184-168	42251-42256	11.02	_	
184-169	42256-42257	±	_	
184-170	42257-42261	4.12	_	
184-171	42262-42263	2	_	
184-172	42264-42269	44.51	_	
184-173	42270-42271	<	_	
184-174	42271-42276	0.001	_	
184-175	42279-42290	Hippocampus	_	
184-176	42291-42292	L	_	
184-177	42293-42303	milliliter	_	
184-178	42304-42311	2534.70	_	
184-179	42311-42312	±	_	
184-180	42312-42318	291.31	_	
184-181	42319-42326	2512.42	_	
184-182	42326-42327	±	_	
184-183	42327-42333	239.22	_	
184-184	42334-42341	2722.55	_	
184-185	42341-42342	±	_	
184-186	42342-42348	301.57	_	
184-187	42349-42350	2	_	
184-188	42351-42355	7.42	_	
184-189	42356-42361	0.001	_	
184-190	42364-42375	Hippocampus	_	
184-191	42376-42377	R	_	
184-192	42378-42388	milliliter	_	
184-193	42389-42396	2573.12	_	
184-194	42396-42397	±	_	
184-195	42397-42403	305.71	_	
184-196	42404-42411	2559.78	_	
184-197	42411-42412	±	_	
184-198	42412-42418	262.83	_	
184-199	42419-42426	2741.44	_	
184-200	42426-42427	±	_	
184-201	42427-42433	289.61	_	
184-202	42434-42435	2	_	
184-203	42436-42440	5.63	_	
184-204	42441-42446	0.004	_	
184-205	42450-42463	Abbreviations	_	
184-206	42463-42464	:	_	
184-207	42465-42466	L	_	
184-208	42466-42467	,	_	
184-209	42468-42472	left	_	
184-210	42472-42473	;	_	
184-211	42474-42479	PANSS	_	
184-212	42479-42480	,	_	
184-213	42481-42489	Positive	_	
184-214	42490-42493	and	_	
184-215	42494-42502	Negative	_	
184-216	42503-42511	Syndrome	_	
184-217	42512-42517	Scale	_	
184-218	42517-42518	;	_	
184-219	42519-42520	R	_	
184-220	42520-42521	,	_	
184-221	42522-42527	right	_	
184-222	42527-42528	;	_	
184-223	42529-42532	RDV	_	
184-224	42532-42533	,	_	
184-225	42534-42538	rare	_	
184-226	42539-42545	damage	_	
184-227	42546-42553	variant	_	
184-228	42553-42554	.	_	

#Text=Note: values are mean (s.d.).
185-1	42555-42559	Note	_	
185-2	42559-42560	:	_	
185-3	42561-42567	values	_	
185-4	42568-42571	are	_	
185-5	42572-42576	mean	_	
185-6	42577-42578	(	_	
185-7	42578-42581	s.d	_	
185-8	42581-42582	.	_	
185-9	42582-42583	)	_	
185-10	42583-42584	.	_	
